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Abstract 
Background and significance 
The prevalence of advanced kidney disease in older patients is increasing with 
a large number of these patients commencing on dialysis. Consequently, withdrawal 
from dialysis is one of the most common causes of death in this population. Shared 
decision making is the goal of health care services worldwide however no research 
has been undertaken on how to facilitate shared decision making for older patients 
with advanced kidney disease.  
Aim 
The aim of this research was to evaluate the effectiveness of a decision support 
intervention facilitating the older patient with advanced kidney disease to make a 
treatment choice that best matches their personal values. The following null 
hypotheses were tested:  
For patients receiving the decision support intervention there will be no 
difference in decision conflict and decision regret compared with those patients 
receiving usual decision making support. For the secondary outcomes, there will be 
no difference in knowledge and quality of life between those patients who received 
the decision support intervention compared with those patients who received usual 
decision making support.  
Methods 
A pragmatic randomised controlled trial was conducted to compare the 
effectiveness of the decision support intervention with standard care. The 
development and evaluation of the decision support intervention was guided by the 
Ottawa Decision Support Framework. Those eligible for the study were patients ≥ 70 
years with advanced kidney disease (eGFR ≤ 20 mL/min/1.73m²) who had not made 
a decision regarding treatment options and were not eligible for a transplant. Those 
who agreed to participate in the study were randomised to either receive the decision 
support intervention or standard care. The primary investigator and outcome research 
assistant were blinded to treatment allocation for data collection and analysis. The 
primary outcomes collected were decision conflict and decision regret and the 
secondary outcomes were knowledge of risk, benefits and symptoms of dialysis and 
quality of life.  
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
Results 
A total of 41 patients consented and were randomised for this study, with 16 
receiving the decision supporting intervention and 21 receiving standard care. Both 
groups had low decision conflict scores. The intervention group had a mean decision 
conflict score of 20.32/100 and the standard care group 15.95/100 (p=0.53). Decision 
regret was also similar between groups with minimal difference between estimated 
marginal means (p=0.64). The decision support intervention was able to significantly 
improve the participants’ knowledge of risks, benefits and symptoms of dialysis with 
the knowledge score in the intervention group being 60.39/100 and the standard 
group 27.51/100 (p=0.001).  
No observable difference between groups was noted for quality of life 
summary scores – physical component score and mental health component score. 
The decision support intervention was helpful in preparing participants to make a 
treatment decision with a score of 83.44/100. This research study was underpowered 
due to unique barriers related to patient population, health professionals and health 
service context. 
Conclusion 
The use of the Ottawa Decision Support Framework in guiding the 
development and evaluation of the decision support intervention has ensured it meets 
stringent international decision support intervention standards. The results 
demonstrated that the decision support intervention increased the patients’ 
knowledge of risk, benefits and symptoms of dialysis. Thereby overcoming barriers 
of health literacy and engaging patients in a shared decision making process. The 
analysis of barriers to recruitment has provided a renewed understanding of the 
barriers and blockages for undertaking research with this population in the Australian 
regional service. The outcomes from this research will provide a foundation for 
further evaluation of the role of decision support interventions in facilitating shared 
decision making for the older patients with advanced kidney disease. 
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 Introduction Chapter 1:
1.1 BACKGROUND AND SCOPE OF THE PROBLEM 
Globally, expenditure on health care is high and predicted to increase further 
due to the ageing of the population and the advancement of healthcare technologies. 
This is evidenced by increasing expenditure of 2.6 % in the year 2013 over the 
previous year and a further rapid increase predicted of approximately 5.3 %  per year 
between 2014–2017 (Deloitte, 2014) . The primary factor contributing to the 
increasing expenditure on health care is the increase in life span in developed 
countries and the prevalence of chronic diseases. The worldwide proportion of older 
people (aged 60 years or over) has risen from 9.2 % in 1990 to 11.7% in 2013 
(United Nations, Department of Economic and Social Affairs, & Population 
Division, 2013). The proportion of older people globally is expected to grow and 
represent 21% of the world population by 2050 (Tonelli & Riella, 2014; United 
Nations et al., 2013). As a consequence of the ageing population, there is a higher 
and growing prevalence of chronic disease such as diabetes, hypertension, 
cardiovascular diseases and chronic kidney disease (CKD) which contribute to 
increased health expenditure (Deloitte, 2014; Eckardt et al., 2013; Tonelli & Riella, 
2014). 
Chronic diseases are also the most common cause of morbidity and early death 
(Couser, Remuzzi, Mendis, & Tonelli, 2011). The World Health Organisation has 
identified cardiovascular, cancer, diabetes and chronic respiratory disease as 
representing a major proportion of global non-communicable disease (Couser et al., 
2011). Chronic Kidney Disease is regarded as a key determinant in the poor 
outcomes for those who have cardiovascular, cancer, diabetes or chronic respiratory 
disease (Couser et al., 2011). The presence of CKD is known to be related to an eight 
to tenfold increase in cardiovascular mortality and also increased risk for those with 
diabetes (Couser et al., 2011; Tonelli & Riella, 2014). In Australia diseases such as 
cardiac, diabetes and kidney failure contribute to one quarter of the disease burden 
(Australian Institute of Health and Welfare, 2009b).   
Chronic kidney disease (CKD) is defined as the presence of kidney damage 
and/or reduced kidney function, for a period greater than 3 months (Chadban et al., 
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2003). The classification of chronic kidney disease has been separated into five 
stages: Stage 1 indicates mild kidney disease and Stage 5 indicates end stage kidney 
disease (ESKD). Globally, the number of deaths from CKD has increased by 82% in 
the last two decades (Radhakrishnan et al., 2014). End Stage Kidney Disease 
(ESKD) is the most severe form of kidney disease (Chadban et al., 2003). The term 
‘advanced kidney disease’ is used within this thesis to denote both late Stage 4 
kidney disease (kidney function less than 20 mL/min/1.73m
2)
 and end stage kidney 
disease. The number of patients with ESKD receiving renal replacement therapy 
(RRT) worldwide is greater than 1.4 million, with an annual growth rate of 8% 
(Radhakrishnan et al., 2014). In the presence of ESKD, renal replacement therapy 
(transplant or dialysis) is usually required for survival (Australian Institute of Health 
and Welfare, 2009). The incidence of ESKD is rising globally due to the growing 
ageing population. In Australia the incidence of dialysis has increased by 19% 
between the years of 2000–2009, with a majority of these patients aged 65 years and 
over (Australian Institute of Health and Welfare, 2012a). In the USA one in four 
patients who started dialysis were over 75 years, in the United Kingdom the mean 
age of patients on dialysis was 65 with France having a mean age of 70.2 years 
(Franco & Fernandes, 2013). This thesis investigates a decision support intervention 
developed specifically to assist the older patient considering dialysis. 
1.2 CONTEXT OF RESEARCH  
Dialysis is an expensive treatment and places a considerable burden on health 
care. In Australia the predicted cost of treating all prevalent and incident cases of 
ESKD between the years of 2009–20 is estimated between $11.3 billion and $12.3 
billion (Kidney Health Australia, 2010). In addition to the economic impact there is 
high degree of symptom burden from the treatment which can impact on quality of 
life for the individual and their family (Almutary, Bonner, & Douglas, 2013; Amro, 
Waldum, Dammen, Miaskowski, & Os, 2014; Australian Institute of Health and 
Welfare, 2011). Dialysis also impacts life expectancy, employment, family 
responsibilities and financial cost, with some Australian people needing to relocate 
closer to a treating centre (Australia Institute of Health and Welfare, 2014). 
The high incidence of comorbid diseases in the elderly, combined with the rise 
in the number and age of cases of ESKD receiving renal replacement therapy (RRT), 
has generated discussion around the appropriateness and benefit of dialysis. A 
Leanne Brown 
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systematic review undertaken as part of this thesis identified that in the older patient 
with ESKD, dialysis may provide some survival advantage however this advantage is 
lost in the presence of severe comorbidities (Joly et al., 2003), with particular focus 
on ischaemic heart disease (Brown, Gardner, & Bonner, 2014; Murtagh et al., 
2007b). Additionally a study undertaken by Hussain, Mooney, and Russon (2013) 
identified that for patients over 80 years of age with poor functional performance or 
severe comorbidities the survival advantage of dialysis was lost. Research has also 
identified that those patients who undertook dialysis had higher rates of admissions 
to hospital (Carson, Juszczak, Davenport, & Burns, 2009) and were more likely to 
die in hospital (Morton et al., 2016). This evidence indicates that in some situations 
initiation of dialysis for the older patient is neither appropriate nor beneficial.  
Worldwide a common cause of death for a dialysis patient is withdrawal from 
dialysis (Davison et al., 2015). Data from the Australian and New Zealand Dialysis 
and Transplant Registry (ANZDATA) indicates that withdrawal from treatment, is 
reported as cause of death for approximately 31.5% of people undertaking RRT 
(ANZDATA Registry, 2016). Withdrawal from RRT in the older population (>65 
years) is the most common cause of death, with 38% of the older population 
choosing to withdraw from RRT (ANZDATA Registry, 2016). This data indicates 
that there is a proportion of people who commence dialysis for whom dialysis 
becomes untenable, with the most common reason for withdrawal from treatment 
being psychosocial (ANZDATA Registry, 2016). Research has identified that 61% 
of patients undertaking dialysis regretted their decision to commence dialysis 
(Davison, 2010). Furthermore this study found that a high proportion of the patients 
undertaking dialysis reported that there was no discussion regarding end-of-life care 
preferences within the last 12 months (Davison, 2010). The study identified that 
almost 50% of the study population identified preference for end-of-life discussions 
(Davison, 2010). This is one of the few studies examining end-of-life care 
preferences. Nonetheless the findings from Davison’s research indicate that it may be 
important for people with advanced kidney disease to have access to information 
needed to assist in objective and informed decision making.  
Renal Replacement Therapy is a treatment to sustain life in patients with 
ESKD, however for the older patient who receives RRT, it can prove to be 
burdensome in terms of time, symptoms and travel for treatment (Almutary et al., 
A randomised controlled trial of a decision support intervention to support  
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2013; Australian Institute of Health and Welfare, 2011; Kidney Health Australia, 
2011; Morton et al., 2012). Furthermore providing support for the person with end 
stage kidney disease can impose a substantial physical and psychological burden on 
the caregiver to the extent where the health related quality of life of caregivers are 
impacted (Belasco & Sesso; Cantekin, Kavurmacı, & Tan, 2016; Gayomali, 
Sutherland, & Finkelstein, 2008; Tong, Sainsbury, & Craig, 2008). The burden of 
RRT on the patient and their caregivers needs to be considered when the health 
professional confers with the patient regarding the treatment choices.  
Over the last century the focus on decision making has evolved, moving from a 
paternalistic approach to a strictly autonomous approach, with a compromise now 
reached to encompass a shared decision making (SDM) approach (Charles, Gafni, & 
Whelan, 1997). Renal clinical practice guidelines endorse the necessity of all patients 
to be included in a shared decision making approach, prior to initiation of dialysis 
and cessation of dialysis (Davison et al., 2015; Palliative Care Australia and Kidney 
Health Australia, 2014; Renal Physicians Association, 2010; Warwick, Mooney, 
Russon, & Hardy, 2014; Williams et al., 2012) . The SDM process is to include the 
patient themselves, their families and multidisciplinary health care team (Williams et 
al., 2012); this is particularly relevant for the older patient when considering a 
treatment choice such as RRT. The current practice paradigm is to steer decision 
making towards home based dialysis therapies. The identified advantages  include 
longer survival, improved quality of life, decreased health system costs and greater 
independence and flexibility (Kidney Health Australia, 2012a). Within 
Queensland—where this research has been conducted—there is a state wide 
benchmark for all dialysis centres to have 50% of dialysis patients undertaking home 
based therapies (Queensland Government, 2007). If this target is not achieved 
financial penalties are enforced. These financial penalties have the potential to 
discourage a shared decision making process between the health professional and the 
patient and for the patient this may result in the loss of autonomy. Moreover, the high 
rate of withdrawal from dialysis and the identification of regret regarding 
undertaking dialysis identifies that health care professionals have yet to achieve a 
high level of shared decision making for this population group despite the 
incorporation of shared decision making into guidelines worldwide. There is a 
paucity of literature examining SDM in the setting of advanced kidney disease for 
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the older population. Gaining a deeper understanding of how a decision support 
intervention could support this population group may assist with providing an 
appropriate mechanism to assist the older person choosing a treatment best matched 
to their individual values. 
1.3 RESEARCH AIM 
The aim of this research was to examine the effectiveness of the decision 
support intervention to support decision making for eligible patients and their 
families who are considering a treatment modality for ESKD.   
The research was directed by the following research questions: 
 To what extent is the decision support intervention effective, in 
supporting decision making for eligible patients, in choosing between 
dialysis and non-dialysis management? 
 To what extent is the decision support intervention user friendly in 
terms of patients utilising it and facilitating a discussion with the renal 
nurses to facilitate shared decision making? 
The following null hypotheses were tested: 
 For patients with advanced kidney disease who are ≥70 years and 
receiving the decision support intervention there will be no 
differences in: 
Primary Outcomes of: 
 Decision regret  
 Decision conflict  
Secondary Outcomes of: 
 Knowledge score 
 Quality of life 
1.4 THESIS OUTLINE 
This thesis is a body of original work evaluating the effectiveness of a decision 
support intervention in facilitating value based decision making for the older patient 
with advanced kidney disease.   
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Chapter Two is a literature review examining decision support interventions 
(DSIs) utilised in chronic disease. The core component of this chapter is a systematic 
review that appraises evidence comparing outcomes of older patients who have 
undertaken either RRT or NDM. The findings from this published manuscript were 
used to inform the content of the DSI.  
Chapter Three describes the study methodology and the theoretical framework 
and how these theoretical and conceptual structures provided a frame for a study 
design to evaluate a complex intervention. This chapter also details the theoretical 
framework and how it has informed the development of the DSI.  
Chapter Four discusses the research methods and presents a comprehensive 
research plan of the pragmatic randomised controlled trial, including the research 
design, methods, analytical plan and ethical considerations. The evaluation of the 
DSI was guided by the theoretical framework. Consistent with best practice in 
research this study protocol has been reported in a peer reviewed publication.  
Chapter Five reports the evaluation of the effectiveness of the customised 
decision support intervention in lowering decision conflict and decision regret and 
also improving knowledge of the risks, benefits and symptoms of dialysis. The 
presentation of these results is consistent with the published study protocol. 
Additionally, the barriers to recruitment have been identified.   
Chapter Six is a discussion of the major findings of this study examining the 
effectiveness of the customised decision support intervention in lowering decision 
conflict, decision regret and improving knowledge for the older patient with 
advanced kidney disease. The results of this study have been reviewed in 
consideration of other empirical evidence. The final section of the discussion 
includes an analysis of the barriers to recruitment experienced throughout this 
research project.  
The final chapter, Chapter Seven concludes with recommendations from the 
study and provides future direction for enhancing research in the area of decision 
support interventions for the older patient with advanced kidney disease.  
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 Literature Review Chapter 2:
2.1 INTRODUCTION 
The concept of shared decision making (SDM) has evolved over the century as a result 
of changes to social hierarchies (Blair & Légaré, 2015). The evolution of SDM occurred in 
conjunction with the implementation of informed consent. Informed consent reflects the 
underlying principles of SDM, where informed consent is defined as ‘a reasoned choice made 
by a reasonable patient using relevant information about the advantages and disadvantages of 
all the possible courses of actions, in accord with his or her beliefs’(Blair & Légaré, 2015, p. 
472). 
Some early research in the conceptualisation of SDM, defined SDM as a balance 
between paternalism and autonomy whereby the patient has some say but not total 
responsibility and the clinician is able to extend their role from information provider to a 
participant in the decision making process (Charles et al., 1997). Shared decision making is a 
form of informed decision making that takes place in a clinical setting and involves the 
interaction between the patient and the health care professionals. A reasoned choice is made 
by the patient using balanced presentation of  evidence in accord with the patients’ values 
(Bekker et al., 1999; Blair & Légaré, 2015).  This decision making process enables both the 
patient and the health care professional to gain an understanding of what is important to the 
patient regarding the treatment choice. Shared decision making has been incorporated into the 
health care policy in Australia, United Kingdom, USA and Canada (BMJ Group, 2012; 
Frosch et al., 2011; Légaré, Stacey, Forest, & Coutu, 2011; National Health and Medical 
Research Council, 2015).  
Despite the presence of the SDM concept since the 1990s the health workforce has 
struggled to incorporate this concept into reality. Several studies have identified sub-optimal 
shared decision making occurring in the context of treatment choices (Barton et al., 2015; 
Song et al., 2013; Song & Ward, 2014). Two of these studies have been undertaken in the 
setting of advanced kidney disease and subsequent treatment choices (Song et al., 2013; Song 
& Ward, 2014). The authors reported that 70% of the participants identified that the risk and 
benefits of dialysis had not been discussed with them (Song et al., 2013). A review of the 
literature identified that patients with advanced kidney disease are not being offered 
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information regarding their treatment choices in a balanced manner (Finkelstein et al., 2008; 
Ludlow, Lauder, Mathew, Hawley, & Fortnum, 2012; Morton, Tong, Howard, Snelling, & 
Webster, 2010; Tong et al., 2014). Evidence suggests that shared decision making has not 
been fully integrated into care of patients with advanced kidney disease (Finkelstein et al., 
2008; Ludlow et al., 2012; Tong et al., 2014; Wong et al., 2016) 
Shared decision making has a pivotal role when there are two or more treatment 
choices that have similar clinical outcomes but a differing impact on quality of life and 
lifestyle. The implementation of SDM can become problematic due to healthcare barriers and 
patient barriers (Bailey et al., 2016). Clinicians are required to share information about the 
risks and burdens of treatment in a setting which is constrained by time, competing tasks, 
patient privacy and lack of training amongst the clinicians (Barton et al., 2015; 
Muthalagappan, Johansson, Kong, & Brown, 2013). Additional barriers to SDM are related 
to the patients’ ability to process this information. These patient barriers include issues such 
as lower education levels, lower health literacy, ethnic diversity and altered cognition due to 
age and frailty (Barton et al., 2015; Muthalagappan et al., 2013). To facilitate SDM in a 
simple and structured manner, and to ensure a balanced presentation of the risk and benefits 
of the treatment options, decision support interventions have been developed for a multitude 
of specialities. The purpose of this study is to examine the effectiveness of the decision 
support interventions in facilitating the older patient with advance kidney disease to make a 
treatment choice that best matches their personal values. In this chapter, the use of decision 
support interventions (DSIs) in chronic disease will be examined and outcome data (decision 
conflict, decision regret, knowledge) discussed. 
2.2  DECISION SUPPORT INTERVENTIONS 
There are many terms in use to describe decision support interventions (DSIs), 
including ‘decision aids’, ‘decision support tools’, ‘shared decision making programs’ and 
‘interactive health communication systems’ (Elwyn, Frosch, Volandes, Edwards, & Montori, 
2010). The use of the term ‘decision support intervention’ is used in this thesis, as a generic 
term that encompasses different types of decision support methods that support patients 
facing health care decisions (Elwyn et al., 2010). Decision support interventions are designed 
to help patients make a specific and deliberate health care choice from the options presented 
(O'Connor et al., 2003). 
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The development of DSIs has progressed over the last fifteen years. The International 
Patient Decision Aid Standards (IPDAS) Collaboration was formed in 2003 for the purpose 
of establishing a shared evidence-informed framework with criteria to improve the 
development, content, implementation and evaluation of DSIs (Elwyn et al., 2006). DSIs 
enable the structuring of evidence-based information regarding treatment choices, in a simple 
unbiased manner. They are designed to enable the patient to make a thoughtful and 
considered decision. The DSIs summarise the evidence from comparative studies within an 
impartial framework adopting a format easily understood by laypeople. Decision support 
interventions aim to help patients identify the value-sensitive nature of the decision and 
subsequently clarify their own individual values in relation to the benefits, harms and 
scientific uncertainties (Ickenroth et al., 2016).  
Health care decisions are regarded as complex when there is uncertainty about  risk and 
benefits with no obvious single best choice (O’Connor et al., 1998a). Decision support 
interventions have been developed to help individuals become involved in making complex 
decisions and as such are recognised as complex interventions (Campbell et al., 2000; 
Campbell et al., 2007). A comprehensive Cochrane Systematic Review titled “Decision aids 
for people facing health treatment or screening decision” was undertaken in 1999 (O’Connor 
et al., 1999) with updates in 2001 (O'Connor et al., 2001), 2003 (O'Connor et al., 2003), 2009 
(O'Connor et al., 2009), 2011 (Stacey et al., 2011) with the most current update published in 
2014 (Stacey et al., 2014). Stacey et al. (2014) reviewed all randomised controlled trials, 
published prior to 30 June 2014, with interventions designed to support the patient in decision 
making. The most recent review will be critiqued within this literature review. The design of 
the search strategy for this literature review took into account the comprehensive nature of 
the Cochrane reviews. This literature review will review the current literature related to 
decision support interventions that have been published since the Stacey et al. (2014) 
systematic review. The literature review search strategy includes all relevant publications 
from 2012 through to March 2016. The strategy will also include other study designs in 
addition to RCTs. Databases search include Reviews-Cochrane Central Register of 
Controlled Trials (CENTRAL), MEDLINE, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), PsychINFO and Academic Elite. The study selection included all 
studies of DSI in chronic disease with English language and age (>65) as limiters. A broad 
definition of DSI was used to encompass any intervention designed to help patients to make 
choices regarding treatment. Chronic disease included: heart failure, diabetes, cardiovascular, 
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cancer, respiratory, chronic obstructive pulmonary disease, chronic kidney disease, arthritis, 
epilepsy and mental illness. Studies were excluded if there were; participants making 
hypothetical decisions; the decision intervention was designed for health care workers; or 
where no outcomes were recorded. The search criteria included chronic disease due to the 
low number of known studies undertaken measuring the impact of DSIs in chronic kidney 
disease. The review will first discuss all the current literature excluding chronic kidney 
disease and the final section will cover the few studies reviewing DSIs and chronic kidney 
disease.  
2.2.1 Review of research into Decision Support Interventions  
A Cochrane systematic review update included all published RCT studies that 
evaluated a DSI as part of the intervention. The review update included 33 new studies for a 
combined total of 115 studies. Of the 115 studies, 76.5% used at least one of the IPDAS 
effectiveness criteria (Appendix A) (Elwyn et al., 2009). These criteria have been categorised 
into:  
1. Choice made attributes (outcomes such as knowledge scores, accurate risk 
perceptions, chosen option congruent with values, informed value-based choice);  
2. Attributes of the decision process (outcomes such as  decisional conflict, patient-
practitioner communication, participation in decision making, proportion 
undecided, satisfaction) (Stacey et al., 2014).  
The review found that 76 of the 115 studies measured the effects of DSI on knowledge. 
Where the DSI was compared to usual care, only 42 studies provided results that could be 
pooled. The DSI achieved a mean difference in knowledge of 13.34% out of 100 (95% CI, 
11.17–15.51: n=42) (Stacey et al., 2014). Interestingly one study reported a higher mean 
difference when the DSI was administered during a clinical consultation (Weymiller et al., 
2007). The participants who received a DSI which included probabilities had improved 
accuracy of risk perceptions (RR 1.82; 95% CI 1.52 to 2.16; n=19). For the studies where 
values clarification were measured DSIs increased the number of participants choosing a 
treatment congruent with their values (RR 1.51; 95% CI 1.17 to 1.96; n=13). The outcomes 
relevant to decision-making process attributes also identified that DSIs are effective in 
lowering decisional conflict (MD -7.26 of 100; 95% CE -9.73 to -4.78; n=22), reducing the 
proportions of participants who were passive in decision making (RR 0.66; 95% CI 0.53 to 
0.81; n=14) and reducing the number of those who remained undecided post DSI (RR 0.59; 
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95% CI 0.47 to 0.72; n=18) (Stacey et al., 2014). Decision support interventions were also 
seen to improve individual-health professional communication. Only nine studies assessed 
this outcome (Stacey et al., 2014). Several of the studies included in this systematic review 
also measured the effect of DSIs on consultation time with results ranging from eight minute 
shorter consultation time to 23 minutes longer (Stacey et al., 2014).  
This review identified a high level of evidence, according to the GRADE criteria, 
demonstrating that DSIs improve knowledge and reduce decisional conflict. The evidence to 
demonstrate that DSIs support patients in becoming more active in decision making and 
improve risk perceptions, is of moderate quality (Stacey et al., 2014). The evidence 
demonstrating congruence between patients’ values and selected treatment option was of a 
low quality (Stacey et al., 2014). There are several limitations to this review and these are a 
critique of the RCTs undertaken rather than the structure and outcomes of this review. The 
RCT studies critiqued in this review have not taken into account the factors such as literacy, 
ethnicity and frailty of the participants. These participant characteristics may have an impact 
on how effective the DSI was in achieving improvement in outcomes. In addition, adherence 
to the chosen treatment has also not been studied. Overall this systematic review is a very 
thorough review of randomised controlled trails measuring the effectiveness of DSIs.  
A systematic review of RCTs for localised prostate cancer examined the effect of the 
DSI on outcomes such as decisional regret, decisional conflict, satisfaction with decision, 
health related quality of life and knowledge (Violette et al., 2015). This review was 
conducted from 1984 to August 2014. The definition of DSI used in this systematic review 
was broader in scope and had differing exclusion criteria, compared with Stacey et al. (2014). 
Studies were not excluded based on DSI format (booklet, online and audio recording) or 
framework. The review included a total of 14 studies which included two studies that have 
been reviewed within the Cochrane Systematic Review (Stacey et al., 2014) described 
previously. The review authors found large heterogeneity for decisional conflict scores, 
satisfaction with decision scores and knowledge score (Violette et al., 2015). Some studies 
found an extremely large effect for decisional conflict (small participant numbers), while two 
large studies (n=324 and n=740) indicated no effect size at all (Violette et al., 2015). Both 
satisfaction with decision and knowledge also reflected these results. Combined estimates 
from two large studies with reliable results found that the DSI achieved a small effect in the 
decisional regret with confidence intervals that included no effect (MD:-3.7; CI-7.4-0.0) 
(Violette et al., 2015). Quality of life was measured in six of the 14 RCTs with only three 
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trials reporting results. The results identified that the DSI had no overall impact on the quality 
of life (Violette et al., 2015). The review also studied the effect of the DSI on treatment 
selection. Stacey et al. (2014) had identified that DSIs reduced the number of people 
choosing discretionary surgery. There were six RCTs comparing treatment choices between 
radical prostatectomy versus radiation therapy. The reviewers found no difference in 
treatment choices between the DSI group and those who received usual care (Violette et al., 
2015).  
Due to the broad definition of a DSI and the inclusion of DSIs regardless of their 
format or framework the outcomes analysed in this systematic review differed from the 
previously discussed systematic review. As noted by the authors the content and method of 
delivery of the DSI (educational rather than interactive) may have an impact on the differing 
outcome results compared with the systematic review by Stacey et al. (2014). Only one of the 
studies reviewed had the DSI facilitating the shared decision making encounter with the heath 
care professional. The studies that chose not to incorporate the DSI within a shared decision 
making encounter may have contributed to some of the negative outcomes recorded.  
The final systematic review to be discussed is a review of decision support 
interventions for cancer screening and treatment. This systematic review appraised evidence 
assessing the effectiveness of a DSI to facilitate decisions regarding cancer screening, cancer 
prevention or early cancer treatment (Triklalinos, Wieland, Adam, Zgodic, & Ntzani, 2014). 
The review also examined DSIs designed for health professionals to assist with promotion of 
shared decision making. There is considerable overlap between the Cochrane systematic 
review and this systematic review with 41 out of 87 studies included in both the Cochrane 
systematic review and this review (Triklalinos et al., 2014). Due to differing inclusion and 
exclusion criteria six studies from the Cochrane systematic review have been excluded from 
this review, and 26 studies, which were excluded from Cochrane systematic review, have 
been reviewed within this appraisal (Triklalinos et al., 2014). Additionally, ten studies have 
been published subsequent to the Cochrane review.  
Of the 87 publications that were synthesised in this review the participants using the 
DSI demonstrated higher knowledge scores compared with control group (MD 0.23; 95% 
credible interval (Crl), 0.09 to 0.35; 42 comparison strata with 12,484 participants) 
(Triklalinos et al., 2014). Decision support interventions also resulted in slightly lower 
decisional conflict score (weighted mean difference = -5.3 units) on the Decision Conflict 
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Scale (DCS) (Triklalinos et al., 2014). No difference was demonstrated in the State-Trait 
Anxiety Inventory Scores (weighted mean difference 0.1; 95% Crl, -1.0 to 0.7). This review 
has been the first to analyse the evolution of DSI delivery techniques over time. Between the 
years of 2010 and 2014 the application of non-human-mediated guidance in the delivery of 
DSI has increased, with a majority of the most recent studies examining the effects of DSIs 
that utilise technology as part of decision making guidance. These DSIs are designed so that 
they are able to elicit preferences explicitly (Triklalinos et al., 2014).  This systematic review 
has demonstrated strong evidence that despite this shift from human-mediated coaching the 
DSIs are still able to increase knowledge without any adverse impact on decisional conflict 
and anxiety. This systematic review adds to the evidence base that supports the use of DSI 
and also highlights that a change in delivery format of the DSI has no negative impact on 
outcomes.   
A pre/post-test study was undertaken, in a primary care setting in the USA, to measure 
individual preferences regarding Prostate Surface Antigen (PSA) screening, readiness to 
decide, preferred role in decision making and knowledge (Barry et al., 2015) . The DSI was 
available online, or in the format of a DVD and booklet. A total of 1,041 participants 
received the DSI either before or after a visit with their primary care clinician and then 
returned the pre-and post-viewing questionnaire (Barry et al., 2015). The results indicated 
key knowledge about PSA screening was high post DSI (Barry et al., 2015). There was a 
change in attitude regarding PSA screening post DSI, with the participants expressing less 
enthusiasm in having PSA screening (Barry et al., 2015). This shift occurred primarily in the 
group who had been uncertain in undertaking PSA screening prior to the DSI (Barry et al., 
2015). This study showed a strong and significant relationship between participants desires to 
engage in a discussion regarding PSA screening with their clinician and the discussion 
actually occurring (Barry et al., 2015).  The results demonstrated how the provision of a DSI,  
before the patient visits a clinician, can influence the content of a clinician visit (Barry et al., 
2015). The study is not an RCT and the participants were selected by the clinicians, with a 
majority of participants predominately white and well-educated. The return rate of the 
questionnaire was only 25% thereby raising the issue of non-response bias. This study 
highlights the lack of evidence available to measure the effectiveness of DSI in vulnerable 
populations. 
Further research to facilitate individual-health professional communication regarding 
prostate cancer was undertaken using a web-based DSI (Davison, Szafron, Gutwin, & 
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Visvanathan, 2014). The study design was one-arm quasi experimental with a total of 49 
participants from a urology clinic in Canada. The participants were newly diagnosed with 
prostate cancer and invited to use the DSI prior to their initial treatment discussion with the 
health professional. The DSI included a summary sheet which the participants had filled out 
to identify their preferences regarding: (i) level of involvement in  treatment decision making; 
education resources they wished to access; (ii) factors influencing their decision and  
(iii) treatment decision (Davison et al., 2014). Results found that a significant proportion of 
participants adopted a more proactive role in treatment decision making than they originally 
intended (Davison et al., 2014). Further results also demonstrated a significant lowering of 
decisional conflict after making a treatment choice compared to the pre-treatment clinical 
consultation (Davison et al., 2014). Evidence from this study suggests that using a DSI assists 
in the facilitation of an individual-health professional consultation within a clinic visit. The 
benefits from this intervention results in: (i) high levels of participant satisfaction regarding 
information provided, (ii) lowered decisional conflict score and (iii) a significant proportion 
of participants playing an active role in decision making (Davison et al., 2014). Despite the 
positive results the small sample size and lack of randomisation makes it difficult to 
generalise these results to the general population and exclude external factors that may 
influenced these outcomes.  
Barton et al. (2015) conducted a pilot study in USA using a literacy appropriate 
medication guide and DSI for participants with rheumatoid arthritis (RA). The study 
population consisted of a control group and two intervention groups, where eligible 
participants were allocated into the three study arms sequentially. After enrolment, but prior 
to the clinic visit, participants in the control arm were given the current medication guide in 
their preferred language. In arms 2 & 3 the participants received an adapted medication 
guide. The adapted guide was designed for low literacy levels. In arm 3, the health 
professionals received the DSI that was to be used during the visit. The use of the DSI by the 
health professionals was discretionary. The adapted medication guide and DSI was developed 
in three different languages (Spanish, English and Chinese) with a Grade 6 reading level. The 
aim of using a low literacy DSI was to help ethnically diverse participants with rheumatoid 
arthritis, choose appropriate management. A total of 166 participants were enrolled from 
ethnically diverse backgrounds. The outcomes included the effect a DSI had on the 
knowledge of rheumatoid medications and level of decisional conflict among ethnically 
diverse populations (Barton et al., 2015).  
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The results found that there was a lower decisional conflict score in the intervention 
group and also an improved knowledge score (Barton et al., 2015). In addition to measuring 
decision conflict and knowledge, Barton et al. (2015) measured the acceptability and 
feasibility of the DSI. The authors found that 78% of the responses from the health 
professionals indicated that they believed the DSI helped with their discussion of medications 
with the participants. Additionally nearly 90% of  the health professionals predicted that the 
DSI would have positive impact on participant knowledge of medication and satisfaction with 
their decision (Barton et al., 2015). The health professionals felt that the DSI was most 
effective when the patient had expressed an interest in participating in decision making 
(Barton et al., 2015). This research demonstrated the ability to lower decision conflict for the 
participants’ and also measured the health professionals’ perception that the DSI was 
effective in addressing participants’ health literacy and enabling improved knowledge of 
medication.  
A multicentre randomised controlled pragmatic trial in 27 clinics in the USA (n=225) 
was conducted to  measure the effect of a decision support intervention for Type 2 diabetes in 
relation to the outcomes of knowledge, decisional conflict and decisional self-efficacy 
(Bailey et al., 2016). The evidence-based DSI was developed in accordance with IPDAS 
criteria (Appendix A) with the subject matter covering topics such as: natural history of Type 
2 diabetes mellitus, full range of treatment options including the benefits and risk of each 
class of medication and a summary fact sheet (Bailey et al., 2016). Simple graphics were 
used, including colour-coded pictographs with plain language summary. The health care 
professionals were blinded to group assignment. The primary outcome of this study was 
knowledge gained about medication with the results identifying a significant improvement in 
knowledge within the DSI group (35% versus 9.9%; p<0.001). The secondary outcomes of 
decisional self-efficacy (3.7 vs -3.9; p<0.001) and decisional conflict (-22.2 vs -7.5; p<0.001) 
were also statistically significant for the DSI group. The blinding of the health professionals 
inhibited the ability of the researchers to provide shared decision making training and 
therefore may have impacted the effectiveness of the DSI and result in an underestimation of 
the impact of the DSI. 
A single blind RCT in the Netherlands (n=1137) studied the effects of a web-based DSI 
regarding diagnostic self-testing (Ickenroth et al., 2016). Participants were blinded for 
randomisation. Outcomes measured were knowledge and informed choice. The results 
demonstrated a significant improvement in the mean knowledge score for the diabetic arm 
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using the DSI (mean score 10.5 +/-SD3.56) versus 9.8 (SD3.71; p=0.031) and a percentage 
with sufficient knowledge of diabetes 67.0% versus 53.5% (p<0.001) (Ickenroth et al., 2016). 
No significant difference was observed for the cholesterol arm (Ickenroth et al., 2016). The 
DSI also increased the number of participants that believed they had made an informed 
choice in the diabetes group (42.9% versus 31.5%; p=0.013) with no significant difference in 
the cholesterol group (Ickenroth et al., 2016). It is difficult to determine why the DSI 
increased knowledge and informed choice in the diabetes arm only. The rationale may be that 
because diabetes is a disease with clear risk factors, with a single investigation to identify the 
presence of diabetes. In contrast cholesterol is a risk factor for multiple diseases and needs to 
be interpreted in conjunction with other risk factors. The explanation of a cholesterol level is 
far more challenging than explaining the result of diabetes self-test. Despite the well-
structured RCT for this study, patient selection was via the internet which may have resulted 
in selection bias toward higher educated participants and thus an overestimation in the 
knowledge score. The study only measured the intention to undertake a self-test and no 
follow-up was undertaken to record whether the participants then followed through with 
undertaking the test.  
The final study to be reviewed is a pilot study conducted in the USA to measure the 
impact of a DSI on reducing uncertainty in women in their 40s, considering mammography. 
Pre-test post-test study design was commenced with a convenience sample of 51 women 
recruited to test the influence of the DSI on decisional conflict and treatment choice (Scariati, 
Nelson, Watson, Bedrick, & Eden, 2015). The results demonstrated that the DSI significantly 
reduced overall decisional conflict (p<0.001) but showed no change in screening intention 
(p=0.132) (Scariati et al., 2015). The results of this study have demonstrated that a DSI can 
lower decisional conflict for those women in their 40s considering mammography. The DSI 
also helped the participants to feel better informed and better supported in making their 
decision and assisted the participants to clarify their values. A contributory factor towards the 
DSI not being able to demonstrate any significant effect on treatment intention may be the 
participants baseline beliefs regarding mammography and risk of breast cancer (Scariati et al., 
2015). Additionally, a large number of participants had previously undertaken 
mammography. The study design (pilot study) and the selection process for recruitment 
(convenience sample), makes it difficult to extrapolate positive results gained here to the 
general population. However, it did identify that the DSI lowered decisional conflict and this 
should be investigated further in a larger well-designed study. 
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A majority of the studies (Bailey et al., 2016; Barry et al., 2015; Barton et al., 2015; 
Davison et al., 2014; Ickenroth et al., 2016; Scariati et al., 2015) including the systematic 
review by Stacey et al. (2014) identified that DSIs were able to improve outcomes such as 
knowledge and decisional conflict. These findings were also supported by the systematic 
review by Triklalinos et al. (2014). This review was also able to demonstrate that a DSI 
designed with the capability of eliciting preferences explicitly doesn’t necessarily require the 
patient-health professional interaction. The systematic review undertaken by Violette et al. 
(2015) failed to demonstrate any effect of the DSIs on decision conflict or knowledge. A 
contributing factor to this outcome is the use of the DSI as an educational tool for some of the 
studies reviewed. This systematic review suggested that the delivery of DSIs be incorporated 
as part of shared decision making process and not to be used independently as an information 
tool. This review of literature identified the effectiveness of DSIs in lowering decisional 
conflict and improving knowledge for a variety of chronic disease conditions.  
2.2.2 Chronic Kidney Disease Decision Support Interventions  
There is limited research on the effectiveness of DSIs in the setting of chronic kidney 
disease. The Cochrane systematic review discussed earlier identified only one DSI specific to 
kidney disease (Manns et al., 2005). This was excluded from the review (Stacey et al., 2014) 
as the intervention was not designed to give the patient a choice. A systematic review by 
Murray et al. (2009) focussed on examining factors influencing decision-making in adults 
living with chronic kidney disease. The authors appraised 40 studies and found four patient 
DSIs, however none of these had been evaluated for effectiveness (Murray et al., 2009). The 
systematic review, failed to identify any studies where patient related outcomes were 
measured. 
A systematic review of the literature (Murray et al., 2009) identified three DSIs related 
to CKD, with three excluded from further analysis. The excluded studies included an online 
tool which had not been evaluated for effectiveness (Healthwise, 2013). The second study 
described the development and validation of a DSI to guide patients in RRT selection 
(Ameling et al., 2012). The main purpose of this study was to design and describe the 
development of the DSI not to evaluate the effectiveness (Ameling et al., 2012). The final 
study was a decision support guideline (Registered Nurses' Association of Ontario, 2009). 
This decision support guideline focussed on giving nurses skills to recognise individuals who 
may be experiencing decisional conflict and to encourage involvement of the individual with 
CKD in reaching quality health decisions (Registered Nurses' Association of Ontario, 2009). 
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This guideline is a useful resource and recognises the importance of utilising a DSI within the 
decision making process but includes no evaluation of DSIs. 
A large observational, prospective multicentre registry was conducted in 26 Spanish 
hospitals (n=1044), to measure the impact of a structured education program including a DSI 
to guide patients to choose a RRT modality (Prieto-Velasco, Quiros, & Remon, 2015). This 
study was primarily concerned with how education and the DSI influenced treatment choice. 
The researchers measured the impact the DSI had on concordance between the patients’ final 
choice and definitive modality. The DSI group had a significantly higher level of 
concordance with kappa value of 0.91 (95% CI, 0.86–0.95) even in the setting of an 
unplanned start to dialysis (Prieto-Velasco et al., 2015). The outcome of this research 
identified that the DSI resulted in significantly less decisional changes compared with those 
who didn’t receive the DSI as part of the education process (Prieto-Velasco et al., 2015). The 
authors also determined a timeframe within which a firm decision is made—2.6 visits with 
the median time until final choice of 1.8 months (Prieto-Velasco et al., 2015). It is important 
to note that the DSI was part of implementation of a structured education process and the 
overall significant results may be attributable to structured education process not the DSI 
alone.  
Winterbottom et al. (2015) conducted a prospective non-randomised comparison study 
in six renal centres in the United Kingdom. The outcomes that were evaluated included:  
(i) usefulness of the DSI, (ii) decision making process including decision preference and  
(iii) decision conflict scale. Of the 274 who consented to take part, only 57% completed both 
questionnaires. The DSI group had higher scores for the usefulness of written information to 
support understanding about kidney disease and dialysis options, clarity of thinking about 
decision, feeling in control of their decision and including their family in the decision making 
process (Winterbottom et al., 2015). The decisional conflict score for the DSI group was low 
but did not reach statistical significance. The study design meant the researchers were reliant 
on voluntary uptake of the DSI by clinicians’ and also voluntary completion of the 
questionnaire by the patients. This may have led to result not fully representative of the 
impact of the DSI. 
Fortnum, Grennan, and Smolonogov (2015b) conducted an Australian multisite pre-
test, post-test study evaluating the impact of a DSI called ‘My kidneys, My choice’. Ninety-
seven participants complete the pre-test survey and 72 (70%) the post-survey. The post-
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survey was only completed once the participant had made a treatment decision. The outcomes 
measured were self-reported knowledge levels, usability of the DSI and treatment decision 
(Fortnum et al., 2015b). The results indicated that the DSI improved knowledge levels 
significantly (p<0.001). The DSI was rated highly by the participants (4.76/5: SD 0.61) and 
where participants reported sharing the DSI with their family there was significant correlation 
with the family member being involved in the decision making process (Fortnum et al., 
2015b). The authors did not measure decisional conflict so it was difficult to ascertain if all 
the patients made a decision that best matched their values.  
Results from the study indicate that 62% of people selected a home dialysis, 11% in 
centre haemodialysis, 16% transplantation and 11% conservative care as their first choice 
(Fortnum et al., 2015b). The authors also had the participants self-report their level of worry, 
flexibility and control. Following education and the use of the DSI, the participants reported 
statistically significant higher levels of worry (Fortnum et al., 2015b). It is difficult to explain 
this as decision support interventions are designed to lower decisional conflict and 
uncertainty. The authors postulated that the reality of understanding the impact of the 
treatment without actually experiencing the treatment has generated this high level of anxiety. 
However, this significant level of worry may be due to the fact there is a high level of 
decisional conflict, indicating that the DSI didn’t fully support the patient in choosing the 
treatment that best matches their personal values.  
The current research examined in this literature review suggests that DSIs improves the 
patients’ knowledge of treatment choices (Fortnum et al., 2015b; Winterbottom et al., 2015). 
Prieto-Velasco et al. (2015) identified high level of concordance between treatment decision 
and definitive modality. This may represent a similar outcome to Winterbottom et al. (2015)  
who demonstrated that the DSI resulted in higher scores in relation to the clarity of which 
they could balance their decision in accordance with their values. Compared to the high 
quality studies undertaken in other areas of chronic disease, where there is a high level of 
evidence demonstrating that DSIs can increase knowledge and lower decisional conflict, the 
outcomes from CKD research is of low quality. There have been no RCTs undertaken, with 
results reported from observational studies having a high risk of bias and confounding. All of 
the studies reviewed have focussed primarily on guiding RRT choice with minimal emphasis 
on the treatment choice of non-dialysis management.  
Research in other areas of chronic disease have identified the effectiveness of decision 
support interventions; however, there remains a significant gap in research evaluating the use 
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of decision support interventions in CKD. Within the literature review no studies have been 
identified evaluating the use of a DSI to help patients choose between dialysis or non-dialysis 
management. The paucity of research has led to the development of a DSI to guide the older 
patient with advanced kidney disease to make a treatment choice between dialysis or non-
dialysis management. 
To guide the development of a decision support intervention, based on best quality 
evidence, a systematic review was undertaken aimed at examining comparative studies 
undertaken for patients with CKD who are 65 years or older.  The systematic review using 
the Joanna Briggs systematic review framework has been published (Brown et al., 2014).  
The results of the systematic review were used to inform the content of a decision support 
intervention. The effectiveness of this DSI will then be tested in a pragmatic randomised 
controlled study.   
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START OF PUBLISHED MANUSCRIPT 
2.3 SYSTEMATIC REVIEW 
2.3.1 Review Title 
A comparison of treatment options for management of End Stage Kidney Disease in 
elderly patients:  A systematic review 
2.3.2 Objectives of the Systematic Review 
The primary objective was to assess the effect of dialysis compared with non-dialysis 
management for the population of 65 years and over with ESKD in terms of survival, quality 
of life, functional capacity, symptoms and hospital admissions.  
2.3.3  Inclusion criteria 
Types of participants 
This review considered studies that included participants 65 years and older. These 
participants needed to have been diagnosed with ESKD for greater than three months and to 
be either receiving RRT (haemodialysis or peritoneal dialysis) or non-dialysis management. 
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The settings for the studies were home, self-care centre, satellite centres, hospital, hospice or 
nursing homes. 
Types of intervention(s)/phenomena of interest 
This review considered studies where the intervention was RRT (peritoneal or 
haemodialysis) for the participants with ESKD. There are several types of RRT and the 
prescription for RRT can vary as well. RRT can be provided in different settings (hospital, 
satellite unit or home) using different techniques (traditional haemodialysis, nocturnal 
haemodialysis, short daily haemodialysis, continuous ambulatory peritoneal dialysis, 
automated peritoneal dialysis). There was no restriction on frequency of dialysis or length of 
time the participant received dialysis. The comparator was a participant not undergoing 
dialysis. Non-dialysis management (NDM) is a term which encompasses healthcare involving 
ongoing follow-up and multidisciplinary support to people who have ESKD and choose not 
to start dialysis (Murtagh et al., 2007b). Other terms used to describe this type of care are 
“conservative management”, “non-dialysis management”, “renal supportive care” and 
“palliative renal care”. 
Types of studies 
This review considered both experimental and epidemiological study designs including 
randomized controlled trials, non-randomized controlled trials, quasi-experimental, before 
and after studies, prospective and retrospective cohort studies, case control studies and 
analytical cross sectional studies. 
This review also considered descriptive epidemiological study designs including case 
series, individual case reports and descriptive cross sectional studies for inclusion. 
Types of outcomes 
This review considered studies that included either the primary outcome or any of the 
secondary outcomes: 
Primary Outcome: 
•  The effects of dialysis on length of survival in older people (65 years and 
over) with ESKD (GFR<15mL/min/1.73m²) compared with non-dialysis 
management. 
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Secondary Outcomes: 
•  The effects of dialysis on quality of life in older people (65 years and over) 
with ESKD (GFR<15mL/min/1.73m²) compared with non-dialysis 
management; 
•  The difference in functional capacity in older people (65 years and over) with 
ESKD (GFR<15mL/min/1.73m²) on dialysis compared with those on non-
dialysis management; 
•  The difference in the number and severity of symptoms in older people (65 
years and over) with ESKD (GFR<15mL/min/1.73m²) on dialysis compared 
with those receiving non-dialysis management; 
•  The difference in the rate of hospital admissions for older people (65 years and 
over) with ESKD (GFR<15mL/min/1.73m²) on dialysis with those receiving 
non-dialysis management. 
ESKD is defined as an estimated glomerular filtration rate (eGFR) of less than 
15mL/min/1.73m² (National Kidney Foundation, 2002). Dialysis includes both haemodialysis 
and peritoneal dialysis (Daugiradas, 2007). 
2.3.4 Search strategy 
The search strategy aimed to find both published and unpublished studies up to 
November 2012. A three-step search strategy was utilized in this review. 
Electronic searches 
An initial limited search of MEDLINE and CINAHL was undertaken.  This was 
followed by analysis of the text words contained in the title and abstract, and of the index 
terms used to describe the article. A second search using all identified keywords and index 
terms was then undertaken across all included databases. Thirdly, the reference list of all 
identified reports and articles were searched for additional studies. There was no restriction 
by date range and only studies published in English were considered.   
The databases searched included: 
 MEDLINE 
 CINAHL 
 PsycARTICLES 
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 EMBASE 
 Cochrane Central 
 Scopus 
 ProQuest 
 Web of Science 
 Science Direct 
The grey literature search consisted of contacting key authors who may be 
knowledgeable about the phenomena of interest so that further unpublished or ongoing 
studies may be identified. In addition, an online search of databases and websites were 
conducted including: 
 • MedNar 
 •National Institutes of Health (NIH) Clinical Trials Database host, 
(http://clinicaltrials.gov/ct) 
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Table 2.1. Search Strategy for EBSCO 
Search ID Search Terms Search Options Databases 
S1 Dialysis OR “Renal 
Replacement Therapy” OR 
“Kidney Replacement 
Therapy” OR RRT OR 
KRT 
Limiters – English 
Language, Age Related:  
Aged 65+ years 
Search modes –
Boolean/Phase 
Academic Search Elite; 
CINAHL with full text; E-
Journals; MEDLINE; 
MEDLINE Complete; 
PsycARTICLES 
S2 “non-dialysis management” 
OR “conservative 
management” OR 
“palliative care” OR 
“supportive care” 
Limiters – English 
Language, Age Related:  
Aged 65+ years 
Search modes –
Boolean/Phase 
Academic Search Elite; 
CINAHL with full text; E-
Journals; MEDLINE; 
MEDLINE Complete; 
PsycARTICLES 
S3 S1 and S2 Search modes – 
Boolean/Phase 
Academic Search Elite; 
CINAHL with full text; E-
Journals; MEDLINE; 
MEDLINE Complete; 
PsycARTICLES 
All studies identified during the database search were assessed for relevance to the 
review based on the information provided in the title and the abstract. A full copy of the 
article was retrieved for all studies that appeared to meet the inclusion criteria. Studies 
identified by study title from reference list searches were assessed for relevance based on 
their abstract and if suitable the full article was retrieved (Appendix B). 
2.3.5 Method of the review 
Two reviewers and an associate reviewer independently assessed the papers selected for 
retrieval. The reviewers who undertook this review used a standardized appraisal instrument. 
In the assessment process a standardised appraisal instrument, the Joanna Briggs Institute 
Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix 
B) was utilised. 
2.3.6 Data collection 
Quantitative data was extracted from the included papers using the standardized data 
extraction tool from JBI-MAStARI (Appendix C). Details regarding the type of participants, 
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the comparison between dialysis and non-dialysis management, the number of participants 
and the outcomes (e.g. quality of life, comorbidities, survival, hospital admissions, functional 
capacity and symptoms) were extracted. 
2.3.7 Data synthesis 
Meta-analysis of the data was not possible due to the difference in clinical and 
methodological dimensions, outcome measurements and heterogeneity of the study 
population.  A narrative summary of the results from the included studies has been 
undertaken by the authors. 
2.3.8 Results 
Description of studies 
The search revealed 1820 potential articles for consideration. An initial review of titles 
and abstracts excluded 1799 as not meeting the inclusion criteria. The remaining 24 articles 
were then retrieved in full (see Appendix D). Of these, 20 articles were excluded as not 
meeting the inclusion criteria (Appendix E). The remaining 4 studies were included in the 
review. Figure 2.1 illustrates the search strategy.   
Methodological quality 
The search process involved independent appraisal by two reviewers of the 24 full text 
papers. An associate reviewer was also used to confirm the assessment of methodological 
quality for the final four papers. All studies were observational in their study design. Murtagh 
et al. (2007b) was retrospective and the other three studies were prospective. De Biase et al. 
(2008) was excluded on the basis of study design, bias, process of dealing with confounders, 
small sample size and no valid comparator group. This study was not included in the review. 
Table 2.2  outlines the studies and the JBI level of evidence. 
  
Leanne Brown 
Chapter 2 | Literature Review 27 
 
Table 2.2. Studies included in Review 
Reference Study Design Comparator 
Y/N 
JBI Level of 
evidence 
Carson et al. (2009) Prospective cohort study of participants 
with GFR < 30 and age >= 70 years 
receiving either dialysis or NDM 
Y 3 
Joly et al. (2003)  Prospective cohort study with 
retrospective analysis of participants with 
CrCl < 10 and age => 80 receiving either 
dialysis or NDM 
Y 3 
Murtagh et al. 
(2007b) 
Retrospective cohort study of participants 
with GFR < 15 and age >= 75 receiving 
either dialysis or NDM 
Y 3 
GFR - Glomerular Filtration rate; NDM - non-dialysis management; CrCl – Creatinine 
Clearance calculated by Cockcroft and Gault (Cockcroft & Gault, 1976) 
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Potentially relevant papers
Identified by literature search (Search strategy was 
over a number of databases and search criteria kept 
broad to avoid missing any unknown research)
n=1820
Duplicate citations removed
n=71
Papers retrieved for full text examination
n=24
Papers assessed for methodological quality
n=4
Citations excluded after evaluation of title and 
abstract
n= 1796
Papers excluded after review of
full text- reasons included no comparison between 
groups or age of participants were not >= 65
n=20
Appendix III illustrates the characteristics of all of 
the excluded studies.
Papers excluded after assessment of 
methodological quality
n=1
Papers included in the systematic review 
n=3 
 
Figure 2.1. Flowchart of study retrieval and selection 
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Summation of the studies  
All three included studies were observational cohort in design (Table 2.2). Using the JBI 
levels of evidence rating, all studies were rated as 3. The lack of randomized controlled trials 
illustrates the ethical challenges confronting researchers in randomizing an individual to 
receive either dialysis or non-dialysis management. Dialysis is a life sustaining treatment and 
to randomize people over 65 to not receive this treatment would be unacceptable to clinicians 
and researchers and unlikely to gain Human Research Ethics Committee approval (Dasgupta 
& Rayner, 2009). 
The geographic location of the studies varied, with two studies conducted in the United 
Kingdom (Carson et al., 2009; Murtagh et al., 2007b) and one in France (Joly et al., 2003).  
The number of participants varied between studies, as did the length of time for recruitment 
and follow-up. Bias was present and reported as a limitation in all three studies. The source of 
bias was primarily related to lack of control over allocation of participants to the intervention 
and the comparator groups. The comparator or control group was not matched with the 
intervention group. The demographic differences between these groups will be discussed 
further on in this review. The studies have identified confounders such as age, late referrals, 
treatment choice, and treatment prescription, vascular access at time of receiving treatment, 
gender, comorbidities and diabetes. The outcomes from the studies differed and statistical 
analysis has been undertaken differently for the separate studies (see Table 2.3, page 31).  
Murtagh et al. (2007b) undertook a retrospective cohort study of participants who 
received dedicated multidisciplinary care during the time period of 1 September to 31 August 
2004 with the study end point date being 30 June 2005. A total of 129 people were selected, 
all aged over 75 years and predicted to need renal replacement therapy (RRT) within the next 
18 months; 52 were in the dialysis group and 77 in the non-dialysis group (Murtagh et al., 
2007b) . Participants excluded from the study were those with an eGFR< 15mL/min/1.73m² 
(calculated using Modification of Diet in Renal Disease formula—MDRD (Levey & Bosch, 
1999)), who presented late and those who had incurable solid organ malignancy.  
Murtagh et al. (2007b) excluded late presenters as they were not seen in the 
multidisciplinary clinic where there is dedicated education, psycho-social support and 
intensive support regarding decision making. The limitations within this study design were 
that the authors were unable to review outcomes such as functional performance scores, 
quality of life and cause of death.   
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Joly et al. (2003) performed a retrospective analysis of a prospectively followed cohort 
study over a twelve-year period. There were 146 participants aged over 80 years who were 
referred to one nephrology centre and included in this analysis (Joly et al., 2003). These 
participants all had ESKD with an eGFR of 10mL/min/1.73m² (according to Cockcroft-Gault 
formula (Cockcroft & Gault, 1976)) or less and were not yet receiving RRT. Those with 
acute reversible kidney failure, or who started dialysis outside of the nephrology centre and 
those who turned 80 after starting dialysis, were excluded from this study. The prospective 
nature of the recruitment enabled outcomes such as functional performance scores, cause of 
death, hospital admissions and demographic data to be collected and included in the study. 
Carson et al. (2009) conducted a prospective cohort study of 202 participants (70 yr) 
who had ESKD. Participants were identified and followed up over a six-year period. All 
individuals who commenced on RRT and were 70 years were included in the intervention 
group for the study and all participants who were being managed in the low kidney function 
(clearance) clinic and had chosen NDM were included in the control group. The individuals 
were followed from the time of first dialysis or when the referral had been made for NDM. 
No set eGFR was used as a starting point for measurement of survival outcomes. Instead the 
authors performed an individual regression analysis of eGFR versus time for each person in 
the intervention group (RRT) to calculate a “threshold eGFR” (Carson et al., 2009). The 
median eGFR (MDRD formula) at start of dialysis was 10.8 mL/min/1.73m² (Carson et al., 
2009). The main outcome was survival (using Kaplan-Meier survival curve), rates of 
hospitalization (days/patient/year) and location of death (home/hospice/hospital/unknown).  
The timing of referral to the renal service was also taken into account within the survival 
outcomes. If the person was referred < 4 months to the service before starting dialysis/similar 
point in NDM, they were categorized as a late referral. The functional performance score was 
not collected nor was quality of life measured. The reason for absence of this data was not 
explained.  
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Table 2.3. Studies included in Systematic Review and summation of results 
Study type – 
Observational 
Non dialysis group Dialysis Group Results 
Joly et al., 
France, 2003 
(Joly et al., 
2003)  
Mean age 84.1 years 
N=37 
eGFR < 10mL/min/1.73m² 
diabetes 21.6% (p=0.008) 
IHD 48.6% 
Socially isolated  
43.3 % 
Karnofsky score 
55  18 (p=0.03) 
serum phosphate (mmol/L) 
1.6 0.4 
Mean age 83.2 years 
N = 107 
eGFR < 10 
mL/min/1.73m² 
diabetes 6.5%  
IHD 42% (nss) 
Socially isolated 
14.7% (p<0.003) 
Karnofsky score 
63  20  
serum phosphate 
(mmol/L) 1.9 0.5 
(p=0.013) 
Median survival (unadjusted) 8.9 months (95% CI, 4 to 
10) in NDM and 28.9 months in RRT (95% CI, 24 to 38) 
P<0.0001. 
12 and 24month survival rates were 73.6% and 60% in 
dialysis group versus 29% and 15% for NDM. 
 
Murtagh et al,  
United 
Kingdom, 2007 
(Murtagh et al., 
2007b) 
Median age 83 yrs 
N=77 
eGFR < 15mL/min/1.73m² 
diabetes 25% 
Median age 79.6 
(P<0.001) 
n=52 
eGFR < 
15mL/min/1.73m² 
diabetes 23.4%  
Median time to death from eGFR 15mL/min/1.73m² to 
death was 18 months in NDM and 19.6 months on 
dialysis. 
Modality choice (Regression coefficient 1.128 P<0.001), 
age (Regression coefficient 0.061 p< 0.028) and co-
morbidity (Regression coefficient   0.408 P<0.081).  Co-
morbidity was the most strongly associated with survival. 
Carson et al, 
United 
Kingdom, 2009  
 
(Carson et al., 
Median age 83  
N=29 
Diabetes 13.8% 
CCI = 3.7 (mean score) 
Median age 76.4 
(P<0.0000001) 
N=173 
Diabetes = 29.5% (NS) 
CCI = 4.0 (mean score) 
Median unadjusted survival for RRT 37.8 months 
compared with 13.9 months for NDM individuals (p= 
0.010)  
After exclusion of first 90 days of dialysis survival 41.9 
months for RRT and 14.8 months for NDM. 
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Study type – 
Observational 
Non dialysis group Dialysis Group Results 
2009) 
  
Hospitalization rates for RRT group was 0.069 (95% CI 
0.068 to 0.070) hospital days per patient days survived 
(25 days per patient per year) compared with   0.043 
(95% CI 0.040 to 0.047) hospital days per patient-days 
survived (16 day per patient per year) for the NDM 
group. No p value reported 
Individuals who chose NDM had 4 fold greater chance of 
dying at home or in hospice than those in RRT cohort 
(OR 4.14) 
 
CCI—Charlson Comorbidity Index; RRT—renal replacement therapy; NDM—non-dialysis management; IHD—ischaemic heart disease; CI—
confidence interval; nss—not statistically significant; ss—statistically significant 
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In all three studies the common outcome of interest was measurement of 
survival. In two studies (Carson et al., 2009; Murtagh et al., 2007b) there was an age 
difference between the intervention and control group that was statistically 
significant as identified in Table 2.3. In all studies there was no age matching and 
within data analysis there was no stratification.  There was also no sub-analysis 
comparing similar cohorts/age groups within these studies. This makes it difficult to 
establish an association between the intervention and outcome. An age difference 
was found by the Murtagh et al. (2007b) study with a far greater number of 75–79 
years old in the treatment group and the control group (NDM) having a higher 
number in the 85–89 year old group. The study undertaken by Joly et al. (2003) 
showed no statistical significance in age differences, however this was most likely 
due to age of the study individuals (age 80 years and over). 
Confounders in the studies 
The potential confounders in the three studies were demographic 
characteristics, time of referral to nephrologist, vascular access at start of dialysis and 
presence of acute kidney injury. Several studies have found that late referral to 
nephrologist and vascular access have altered outcomes (Chan, Dall, Fletcher, & 
Trivedi, 2007; Foote et al., 2012). There is also growing evidence regarding the 
impact of acute kidney injury on long-term outcomes for individuals (Chawla & 
Kimmel, 2012). These confounders have the potential to alter the primary and 
secondary outcomes as the differences in outcomes may be due to the confounders 
and not the intervention.  
Joly et al. (2003) found several differences in the characteristics between the 
groups in their study. The individuals in the control group (NDM) had a lower 
Karnofsky score (functional performance score), were more likely to be socially 
isolated, referred late to the renal service and had a higher incidence of diabetes 
mellitus (Joly et al., 2003). These differences all reached statistical significance. The 
other two studies (Carson et al., 2009; Murtagh et al., 2007b) only describe age as a 
possible confounder with similar disease characteristics between groups such as 
diabetes or IHD as seen in Table 2.3. 
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Length of Study 
The time frame for recruitment and data collection for each of the studies 
varied and did not appear to be based on study design elements. There was no 
calculation or discussion around the length of the studies. This was most probably 
because these studies were some of the first comparative studies to be conducted and 
it was difficult to determine the average length of time an individual could live for on 
NDM. A study conducted over a short time frame such as six months may not result 
in many deaths and therefore it would be difficult to calculate and compare survival 
rates between groups. Murtagh et al. (2007b) selected individuals who received 
multidisciplinary care over a 12-month period with follow-up for another 10 months. 
Carson et al. (2009) had a longer time frame and recruited all individuals during a 
seven-year period, which had started dialysis. In Carson et al. (2009) study, the NDM 
population was recruited from the time of decision to receive NDM and tracked until 
death or end of the study nine years later. Joly et al. (2003) recruited all 
octogenarians (80 years and over) consecutively over a 12-year period from a single 
centre. The rapid drop in participants due to death appeared to occur in the first 24 
months for all studies, which indicates that Murtagh et al. (2007b) study (covering a 
12-month period) would have captured a rich source of data within an adequate time 
frame. 
Survival Rates 
The primary outcome for all three studies was survival from time of 
recruitment to the study’s end-point (death or end of study). The survival rates have 
been summarised in Table 2.3. Murtagh et al. (2007b) found a median survival of 18 
months for the NDM group and 19.6 months in the RRT group. The median survival 
in Joly et al. (2003) study differed (8.9 months for the NDM group and 28.9 months 
for the RRT group) which may possibly be due to the older age of this sample 
compared with the other studies. In Joly et al. (2003) study there was no statistical 
difference in age between the RRT group and NDM group. Carson et al. (2009) 
reported a median survival of 13.9 months for the NDM group and 37.8 months for 
the RRT group. When Carson et al. (2009) excluded late or emergency referrals and 
data related to first 90 days receiving dialysis, the survival extended to 43 months for 
RRT and 25.8 months for NDM. This difference after adjustment was not 
statistically significant. The variation in age of the population for all three studies 
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and the different survival data collected makes it difficult to pool these results and 
generalize regarding outcomes for RRT versus NDM.   
Recruitment Process of participants 
In all three studies, participants were recruited through multidisciplinary clinics 
of the renal department. A General Practitioner or Family Physician referred the 
participants to the clinics. The outcomes from these studies are therefore only 
applicable for similar individuals who are managed within the nephrology clinics. 
All three studies provided education and clinical management via a 
multidisciplinary service with a shared decision making approach between 
individuals, families and health professionals. This method of selection for the 
intervention (RRT) and comparator (NDM) groups leads to a selection bias, which 
was identified by authors of the three studies. Murtagh et al. (2007b) reported no 
difference between groups in terms of comorbidities although given the selection 
process, it could have been expected that a higher number of individuals with 
comorbidities were referred for NDM. In Joly et al. (2003) study where the 
population was older, there was a statistically significant difference between groups 
in social isolation, functional performance score (Karnofsky), late referral, diabetes 
and serum phosphate score as identified in Table 2.3 (Joly et al., 2003). The NDM 
group had lower functional performance (Karnofsky) scores, greater social isolation, 
later referral, higher number of people with diabetes and lower serum phosphate 
levels (Joly et al., 2003). In Carson et al. (2009) study there was no difference 
between the selected characteristics of each group (with the exception of age which 
has been discussed elsewhere).   
Participants in the Studies 
The participants involved in the three studies were all 65 years and over, with 
their clinical management conducted through a multidisciplinary clinic. The 
participants all had ESKD. The intervention was primarily haemodialysis with a 
small group in Carson et al. (2009) study receiving peritoneal dialysis. There was 
some difference in age and gender distribution between the studies. In Joly et al. 
(2003) study there was an uneven distribution of gender with a greater number of 
females in the NDM group although this did not reach statistical significance. 
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Description of Intervention 
The intervention for all three studies was renal replacement therapy (RRT), or 
as described in the studies—dialysis. Within and between each of these treatments, 
the outcomes can vary depending on the dialysis prescription (e.g. number of dialysis 
hours, blood flow rate) and type of access (i.e. fistula, temporary or permanent 
haemodialysis catheter). None of the studies described the setting for haemodialysis 
(e.g. in centre dialysis, home dialysis) which also may have an impact on the 
outcome. 
All three studies compared outcomes between RRT and NDM. Joly et al. 
(2003) described RRT as being haemodialysis with a target urea reduction ratio 
≥65%, thrice weekly treatment, bicarbonate dialysate, high flux dialyser membrane. 
This is the only study that describes the intervention in any detail. 
The RRT options in Carson et al. (2009) study included haemodialysis (HD) 
and peritoneal dialysis (PD), although the treatment parameters were not described. 
The individuals who received PD were excluded from the rate of hospitalization 
calculations, although no rationale was provided. Murtagh et al. (2007b) did not 
describe the type of dialysis at all. This may be because the authors have assumed 
equal outcomes for all types of dialysis or because the dialysis delivered was the 
most common form (HD), with the prescription of this being set to achieve a Urea 
Reduction Ratio of ≥65%. 
When comparing outcomes between individuals who received the intervention 
(i.e. RRT) and control (NDM), there needs to be clarity around how and where the 
intervention was delivered as there may be differing outcomes between individuals 
who receive the two included types of RRT.  
Description of Comparator 
The comparator group is non-dialysis management (NDM). NDM, as described 
by Joly et al. (2003) and Carson et al. (2009), involves regular follow-up with the 
general practitioner focusing primarily on symptom management (fluid overload, 
anaemia and uremic symptoms), and psychological, social and spiritual support. The 
selection of participants to this group in all three studies was undertaken at a 
multidisciplinary team discussion either in a clinic setting (Carson et al., 2009; 
Murtagh et al., 2007b) or at a patient review meeting (Joly et al., 2003). In addition 
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some of the individuals in both the Carson et al. (2009) and Joly et al. (2003) studies 
who were selected to be appropriate for the intervention group, also chose to receive 
NDM. 
Metrics and Statistical Analyses  
The objective of all three studies was to compare clinical outcomes between 
the intervention group (those receiving RRT) and the control group (those receiving 
NDM) in the older person. The metrics differ between each study in this review, with 
survival data and some demographic characteristics the only common element 
between studies. In two studies (Joly et al., 2003; Murtagh et al., 2007b), the timing 
of data collection was based on the individual’s eGFR whereas survival in Carson et 
al. (2009) study was calculated from the date of dialysis initiation or a comparative 
time point for NDM. (Joly et al., 2003) collected data and undertook survival 
calculations when the eGFR was approximately 10mL/min/1.73m² or less.  
Murtagh et al. (2007b) collected the data and calculated survival from eGFR 
15mL/min/1.73m² or less. This difference in collection of data may have resulted in 
Murtagh et al. (2007b) capturing a greater number of deaths and also a greater 
number of individuals not yet starting dialysis. The mean eGFR of individuals in 
Murtagh et al. (2007b) study who started dialysis was 8.1 mL/min/1.73m² with eight 
people in the dialysis group dying before reaching this point. In Joly et al. (2003), 
there was no recorded mean eGFR for those individuals who started dialysis. In the 
Carson et al. (2009) study the mean eGFR was 10.8mL/min/1.73m², 
2.8mL/min/1.73m² higher than Murtagh et al. (2007b) study. Whether this result was 
significant in terms of outcomes and comparison of outcomes was difficult to 
determine (Carson et al., 2009; Joly et al., 2003), as not only was the starting eGFR 
different but the methods of calculating the eGFR was also different. It was not 
possible to compare the survival outcomes between each study as the baseline at 
which the data was collected differed.  
The other outcomes measured in all three studies were age, presence of 
diabetes and comorbidity score. The difference in age was statistically significant in 
both Murtagh et al. (2007b) and Carson et al. (2009) studies, with no difference in 
Joly et al. (2003) study. In Murtagh et al. (2007b) and (Carson et al., 2009) studies, 
there was no difference between groups with respect to the number of people with 
diabetes and ESKD. There was however, a statistically significant difference in the 
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number of people with diabetes in the RRT and NDM groups in Joly et al. (2003) 
study. This difference is of clinical relevance as diabetes is a comorbidity and could 
affect physician decisions regarding recommendation for NDM (Carson et al., 2009). 
Despite the presence of diabetes, this comorbidity alone did not influence one-year 
survival in any of the studies.  
Table 2.3 identified the survival outcomes and the variation between studies, 
Murtagh et al. (2007b) reported that dialysis provides a survival advantage with one 
year survival rate for the intervention group (RRT) being 84% and 68% for the 
control group (NDM).  The median time from eGFR of 15mL/min/1.73m² to death or 
end of study was 19.6 months for intervention group (RRT) and 18.0 months for 
control group (NDM) (Murtagh et al., 2007b).  Joly et al. (2003) found a median 
survival of 28.9 months for the intervention group (RRT) and 8.9 months for the 
control group (NDM).  With Carson et al. (2009), the median adjusted survival was 
compared in patient months with the intervention group (RRT) living for 41.9 
months compared with 14.8 months for the control group (NDM).  When further 
analysis was undertaken to examine the influence of various factors Murtagh et al. 
(2007b) showed that treatment choice (RRT), age and comorbidity were the factors 
strongly associated with survival.  For instance, participants with a comorbidity 
grade of 2 received no survival advantage when undertaking dialysis; ischaemic heart 
disease (IHD) was independently associated with survival and that the survival 
benefit of dialysis was negated when IHD was present (Murtagh et al., 2007b).   
In contrast, Joly et al. (2003) found that the presence of IHD did not have a 
major effect on survival, however the presence of peripheral vascular disease had a 
negative prognostic influence for those people receiving RRT.  The negative 
influence did not occur until after the person had been receiving dialysis for greater 
than 12 months.  This difference was not found in either Murtagh et al. (2007b) or 
Carson et al. (2009) studies.  In addition to this, both Joly et al. (2003) and Carson et 
al. (2009) found that the timing of the referral may affect the survival outcome.  
Carson et al. (2009) performed a sub-analysis of the intervention group which 
excluded emergency referrals, resulting in an improvement of survival by 
approximately two and a half months.  The individuals who were referred late in the 
Carson et al. (2009) study tended to have a higher likelihood of choosing dialysis as 
their treatment option (statistical significance not reported). In contrast Joly et al. 
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(2003) reported that the control group (NDM) had a higher number of late referrals 
(51.4%) compared with the intervention group 28.9% (p=0.014).  It is difficult to 
explain the difference in treatment choices between studies.  The only noticeable 
difference is that Joly et al. (2003) study contained primarily octogenarians.  Joly et 
al. (2003) also found that there was a significant difference in survival between 
individuals with severely reduced functional performance scores (Karnofsky score ≤ 
40) and those requiring assistance or fully independent (Karnofsky score 50 – 70 or ≥ 
80).  Unfortunately other studies did not collect data regarding functional 
performance so it was difficult to determine if these results were only limited to the 
population in Joly et al. (2003) study.   
The number of hospitalizations and location of death are important factors to 
consider when comparing outcomes between intervention and control groups. Carson 
et al. (2009) was the only study to report on these factors with the intervention group 
hospitalized (25 days per patient per year ) more frequently than the control group 
(16 days per patient per year) as described in Table 2.3 Page 31). 
The Renal Physicians’ Association has reported a link between nutritional 
status and mortality in dialysis patients (Renal Physicians Association, 2010). Only 
two of the three studies in this review recorded indicators of nutritional status. 
Carson et al. (2009) collected baseline serum albumin levels which were not 
statistically different between groups, however no further analysis was undertaken on 
this data. Joly et al. (2003) found that good nutritional status (defined as BMI = 22) 
acted as a protective factor for those receiving dialysis in the first 12 months with the 
hazard ratio of 0.83, indicating a reduction in the risk of death by 17% with each one 
point increase in BMI. The three significant variables in Joly et al. (2003) study—
late referral, BMI and peripheral vascular disease, were combined to establish a 
predictive model. This model demonstrated that early referral, a BMI of 22 and a 
Karnofsky score greater than 40 were significant predictors for survival for 
participants in the study (Joly et al., 2003). The difference in mortality for late 
referral to a nephrologist can be seen by the fact that the early referral group had a 
probability of death in the first year of 15% and the late referral group a probability 
of death in the first year of 83% (Joly et al., 2003). These results provide another 
level of understanding of possible influencing factors on survival of the older person 
who is considering treatment options. 
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2.3.9 Discussion 
The objective of undertaking the systematic review was to compare outcomes 
in people over the age of 65 years with ESKD who received the intervention (RRT) 
compared with those in the control group (NDM).  The goal was to conduct a meta-
analysis of data relating to outcomes such as survival, hospital admission rates, 
functional capacity, symptoms and severity of the symptoms and quality of life. Due 
to the variation in study design and differing outcomes only a narrative analysis was 
able to be undertaken. The primary outcome measured within these three studies 
was: 
Primary Outcome 
 Survival 
Secondary outcomes 
The Secondary outcomes are identified below: 
 Impact of factors on survival (including comorbidity, peripheral 
vascular disease, presence of diabetes, age, functional performance 
score, modality, late referral, body mass index (BMI)); 
 Rate of hospitalizations; 
 Location of death. 
The three studies included in this review were observational research with one 
retrospective and two prospective in design. The three studies were not homogenous 
and differed in the clinical and methodological dimensions. The clinical dimensions 
of difference were age of population, starting point of data collection and outcome 
measures. The methodological differences were inclusion criteria and study 
timeframe. Differing outcome data was obtained from these studies which were 
important considerations for identifying appropriateness of dialysis options for the 
older population with CKD (or ESKD). 
The presence of known and unknown confounders within the studies reviewed 
makes it difficult to determine an association between extended survival and RRT. 
The confounders that have been discussed may alter the outcomes of survival in the 
NDM group. The difference in age between groups reported in two studies (Carson 
et al., 2009; Murtagh et al., 2007b) could result in the RRT group having a survival 
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advantage. The age of the population for each of the studies varied with two studies 
having a population where the median age for NDM group in both studies was 83 
years and the median age for the RRT group was 75 years (Carson et al., 2009) and 
79.6 (Murtagh et al., 2007b). There was no statistical difference in the mean age of 
each group in the Joly et al. (2003) study (mean age 84.1 years). The higher 
incidence of diabetes, reduced functional performance, late referral and social 
isolation for the NDM group (Joly et al., 2003) may have also resulted in the marked 
survival differences between those groups. Evaluating evidence regarding survival 
requires attention to potential confounders and the influence these may have on 
causality in the relationship between RRT and increased survival. 
All three studies found a statistically significant survival advantage with 
dialysis. Further analysis of the participant characteristics by Murtagh et al. (2007b) 
found that the survival advantage was negated by the presence of a high comorbidity 
score, in particular the presence of ischaemic heart disease. Joly et al. (2003) also 
found that the survival benefit of dialysis could be significantly reduced if the person 
had poor functional performance and was negatively affected after 12 months if there 
was the presence of peripheral vascular disease. Carson et al. (2009) did not identify 
any factors that altered survival benefit but did demonstrate that individuals who 
elected to receive NDM survived for greater than 12 months (median survival 13.9 
months). Murtagh et al. (2007b) also demonstrated a survival in the NDM group of 
greater than 12 months (median survival 18.0 months).  
Joly et al. (2003) developed a predictive model for mortality using the 
covariates of: late referral, BMI and the presence of peripheral vascular disease. The 
model showed that for individuals who were referred late, or had a low BMI and the 
presence of peripheral vascular disease there was an 83 % chance of death within the 
first year of commencing dialysis. This evidence may help individuals, family 
members and the renal multidisciplinary team to understand the cumulative effect of 
poor nutrition, late referral and peripheral vascular comorbid diseases. Caution is 
also warranted, as this predictive model was only relevant to those people who were 
over 80 years of age referred to a nephrology service. The practices and decisions 
regarding late referrals to a nephrology service and initiation of dialysis may also 
vary between countries. Late referrals are reported by Foote et al. (2012) in the 
registry study as increasing risk of death for dialysis patients. In the Carson et al. 
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(2009) study the individuals referred late were more likely to choose dialysis rather 
than those identified in the Joly et al. (2003) study, who were more likely to be 
maintained on NDM.   
The frequency of hospitalization can be altered by the choice of treatment and 
may influence a person’s decision whether to receive dialysis or not. Only one study 
reported the effect of RRT on rate of hospitalization. Carson et al. (2009) found a 
difference in hospitalization rates between the intervention group (25 
days/patient/year) and the control group (16 days/patient/year). In addition to the 
increased hospitalization risk, those receiving HD also spend approximately 18 hours 
per week at a hospital receiving dialysis. The amount of time spent away from home 
and family as well as the inflexible HD treatment schedule may affect the quality of 
life for people who receive HD. Unfortunately, none of the studies included in this 
review captured the possible effect HD may have on quality of life. Only one study 
examined the location of death. Carson et al. (2009) considered location of death as a 
surrogate for the “medicalization of death” and found that the intervention group had 
a higher incidence of death in hospital. This outcome may also influence an 
individual’s quality of life and also the families experience with illness and death. 
The level of evidence available and lack of similar prognostic studies limits the 
ability of the reviewers to undertake a meta-analysis and provide a solid evidence 
base in regards to outcomes in the older person who receives RRT or opts for NDM. 
The outcomes from these three studies cannot be generalized to all people who have 
ESKD. The studies included in this review were based on populations being treated 
by nephrologists and a multidisciplinary team. In addition, there were very few 
participants in the studies who received PD with a majority receiving HD as the form 
of RRT. It would be incorrect to extrapolate these outcomes to a population with 
ESKD being managed in a General Practice (primary health care) setting or in older 
people who opt for peritoneal dialysis. 
What was also lacking in this body of evidence was quality of life data. There 
was only one study (external to this systematic review) that undertook a comparison 
of quality of life scores for RRT and NDM. Unfortunately De Biase et al. (2008) 
failed to have an appropriate comparator group, the referral process was flawed, and 
the timing of data collection was not consistent. Considering there is a high incidence 
of withdrawal from dialysis in many countries (24% in Australia and New Zealand; 
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(McDonald, Excell, & Livingston, 2010)) and that 61% of people regret their 
decision to start dialysis (McDonald et al., 2010) it is important to understand other 
factors (e.g. quality of life, social support, burden on others) that may influence an 
older person’s decision to commence RRT, and not merely longevity. 
2.3.10 Conclusion  
The lack of homogeneity, presence of bias and the potential for confounding 
within the studies reviewed meant the meta-analysis of the data was unable to be 
undertaken. The summation of the evidence has been presented within this 
systematic review. All three studies showed a survival advantage for the intervention. 
This advantage was lost in the presence of severe comorbidities (Joly et al., 2003) in 
particular ischaemic heart disease (Murtagh et al., 2007b). In addition, if there was 
very poor functional performance, then survival would also be substantially reduced 
(Joly et al., 2003). What is important to note is that two of the studies (Joly et al., 
2003; Murtagh et al., 2007b), demonstrated that participants in both groups 
(intervention and control) survived for greater than 12 months with ESKD. The 
group that chose to receive NDM were more likely to die at home or in a hospice and 
to have fewer episodes of hospitalization (Carson et al., 2009).  There is also 
evidence to suggest that the combination of late referral, low BMI and peripheral 
vascular disease will increase the risk of death within 12 months for those individuals 
who have chosen dialysis (Joly et al., 2003). 
END OF PUBLISHED MANUSCRIPT 
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2.4  SUMMARY  
The literature review of DSIs in chronic disease has identified the effectiveness 
of DSIs in lowering decision conflict and improving knowledge. This literature 
review has identified the paucity of evidence in relation to the effectiveness of DSI 
for patients with advanced kidney disease.  
The evidence summarised within the systematic review has been utilised in the 
content of the decision support intervention for patients with advanced kidney 
disease. The limitations of the evidence outlined in the review would also need to be 
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considered in this discussion. Key themes such as prognosis related to age, 
comorbidities and risk factors has been adopted and utilised as part of this evidence-
based decision making intervention. In addition to this, the author has also tracked 
key clinical outcomes such as quality of life, survival, comorbidities and functional 
performance. The results from this published systematic review (Brown et al., 2014) 
have contributed to the evidence base in regard to outcomes for the older patients 
who choose either dialysis or non-dialysis management. The conceptual framework 
outlined in the next chapter provides structure to guide the empirical research. 
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 Methodological and Theoretical Chapter 3:
Framework 
3.1 INTRODUCTION 
The effectiveness of decision support interventions (DSI) in lowering 
decisional conflict and improving knowledge in chronic disease has been 
demonstrated by numerous randomised controlled trials. However, the evidence 
demonstrating that DSIs have a similar effect in the older population with advanced 
kidney disease is lacking. This research is of a high priority due to the impact that 
advanced kidney disease and ageing of the population has on consumption of health 
care resources (Couser et al., 2011).  
Advanced kidney disease is one of the major consumers of health care due to 
the increasing numbers of people receiving dialysis. The dialysis population has been 
increasing by between 6–12% yearly over the last two decades (Couser et al., 2011). 
The main population group driving these increasing numbers are older individuals 
commencing on dialysis (Australia Institute of Health and Welfare, 2014; Gilg, 
Caskey, & Fogarty, 2016). There is a need for a well-structured and theoretically 
driven approach to evaluate the effectiveness of a DSI in assisting the older 
individual with advanced kidney disease to make a treatment choice. The 
methodological framework for this research design is Positivism which supports the 
use of a randomised controlled trial to generate high quality evidence.  
The Ottawa Decision Support Framework (ODSF) (O’Connor, 2006) provided 
the conceptual model that guided the development and application of the intervention 
in the research. The use of ODSF has strengthened the credibility of the DSI and the 
research evidence generated in this study.  
3.2 METHODOLOGICAL FRAMEWORK 
This study is framed by a positivist methodology. Positivism is a system of 
thought that recognises knowledge that can be scientifically verified, is based on 
logical or mathematical proof and uses scientific methods to develop a theory that 
describes and predicts patterns in the physical world (Welford, Murphy, & Casey, 
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2011). The use of a randomised controlled trial in this research will provide the 
scientific evidence regarding decision making in the older population with advanced 
kidney disease to reveal an understanding of how this population group functions, 
which is the fundamental approach of Positivism. Positivism is often described as a 
research paradigm and one of several utilised in nursing research (Weaver & Olson, 
2006). A research paradigm incorporates ontological, epistemological and 
methodological characteristics. The ontological position of this research design is 
that human behaviour such as ‘decision making’ can be known in the same way the 
natural world is known. It is measureable and able to be predicted so knowledge can 
be derived from rigorous inquiry into the human condition. The epistemological 
position informing this research design is one of validity and objective observation 
and generalizability. The assumption is that knowledge can be discovered with use of 
appropriate measurement instruments and management of mediating influences. The 
selection of the study design and use of validated measurement instruments has been 
guided by the epistemological position. Consistent with these assumptions this 
research design has used hypothesis driven experimental methods and validated data 
instruments in ‘real life’ research conditions.   
Since the work of David Sackett in 1996, the contemporary positioning of 
positivism in the field of clinical care and health service is emphasised through the 
process of evidence-based clinical practice (EBP). Evidence-based practice is 
defined as the conscientious, explicit and appropriate use of the most up to date 
evidence to assist with making decisions regarding individual care (Sackett, 
Rosenberg, Gray, Haynes, & Richardson, 1996). The generation of knowledge to 
inform EBP occurs through the use of deductive reasoning and hypothesis testing 
through application of statistical analysis. The type of evidence required varies with 
the type of research questions asked. When questioning the effectiveness of an 
intervention the ideal study design is a randomised controlled trial (RCT) (National 
Health and Medical Research Council, 2000). Evidence for clinical practice has been 
classified into levels of evidence. The level of evidence identifies the study design 
used by researchers to assess the effectiveness of the intervention (National Health 
and Medical Research Council, 2000). According to the EBP classification system, 
the level of evidence allocated to a particular study design primarily identifies the 
degree to which bias has been eliminated from the design of the study. The 
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systematic review of RCTs is considered the highest level of evidence (Level 1 in 
NHMRC evidence hierarchy) in scientific research. This process involves the 
identification and review of the RCTs relevant to the intervention, with the 
magnitude of intervention effect illustrated (National Health and Medical Research 
Council, 2000). A well-designed RCT is considered Level II evidence in the 
NHMRC hierarchy of research evidence. For an individual study, the RCT is 
considered the best source of evidence, as it is designed to eliminate bias and lower 
the risk of systematic errors (National Health and Medical Research Council, 2000). 
The RCT is a key contributor to evidence-based practice as this method provides the 
highest empirical evidential support (Sami & Sedgwick, 2011). The use of an RCT in 
this study is informed by positivism methodology and will assist in the contribution 
of evidence to uniform clinical practice. 
There are a range of approaches to the design of an RCT with varying levels of 
conformity to the epistemological rules. The development of this research design has 
drawn upon a pragmatic RCT design instead of an explanatory RCT as the aim was 
to measure the effectiveness of the DSI in a routine care setting of an outpatient 
clinic. It was not feasible to undertake a double blind study, as the intervention could 
not be blinded to either participants or the renal nurses delivering the intervention. 
The identification and explanation of the DSI to the participants is a key component 
of the study as is the renal nurse undertaking training and understanding the delivery 
of the DSI. However, research assistants involved in outcome data collection and the 
lead investigator who undertook the data analysis were blinded to study allocation. 
The pragmatic RCT reduces the level of manipulation of the research environment 
with the use of “standard care” rather than placebo, broad inclusion criteria and 
single blind methods representing and accommodating the realistic clinical situation 
(Hotopf, 2002; Macpherson, 2004). 
The development of this study has drawn upon a pragmatic RCT design to 
measure the effectiveness of the DSI in a routine care setting such as outpatient 
clinic. Blinding to the intervention is not possible and for pragmatic reasons the 
effect of the DSI cannot be compared to a placebo but has been compared with 
“standard care”. Informed by the assumptions of positivist methodology, measures 
have been taken within the study design to ensure that methodological requirements 
are met to the extent that has been feasible.   
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Whilst these measures improve the quality of research design of a pragmatic 
RCT, consideration also needs to be given to the strength of the key elements of the 
intervention itself. Theoretically informed processes for intervention design and 
implementation is a key step in positivist research. A theoretical approach not only 
informs the development and delivery of the intervention but also provides guidance 
for evaluation and facilitates examination of casual mechanisms (Angus et al., 2006). 
The use of a theoretical process for intervention development has enabled 
transparency of research process and reproducibility of the study design and 
outcomes.   
Theories are defined by their scope. A broad theory applicable to wide range of 
occurrences is known as a grand or macro theory, it is generally non-specific with 
abstract concepts (Angus et al., 2006). The theory used to inform the development of 
the DSI for this research study is categorised as a mid-range theory and is designed 
to generate empirical evidence. A mid-range theory has a defined scope, addresses 
specific events and reflects clinical practice (Angus et al., 2006). The strength of a 
mid-range theory is the results can be applied to different research questions external 
to the specific circumstances of testing (Angus et al., 2006). 
3.3 THEORETICAL FRAMEWORK: THE OTTAWA DECISION 
SUPPORT FRAMEWORK  
Numerous health care decisions are regarded as complex when there is 
uncertainty about risk and benefits (O’Connor et al., 1998a). Decision support 
interventions have been developed to help patients become involved in making 
complex decisions. The aim of a DSI is to prepare patients for decision making and 
help them to understand probable benefits and risks associated with various options, 
consider their values or beliefs in relation to risks and benefits, and to encourage 
active participation with health professionals in choosing a treatment option 
(O’Connor et al., 2009). Active participation is supported through the inclusion of 
coaching and/or guidance within the decision making process. A Cochrane 
systematic review identified that DSIs improve knowledge regarding options and 
reduce decisional conflict in relation to personal values (Stacey et al., 2014). While 
there is strong evidence demonstrating the usefulness of DSIs very little attention has 
been paid to the theoretical framework underlying the development of these DSIs 
(Durand, Stiel, Boivin, & Elwyn, 2008).  
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Durand et al. (2008) analysed rigorously developed DSIs to determine what 
contribution decision-making theory had in the DSI conception, design, development 
and evaluation. The authors found only 17 of the 50 DSIs described a theory or 
theoretical framework informing the development of the DSI. Of the 17 DSIs that 
used a framework, the ODSF was identified as providing a theoretical framework for 
four (of these decision support interventions).   
The Ottawa Decision Support Framework is an evidence-based, mid-range 
theory developed to guide patients to make health or social decisions (O’Connor, 
Stacey, & Jacobsen, 2011). This theoretical framework has been developed from 
theories of decisional conflict, social support and expected utility (O’Connor et al., 
1998b). The framework was developed for health decisions where decisional conflict 
is high and particularly for decisions that need to be made when there is a new 
diagnosis or new circumstance. These type of decisions require careful consideration 
because of the uncertainty of benefits/risks and the personal values involved 
(O’Connor, Jacobsen, & Stacey, 2002). In situations where there is no immediate 
need for a decision or the decision must be made in an emergency setting, the ODSF 
is not as beneficial (O’Connor et al., 2002). The ODSF has been used to guide the 
development of over 30 distinct DSIs (O’Connor, 2006). The theoretical framework 
is applicable to all patients involved in the decision making process and includes the 
health professional, patient and their relevant family members. The underlying belief 
is that patients’ decisional needs affect the decision quality which in turn influences 
actions or behaviours, health outcomes, emotions and health care usage (O’Connor, 
2006). A diagrammatic representation of the ODSF can be seen in Figure 3.1 (page 
52). The three concepts of the ODSF are: assessing the patients’ needs or 
determinants of decision, providing decision support, and evaluating decision quality 
and outcomes of decisions.   
3.3.1 Decisional Needs 
According to the theories underpinning the ODSF the selection of one option 
over another is dependent on several factors. The first factor is the patient’s 
perception of the decision. This perception is determined by knowledge about the 
options, whether the outcome matches their personal values, certainty of the decision 
being the best option and readiness to make a decision (O’Connor et al., 2002). The 
second factor is the perception of others, such as what decision would other people 
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make in this situation, how much pressure or support are others offering and what is 
the patient’s role in decision making with others (health care professionals and 
family members) (O’Connor et al., 2002). The third factor is resources, such as do 
the patients have the personal ability or attributes to make a decision and is there 
enough external assistance to support them to make a decision (O’Connor et al., 
2002). The final factor is personal/clinical characteristics, for instance age, 
education, social background, ethnicity and clinical factors such as duration of the 
illness and stage of the diagnosis (O’Connor et al., 2002). The assessment of these 
factors helps the health professional to identify which factors are suboptimal.  
3.3.2  Decision Support 
The decision support process within the theoretical framework of the ODSF 
involves preparing both the patient and health professional for decision making and 
structured counselling. The aim of decisional support is to tailor the support 
according to the patient’s suboptimal determinants (e.g. decisional conflict, lack of 
knowledge, inadequate resources) (O’Connor et al., 2002). Decisional support within 
the ODSF involves the principles of coaching and guidance. Coaching is defined as 
the provision of support by a trained individual that is non-directive and facilitates 
the patient to make a decision (Stacey et al., 2013). Guidance is provided through the 
use of explicit elements within a DSI that aims to facilitate the patient to undertake a 
self-directed process of decision making (Stacey et al., 2013).  
The DSI and follow-up counselling session will provide facts and probabilities 
relevant to the patients’ health situation. The DSI and counselling session will also 
provide options and outcomes when the knowledge is insufficient. Decision support 
will involve confirming expectations of outcomes are realistic through the use of 
probabilities and facts. In addition, the patient’s personal values will be clarified 
through the use of a values clarification exercise if they have unclear values, this 
exercise helps to provide guidance in the decision making process. The patient’s 
decision making skills will be enhanced via coaching to provide them with the 
resources to consider their values and communicate these to relevant others 
(O’Connor et al., 2002). Decision support needs to be gender, age, socially and 
ethnically appropriate.  
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3.3.3 Decision Quality 
The design of the ODSF ensures that evaluation of the quality of the decision is 
a separate entity to the outcomes of the decision. The framework identifies an 
optimal decision as “one that is informed, consistent with personal values, acted 
upon and in which individuals express satisfaction with decision making” (O'Connor, 
1995). This framework is supported by evidence identifying  that DSIs should 
improve the quality of the decision-making process and also result in increasing the 
likelihood of patients making health care decisions that are most consistent with their 
values (Sepucha et al., 2013). Decision making utilising the ODSF should result in 
reduced decisional conflict, improved knowledge, realistic expectations, clear values, 
agreement between values and choices, successful implementation of chosen option 
and self-confidence and satisfaction with decision making (O’Connor et al., 2002). If 
an optimal decision has been made based on the individual’s personal values then the 
resultant effect will be adherence to the decision (Sandman, Granger, Ekman, & 
Munthe, 2012), reduced decisional conflict (Stacey et al., 2014), improved health 
related quality of life (Greenfield, Kaplan, & Ware Jr, 1985) and appropriate use of 
health care resources (Man-Son-Hing et al., 1999). 
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Decisional Needs
 Decisional conflict
 Knowledge and expectations
 Values
 Support and resources
 Decision:  type, timing, stage, learning
 Personal/clinical characteristics
Decision Quality
 Informed
 Values-based
Actions
 Delay, continuance
Impact
 Values-based health outcomes
 Regret & blame
 Appropriate use of costs and services
Decision Support
 Clarify decision and needs
 Provide facts, probabilities
 Clarify values
 Guide in deliberation and communication
 Monitor/facilitate progress
Counseling     Decision Tools     Coaching
  
Figure 3.1. Ottawa Decision Support Framework 
(Copyright 1996 by O’Connor; reprinted with permission of author)  
 
The use of ODSF to guide the development of a DSI provides a theoretical 
framework and also ensures that the DSI meets the International Patient Decision 
Aid Standards (IPDAS). International Patient Decision Aid Standards have been 
developed by a group of researchers, practitioners and stakeholders from around the 
world to enhance the quality and effectiveness of decision support interventions 
through the use of IPDAS. The purpose of IPDAS collaboration was to develop 
standard criteria to guide development and evaluation of DSIs to ensure that the DSI 
is of high quality and effective (Elwyn et al., 2009). These standards confirm that 
DSIs must provide information on the disease, the options available, a summation of 
the benefits and risks, and the scientific uncertainties (Elwyn et al., 2009) They also 
recommend that the probabilities of the outcomes should be tailored to the patients’ 
health risk factors, personal values be clarified, and outcomes be presented in a 
functional manner (Elwyn et al., 2006). Finally the IPDAS recommends the DSI 
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provide coaching and guidance on the decision making process and communication 
(Elwyn et al., 2006).  
The internationally approved set of IPDAS criteria (Appendix A, page 169) 
was reviewed and the IPDAS instrument was developed displaying the agreed 
dimensions and items (Elwyn et al., 2009). Further development is still required as 
the instrument does not provide any recognition of the importance of theoretically 
derived DSIs. Currently there are no items to assess the use of theory in the 
development methods. This should be a key item within the criteria considering 
IPDAS is being used to assess DSIs and consideration should be afforded to the 
framework of the design and mode of action of the DSI (Elwyn et al., 2009). The 
development of DSIs utilising only IPDAS as the guide results in an absence of a 
theoretical framework underpinning the delivery, measurement and implementation 
of the DSI.  The use of ODSF to guide the development of the DSI for this research 
ensures a theoretical framework. International Patient Decision Aid Standards 
criteria (Appendix A) has been used to assess the quality of the DSI developed as 
part of our research against international standards during the development process. 
This assessment will be discussed further when describing intervention development. 
Hypotheses generated from the ODSF examining the effect of DSIs have been 
tested in RCTs. A review of the studies utilising the ODSF found 23 RCTs 
evaluating the effects of ODSF guided DSIs (Causarano et al., 2015; Deschamps, 
Taylor, Neubauer, Whiting, & Green, 2004; Dodin, Légaré, Daudelin, Tetroe, & 
O'Connor, 2001; Drake, Engler-Todd, O'Connor, Surh, & Hunter, 1999; Goel, 
Sawka, Thiel, Gort, & O’Connor, 2001; Hunter et al., 2005; Laupacis et al., 2006; 
Légaré et al., 2003; Leighl et al., 2011; Man-Son-Hing et al., 1999; Mathieu et al., 
2007; Mathieu et al., 2010; McAlister et al., 2005; Nagle et al., 2008; Nassar, 
Roberts, Raynes-Greenow, Barratt, & Peat, 2007; O’Connor et al., 1998b; O’Connor 
et al., 1998c; Oakley & Walley, 2006; Schwartz et al., 2009; Shorten, Shorten, 
Keogh, West, & Morris, 2005; Stacey et al., 2016; Tiller et al., 2006; Wakefield et 
al., 2008). This evidence supports the importance of the theoretical elements within 
the DSI and the effectiveness of these in guiding decision making. The RCTs 
demonstrated that decision making guided by a theoretical framework (ODSF) was 
improved through reducing uncertainty, and there was increased likelihood that the 
decision was based on improved knowledge and personal values (Stacey et al., 
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2014). The DSIs also generated realistic expectations of treatment and provided 
support for the  individuals during the decision making process (O’Connor et al., 
1998a). High quality evidence also suggests that DSIs may work better than standard 
education in ensuring realistic expectations of benefits and risks (O’Connor et al., 
1998a). The effect DSIs have on patient choice and uncertainties are variable. Some 
DSIs  have been able to demonstrate a reduction in uncertainty however this effect 
was negated if the patients already have strong view regarding options (O’Connor et 
al., 1998a).   
The RCTs undertaken to evaluate the ODSF vary in their information type and 
field of health care. The studies include topics such as: women after menopause 
(O’Connor et al., 1998c); pregnancy in older women (Drake et al., 1999); breast 
cancer (Goel et al., 2001); mammography (Mathieu et al., 2007); prenatal (Hunter et 
al., 2005; Nagle et al., 2008); screening (Tiller et al., 2006); obstetrics (Nassar et al., 
2007; Shorten et al., 2005); supporting treatment decision making in advanced cancer 
(Leighl et al., 2011); appropriate and timely access to hip or knee arthroscopy 
(Stacey et al., 2016); post mastectomy breast reconstruction (Causarano et al., 2015)  
and non-valvular atrial fibrillation (Man-Son-Hing et al., 1999). The population sizes 
in these studies varied from between 30–434 participants. 
A majority of the studies listed achieved significant results for outcomes such 
as knowledge, decisional conflict, informed choice and clarity of values. The RCTs 
measuring the impact of DSI on appropriate and timely access to hip or knee 
arthroplasty had 343 participants with average age of 66 years and a relatively even 
distribution of men and women (Stacey et al., 2016) . Stacey et al. (2016) found that 
the participants achieved good decisional quality (informed choice that matched their 
values) 56.1% for the DSI group and 44.5% in the control group (p=0.050) and 
higher knowledge scores 12.4/18 for the DSI group compared with 11/18 for the 
control group (p<0.001). The non-valvular atrial fibrillation trial had 287 participants 
with an average age of 65 years and a mix of male and female participants (Man-
Son-Hing et al., 1999). The DSI was a combination of a 29 page booklet, personal 
worksheet and 20 minute audiotape which acted as a guide for the booklet and 
worksheet (Man-Son-Hing et al., 1999). The outcomes from this RCT found that 
those patients who received the DSI who had made a choice about treatment, were 
more knowledgeable and had more realistic expectations about the risk of stroke and 
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bleeding (Man-Son-Hing et al., 1999). Leighl et al. (2011) undertook a study in 
examining the effectiveness of a DSI in the setting of participants (n=100) with 
advanced colorectal cancer considering first-line chemotherapy. This study found no 
difference in decisional conflict and anxiety between groups, but did demonstrate 
that patient understanding in the role of palliative care increased in the DSI group 
(p<0.001) (Leighl et al., 2011).  
One study that investigated treatment approaches for breast cancer 
(mastectomy or breast conserving therapy) failed to achieve the study outcomes 
(Goel et al., 2001). The authors noted that this may have been due to the acute setting 
and the choice of measurement tool (decision conflict scale) which has primarily 
been used in a chronic setting (Goel et al., 2001). Additionally a pilot study with 30 
participants undertaken by Oakley and Walley (2006) failed to achieve significance 
for the primary outcome. However, the reasons for failure to achieve significance 
difference differed and were most likely due to an inadequate sample size for the 
outcome. The pilot study conducted by Causarano et al. (2015) with 41 participants 
assessed the effectiveness of the DSI to help women choose options regarding breast 
reconstruction post-mastectomy. Despite the fact the participant numbers were low 
and the study was designed as a pilot study, the DSI was able to increase decision 
self-efficacy (p=0.05) and lower decisional conflict after receiving the DSI (effect 
size 0.69) (Causarano et al., 2015). It is evident that a majority of DSIs utilising 
ODSF as the theoretical framework achieved significant results in improving 
decision quality.  
A review of the literature found that there have been no DSIs developed for 
CKD utilising the ODSF. Recently two DSIs have been developed utilising IPDAS 
to guide the development process (Ameling et al., 2012; Fortnum et al., 2015b). As 
identified earlier IPDAS is a set of standards with no theoretical framework guiding 
the development, implementation, measurement and evaluation. The DSI developed 
by Fortnum et al. (2015b) reported statistically significant higher levels of ‘worry’. 
This may be partially due to the absence of a theoretical guided development and 
evaluation of the DSI. Use of a validated theoretical framework to guide the 
development of the intervention ensures the inclusion of all key elements required to 
make a quality decision.  
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
56 Chapter 3: Methodological and Theoretical Framework 
 
3.4 DEVELOPMENT AND PRELIMINARY EVALUATION OF DECISION 
SUPPORT INTERVENTION 
The process of development of the decision support intervention is outlined in 
Figure 3.2. The key steps of this process were identified as critical by O’Connor and 
Jacobsen (2003) and reflects a model development process outlined by Coulter et al. 
(2013). The process undertaken in developing the decision support intervention 
included; (i) assessing a need, (ii) defining the objectives, (iii) identifying 
framework, (iv) identifying the methods of decision support to be used and (v) study 
design and measures to evaluate the DSI. The components of OPTIONS are based on 
the ODSF but are also supported by decision science evidence.  
3.4.1 Scope and Purpose of the Intervention 
The identification of the scope, purpose and target audience for the DSI 
involved a review of the evidence regarding decision making in chronic kidney 
disease. The literature review undertaken in Chapter Two identified the paucity of 
evidence in relation to the use of DSIs for advanced kidney disease. The DSI has 
been designed to facilitate decision making for the older patient with advanced 
kidney disease in choosing between two treatment options—dialysis and non-dialysis 
management.  
The DSI presents these options in a balanced and easy to follow manner and 
hereafter will be referred to as OPTIONS. The purpose of OPTIONS is to ensure the 
patients with advanced kidney disease make a treatment choice that best matches 
their own personal values thereby lowering decisional conflict and regret.  
3.4.2 Information content 
The use and validation of the ODSF as the theoretical framework has been 
discussed in Section 3.3. Descriptions of the elements of OPTIONS are detailed 
below with the linkage to the key elements of ODSF—decisional needs, decisional 
quality and decision support. The DSI can be viewed in Appendix F (page 179). 
The first section of the DSI (workbook and audio recording) introduces the 
question to be answered and target audience, and identifies the learning objectives. 
This is followed by a brief description about kidneys and definition of end stage 
kidney disease (ESKD). This section also enables the reader to identify with some 
features of kidney disease that have been outlined. The options (dialysis or non-
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dialysis management) are then explained so that the reader understands what is 
involved. This section helps to clarify the decision.  
  
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
58 Chapter 3: Methodological and Theoretical Framework 
 
 
  
Systematic Review – 
narrative analysis 
Synthesis of other 
evidence 
Synthesis of 
evidence regarding 
individuals’ 
information needs 
and patient 
experiences 
Decision 
Support 
Intervention 
OPTIONS 
Steering Committee (n=3) 
Expert independent panel (n=5) 
Final Version OPTIONS Decision 
Support Intervention 
Scope and purpose of 
decision support 
intervention and the 
target audience 
defined 
Figure 3.2.  The process of development of OPTIONS 
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The second section provides detail around each choice and also presents the 
best available evidence regarding the pros and cons (risks and benefits) of 
undertaking dialysis or non-dialysis management. Probabilities are provided and 
referenced appropriately. Side effects and possible harms are also discussed and 
referenced. Section 2 presents the facts and probabilities. The pros and cons and 
further information regarding dialysis and non-dialysis management have been 
presented in a complete and unbiased manner to enable patients to process the 
content without bias and facilitate informed decision making. This presentation 
reflects a key element of the IPDAS criteria and ODSF (Abhyankar et al., 2013; 
Bekker et al., 1999; O’Connor et al., 2002).  
The third section is the summary of the pros and cons of dialysis and non-
dialysis management. The summation of key facts enables a review of the key points 
in a tabular manner. This representation of the facts in a different format allows the 
reader to again process and revisit the pros and cons. 
The fourth section provides guidance on how to make a treatment choice and 
incorporates a values clarification exercise. This section enables the reader to clarify 
their values through the exercise within the worksheet. Examples of two real life 
scenarios help the reader to visualise how this worksheet could help them document 
their values on either side of the scale (pros/cons). The use of the values clarification 
exercise has been designed to help the patient think about desirability of options 
regarding dialysis or non-dialysis management in regard to their own individual 
preferences. This exercise represents a structured approach to facilitate the patient to 
make a decision and is underpinned by evidence regarding informed decision making 
(Bekker et al., 1999; Fagerlin et al., 2013; Stacey et al., 2013).  
The final section allows the reader to record any further questions they may 
have to ask the renal nurse, identify who would make the decision about their 
treatment and then identify on a scale which way they are leaning with their decision. 
This section enables the reader to identify any uncertainty and unresolved decision 
needs. The decision counselling/coaching with the renal nurse in combination with 
recording uncertainty within the worksheet will facilitate resolution of any 
uncertainty and provide decision support with the aim of improving decision quality 
through addressing unresolved needs. The incorporation of counselling within the 
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shared decision making process provides appropriate structured decision support and 
has been demonstrated to improve knowledge (Stacey et al., 2012) 
The booklet and audio recording is designed to be taken home by the patient 
and reviewed with their family/friend. The reader will then undertake the values 
clarification exercise (worksheet) and take this to the next consultation with the renal 
nurse. The renal nurse will then revisit the clarity of the individual’s decision, review 
their understanding of the facts and probabilities and if there is uncertainty guide 
deliberation of the decision.  
The format of OPTIONS closely followed the format of a DSI which has 
already been written and evaluated, involving end organ treatment choices. The DSI 
is titled “The use of Intubation and Mechanical Ventilation for Severe Chronic 
Obstructive Pulmonary Disease (COPD)”. This DSI (COPD) has been evaluated and 
results found the effectiveness and clarity of presentation of information was 
favourable (Wilson et al., 2005). The COPD decision support intervention was 
guided by the ODSF and evaluated in a pre/post-test study (Wilson et al., 2005). The 
study demonstrated that the DSI was able to significantly improve the accurate 
expectation of the participants (P<0.001) and also significantly lower decisional 
conflict (p<0.001) (Wilson et al., 2005). Furthermore 88% of the participants found 
that the DSI was “not at all” difficult to understand (Wilson et al., 2005). The 
presentation of information in OPTIONS reflected closely the COPD DSI as they are 
both end-organ treatment choices. The positive outcomes achieved following the 
evaluation of COPD DSI, justifies using this format as the framework for the content 
of the OPTIONS. The active components of OPTIONS also follow a similar format 
to other DSIs developed to assist patients with advanced kidney disease in making 
treatment decisions such as ‘Dialysis Decision Aid: making the right choice for you’ 
(Bekker et al., 2015), ‘My Kidneys, My Choice’(Kidney Health Australia, 2012b), 
‘Preparing for Kidney Treatment: You have a choice’ (Ameling et al., 2012) and 
‘Choosing Dialysis’(Arbor Research Collaborative for Health, 2017). The 
differentiating feature of OPTIONS from these DSIs is the presentation of best 
available evidence around the pros and cons of dialysis and non-dialysis 
management. The decision support intervention developed by Ameling et al. (2012) 
also presenting factual evidence regarding pros and cons of each treatment, however 
there was no comparison between dialysis and non-dialysis management. The design 
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of OPTIONS as a decision support intervention for end organ treatment choice 
separates it from other decision support interventions available for advanced kidney 
disease.  
3.4.3 Synthesis of evidence regarding information needs 
Needs assessment can assist with identifying population groups that are not yet 
receiving the decision support they need. Research over the last ten years has 
assessed decisional needs of the population with advanced kidney disease. It is for 
this reason that further assessment of needs of this population was not been 
undertaken as part of this research study. Instead a synthesis of previous studies 
reviewing patients’ information needs in relation to advance kidney disease and 
treatment decision has been used in conjunction with theoretical framework to 
inform the structure and content of OPTIONS.  
A review of research identified a common theme where patients with advanced 
kidney disease were not being offered treatment choices in a balanced manner 
(Finkelstein et al., 2008; Ludlow et al., 2012; Marron et al., 2005; Morton et al., 
2010; Van Biesen, van der Veer, Murphey, Loblova, & Davies, 2014). A systematic 
review of the views of patients and carers in treatment decision making (Morton et 
al., 2010), and findings from qualitative focus groups and systematic literature 
reviews (Ameling et al., 2012) was used as a foundation to guide information content 
of OPTIONS. Morton et al. (2010) when reviewing the views of patients, identified 
common themes regarding patients information requirements such as confronting 
mortality, lack of choice, gaining information about options and weighing 
alternatives. These information requirements were also reflected in the feedback 
received from the focus groups conducted by Ameling et al. (2012) and two further 
studies undertaken by Finkelstein et al. (2008) and Winterbottom, Conner, Mooney, 
and Bekker (2007).  
The common themes identified within these studies have highlighted the need 
for a simple well balanced decision support intervention. This decision support 
intervention needs to be able to describe risks and benefits of treatment choices in 
consideration of mortality and to facilitate decision making not just provide 
information.  
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The studies discussed above have assisted with the identification of key content 
areas and the need for information to be presented in a simple balanced manner. 
Recent evidence (Fortnum, Grennan, & Ludlow, 2015a; Tong et al., 2014; Tonkin-
Crine et al., 2015; Van Biesen et al., 2014) also supports the key content of the 
OPTIONS. 
3.4.4 Content of Decision Support Intervention 
Using evidence-based principles enabled the identification and development of 
key content areas and major risks and benefits. Best available evidence regarding 
patient outcomes was informed by the systematic review described in the earlier 
chapter (Brown et al., 2014). In addition further published evidence regarding 
morbidity of dialysis patents (ANZDATA Registry, 2016), symptom prevalence, 
hospital admissions, quality of life and functional performance has also been 
incorporated into the study intervention (Carson et al., 2009; Joly et al., 2003; 
Kurella Tamura et al., 2009; Murtagh, Addington-Hall, & Higginson, 2007a; Seow, 
Cheung, Qu, & Yee, 2013).  
The DSI uses an illustrated workbook consisting of pictorial icons and bullet 
points to help participants in the intervention group to understand the information 
presented. The workbook includes instructions on how to use the decision support 
intervention, learning objectives, definition of advanced kidney disease, symptom 
identification, key points discussed, advantages and disadvantages of dialysis, 
advantages and disadvantages of non-dialysis management, summary of choices, 
steps on how to make a choice regarding treatment, two real patient’s scenarios 
outlining their decision making process, what to do if unable to make a decision, 
sources of further reading, support group contact details and references. The text of 
the workbook has been analysed for readability using FK grade-level function 
available on Microsoft Word Document using Windows XP. The use of audio 
recording and workbook is designed for comprehension at education level of 
Year/Grade 8 (12–14-year-old) which is consistent with the ODSF and IPDAS 
requirements.   
A values clarification exercise was developed to guide individuals through a 
summary of the pros and cons of dialysis and non-dialysis management, based on the 
information and discussion covered within the booklet and audio recording. A 
‘colour my values’ exercise was provided to assist participants to determine the 
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importance of each of the issues. The participants were asked to shade and write 
comments about the important issues such as: “live longer”, “relief of symptoms”, 
“lengthen life longer than a year”, “medical condition or mobility”, “discomfort”, 
“complications” and other pros and cons. They were also asked to write down any 
other additional thoughts and work through the final decision making steps such as 
“who should decide about my treatment?” and record which way they were leaning 
with their decision.  
3.4.5 Assessment of Decision Support Intervention 
It is important to undertake a quality assessment of this DSI. To assess the 
quality of the design and development of the DSI the IPDAS criteria has been 
utilised. The IPDAS criteria has been developed by a multinational group of 
researchers, practitioners and stakeholders whose purpose is to enhance quality and 
effectiveness of DSI through the establishment of criteria to facilitate evaluation of 
content, development, implementation and evaluation of DSIs (Joseph-Williams et 
al., 2014b).  
The DSI meets a large number of the IPDAS criteria. The strength of the DSI 
according to the IPDAS criteria are: (i) is the presentation of options in sufficient 
detail for decision making; (ii) presentation of probabilities of outcomes in an 
unbiased and understandable way; (iii) methods provided for clarification of values; 
and (iv) structured guidance is provided to facilitate decision making (Elwyn et al., 
2009).  
The weaknesses of the intervention according to IPDAS are: (i) is there is no 
evaluation of the intervention, and (ii) quality of scientific evidence has not been 
discussed, (iii) publication date not displayed and (iv) no information about the 
proposed update policy has been provided. The information in regards to the 
synthesis of evidence and the quality of evidence was not placed within the booklet 
as there were concerns regarding the effect this information would have on 
readability levels. The provision of citations and references at the end of the booklet 
links the reader to the source evidence. A description of the synthesis of evidence has 
been provided in the published systematic review (Brown et al., 2014) and study 
protocol (Brown, Gardner, & Bonner, 2016). The publication date and proposed 
update policy will be included within the DSI once the research study is complete 
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and any further changes have been made to the DSI. This research study has 
provided the evaluation of the DSI. 
3.4.6 Steering Committee  
The draft DSI (including the script for the audio recording) was critiqued by 
two experts in nephrology and one expert in education. Feedback regarding language 
and content was received and adjusted accordingly. Additionally, the decision 
support intervention was presented to the QUT University Panel and further feedback 
received. There was also further rigorous review when applying for ethics approval. 
The ethics committee was satisfied with the balanced representation of facts. 
3.4.7 Expert independent panel  
The revised draft was distributed to the expert independent panel. The expert 
panel consisted of a nephrology expert, renal supportive care expert, consumer 
representative, nephrology nurse practitioner and specialist in aged care. The expert 
panel were asked to evaluate the DSI by completing a standardised questionnaire 
based on IPDAS criteria (see Appendix G, Page 230). The overall score achieved 
was 80% which indicates the DSI is of high quality according to IPDAS criteria. 
Extra feedback was provided on format, readability, information included and 
balance of content. A variety of comments were received in addition to the scoring of 
the DSI against the IPDAS criteria. For example, the renal supportive care expert 
wanted more information regarding the burden of travel to and from dialysis to be 
discussed. Also there was conflicting feedback regarding the representation of facts 
regarding dialysis from the consumer representative and nephrology nurse 
practitioner. The consumer representative felt that a more positive slant needed to be 
placed on the dialysis information. In contrast after showing it to her patients, the 
nephrology nurse practitioner received feedback stating that dialysis was represented 
in a much more positive light compared with non-dialysis management. No changes 
were made as a result of this feedback. The nephrology expert requested that 
probabilities be provided with age equivalent data for the overall population. All 
feedback elicited was reviewed by steering committee and comments incorporated as 
changes to produce the final DSI.  
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3.5  SUMMARY 
Positivist methodology has provided a framework for the generation of 
knowledge to inform evidence-based clinical management for patients with advanced 
kidney disease. The methodological complexities of evaluating decision making in 
the setting of advanced kidney disease required the use of a sophisticated theoretical 
framework such as the ODSF, to guide the development of the DSI. The proven 
effectiveness of the ODSF on improving knowledge, lowering decisional conflict, 
creating more realistic expectations and improving clarity of values denotes this as 
an appropriate and valid theoretical framework to be used for this study. The use of a 
pragmatic RCT to evaluate the effectiveness of the DSI was designed to conform to 
the gold standard of clinical research to the extent that is possible when full control 
of all study variables is not feasible. Examining the effectiveness of the DSI as a 
complex intervention focused the research on patient specific outcomes, with the 
next chapter discussing the methods utilised to undertake this study. 
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 Research Methods Chapter 4:
4.1  INTRODUCTION 
A review of the literature identified an absence of high quality research 
regarding the effectiveness of decision support interventions for patients with 
advanced kidney disease. The development of a decision support intervention (DSI) 
for this patient cohort was guided by the Ottawa Decision Support Framework 
(O’Connor et al., 1998b). This framework has been evaluated in numerous 
randomised controlled trials and found to support value-based decisions. The 
information content of the DSI was informed by a systematic review undertaken for 
this research to evaluate nominated outcomes for older patients who have received 
dialysis compared to those having non-dialysis management. This chapter presents 
all elements of the research approach used to evaluate the DSI in this study. 
OPTIONS is a complex intervention and was evaluated using a pragmatic 
experimental research design. The use of experimental design provides the researcher 
with the best source of evidence to demonstrate the relationship between the 
intervention and the outcome (National Health and Medical Research Council, 
2000). 
The study protocol for this project was published in the Journal of Advanced 
Nursing and is included in this chapter. Publishing the protocol enabled critical peer 
review and has ensured a priori rigour of research. Publication has also guaranteed 
study fidelity in outcome analysis which followed the original intent. Data 
management plans, and ethical considerations will also be discussed in this chapter 
as they relate to study design.  
4.2  STUDY DESIGN 
The study design used a pragmatic randomised controlled trial (RCT) to 
evaluate the effectiveness of OPTIONS in supporting the patient with advanced 
kidney disease to make a choice between dialysis or non-dialysis management. This 
RCT has also evaluated the usefulness of OPTIONS from both participant and 
nursing perspectives.  
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Decisions about study design are dependent on the study question being asked. 
A pragmatic RCT design seeks to answer the question “will this intervention be 
effective under usual conditions?”  
Table 4.1 summarises the most extreme differences in domains between 
pragmatic and explanatory trials as described by Thorpe et al. (2009). The evaluation 
of the intervention for this research required a hybrid design with a combination of 
explanatory RCT elements (high internal validity through blinding) and pragmatic 
(‘usual care’ and clinically meaningful primary outcome) as displayed in this hybrid 
approach, which embraces the strength of the explanatory RCT elements to ensure 
high internal validity through reduction of bias with the pragmatic characteristics of 
everyday applicability. The use of the pragmatic RCT design is the ideal 
methodology that best aligns with the conceptual framework to evaluate a complex 
intervention in a routine setting. 
The methodological complexities of development, delivery and evaluation of 
OPTIONS, relate to the nature of the clinical situation, whereby participants are 
undertaking value-sensitive health decisions in everyday situations. The decisions to 
be made are complex and often have no clear ‘best choice’, either because the 
outcomes are uncertain or due to the fact that the decision involves trade-offs 
between advantages and disadvantages of receiving treatment (Wennberg, 2002). 
Accordingly, OPTIONS conforms to the features of a complex intervention in that 
there is interaction between the patient with advanced kidney conditions and the 
renal nurse delivering the intervention. The patient’s response to OPTIONS is 
unpredictable with the opportunity of several different outcomes, being either:  
unable to make a decision, choosing dialysis or choosing non-dialysis management. 
The pragmatic RCT design allows for evaluation of a complex intervention (Hotopf, 
2002). The elements of the study that are characteristic of a pragmatic design as 
identified in Table 4.1, include specific features of the patient and comparison group, 
broad inclusion criteria, and specific outcomes.  
To address threats to bias, the study design includes control strategies for 
blinding at the points of randomisation, data collection and outcome data analysis. 
These design elements contribute to the study’s internal and external validity. The 
research questions that have been developed are in alignment with the pragmatic 
approach and are outlined below (Thorpe et al., 2009).  
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
68 Chapter 4: Research Methods 
 
Table 4.1 Comparison of Pragmatic, Explanatory and OPTIONS study domains   
Domain Pragmatic trial Explanatory Trial OPTIONS Study 
Participants 
Eligibility Criteria All participants who 
have condition of 
interest are enrolled  
Criteria restricts 
participants to those 
shown to be highest 
risk of unfavourable 
outcomes 
Condition of interest -
(CKD and ≥ 70 yrs 
with eGFR 
≤20mL/min) enrolled 
Interventions and Expertise 
Intervention Flexibility Flexible delivery of 
intervention 
Inflexible delivery of 
intervention 
Formalised 
intervention  
Intervention practitioner 
expertise 
Intervention typically 
delivered all 
practitioners. 
Intervention only 
delivered by 
experienced 
practitioners. 
Nurse must undertake 
training to deliver 
intervention  
Comparison 
group/intervention 
Standard care May use placebo rather 
than ‘usual practice” 
Standard care  
Comparison 
intervention practitioner 
expertise 
Usual practice applied 
by full range of 
practitioners  
Practitioner expertise in 
applying usual 
practice/placebo  is 
standardised  
Usual practice is 
delivered by nurses  
Follow-up and outcomes 
Follow-up intensity No formal follow-up 
visits of participants at 
all.  
Frequent visits, and 
data collection greater 
than  routine practice 
Follow-up with 3 
visits over 6 months.  
Primary trial outcome Primary outcome is 
clinically meaningful 
to participants  
Primary outcome is 
known to be direct and 
immediate 
consequence of the 
intervention.  
Primary outcome is 
clinically meaningful 
to participants  
Compliance/Adherence 
Participant compliance 
with intervention 
There is unobtrusive 
measure of 
compliance  
Participants 
compliance with the 
intervention is 
monitored closely  
Compliance with the 
intervention is 
required  
Practitioner adherence 
to study protocol 
Unobtrusive measure 
of practitioner 
adherence  
Close monitoring of 
participating clinicians 
and adherence to 
protocol 
Unobtrusive measure 
of practitioner 
adherence 
Analysis 
Analysis of primary 
outcome 
Analysis includes all 
patients (intention-to-
treat analysis). . 
An intention-to-treat 
analysis is usually 
performed. Analyses 
are conducted to 
answer narrowest 
questions. 
Analysis includes all 
patients (intention-to-
treat analysis). . 
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4.3 RESEARCH QUESTIONS 
The research questions are: 
1. To what extent is OPTIONS effective in supporting decision making for 
eligible patients when choosing between dialysis or non-dialysis 
management of advanced kidney disease? 
2. To what extent is OPTIONS user-friendly in terms of patients and renal 
nurses? 
The primary outcome of the study is decision regret and decision conflict in 
decision making for advanced kidney disease management. The following hypothesis 
was tested: 
Hypothesis One 
Patients with advanced kidney disease, who are ≥70 years and using 
OPTIONS, will have lower scores on the decision regret and decision conflict 
scale when compared with individuals who receive standard decision making 
support  
The secondary outcomes of the study are knowledge and quality of life. 
These outcomes have been tested by hypotheses 2 and 3. 
Individuals with advanced kidney disease, who are ≥70 years and using 
OPTIONS, when compared with patients who receive standard decision 
making support will have: 
Hypothesis Two 
 Higher knowledge score indicating sound knowledge of the benefits 
and risks of dialysis.  
Hypothesis Three 
 No difference in quality of life score. 
4.4 PUBLICATION—STUDY PROTOCOL 
4.4.1 Introduction 
This study protocol describes the pragmatic RCT which measured the 
effectiveness of OPTIONS in supporting older people with advanced kidney disease, 
consider the choice between dialysis and non-dialysis management. The study 
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control arm was standard education and decision making support provided by the 
renal nurses. The intervention arm was OPTIONS which includes a consultation with 
a renal nurse trained in the use of this decision support intervention. The primary 
outcomes were decision regret and decision conflict. Secondary outcome measures 
were knowledge and quality of life.  
The development and publication of the study protocol involved a rigorous 
peer review process. The publication of the study protocol has ensured dissemination 
of research intent to researchers in the field. Due to word limit restrictions for 
publication, additional information has been provided relating to key points in the 
manuscript. A detailed description of the study setting has been included as specific 
sites and characteristics of these sites were not mentioned within the protocol 
publication.  
Standard care has been described in greater depth to enable the reader to fully 
understand the difference between the intervention and standard care. An expansion 
of details regarding how the renal nurse manages the intervention group when they 
return for first visit has also been included. Further details have been provided 
regarding recruitment to assist with contextualisation of the recruitment issues 
experienced. As a result of recruitment issues changes were made to the data 
collection time points and data analysis plan. These key features of the study design 
will be described with the rationale for deviation from the published study protocol. 
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4.5 PUBLISHED MANUSCRIPT 
START OF PUBLISHED MANUSCRIPT 
4.5.1 Abstract 
Aim 
To assess the effectiveness of a decision support intervention using a pragmatic 
single blind Randomized Controlled Trial. 
Background 
Worldwide the proportion of older people (aged 65 years and over) is rising. 
This population is known to have a higher prevalence of chronic diseases including 
chronic kidney disease. The resultant effect of the changing health landscape is seen 
in the increase of older patients (aged 65 years and over) commencing dialysis. 
Emerging evidence suggests that for some older patients’ dialysis may provide 
minimal benefit.  In a majority of renal units non-dialysis management is offered as 
an alternative to undertaking dialysis. Research regarding decision making support 
that is required to assist this population in choosing between dialysis or non-dialysis 
management is limited.  
Design 
A multi-site single blinded pragmatic randomized controlled trial is proposed. 
Methods 
Patients will be recruited from four Queensland public hospitals and 
randomized into either the control or intervention group. The decision support 
intervention is multimodal and includes counselling provided by a trained nurse. The 
comparator is standard decision making support. The primary outcomes are 
decisional regret and decisional conflict. Secondary outcomes are improved 
knowledge and quality of life. Ethics approval obtained November, 2014 (Appendix 
H). 
Discussion 
This is one of the first randomized controlled trials assessing a decision support 
intervention in older people with advance chronic kidney disease. The results may 
provide guidance for clinicians in future approaches to assist this population in 
decision making to ensure reduced decisional regret and decisional conflict.  
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Trial registration  
Australian and New Zealand Clinical Trials Registry Number 
ACTRN12614001090606 l (Appendix I) 
Keywords 
Nurse, Decision making, chronic kidney disease, dialysis, non-dialysis 
management, conservative kidney management, Randomized Controlled Trial.  
Why this study or review is needed? 
 Research has shown that decisional regret is high in people undertaking 
dialysis and withdrawal from dialysis is one of the most common causes of 
death. 
 There are no decision support interventions available that have been 
designed specifically for the older person with advance kidney disease. 
 Limited research is available to determine if decision support interventions 
for the older person with advance kidney disease will lower decisional 
regret and decisional conflict. 
4.5.2 Introduction 
Globally, expenditure on health care is high and predicted to increase further 
due to the aging of the population and the advancement of health care technologies. 
This is evidenced by increasing expenditure of 2.6% in the year 2013, and a further 
rapid increase predicted of approximately 5.3% per year between 2014–2017 
(Deloitte, 2014). The primary factor contributing to the increasing expenditure on 
health care is the increase in life span in developed countries and the prevalence of 
chronic diseases. The worldwide proportion of older people (aged 60 years or over) 
has risen from 9.2 % in 1990 to 11.7 % in 2013 (United Nations et al., 2013). The 
proportion of older people globally is expected to grow and represent 21 % of the 
world population by 2050 (United Nations et al., 2013). As a consequence of the 
aging population, there is a higher prevalence of chronic diseases such as diabetes, 
hypertension, cardiovascular diseases and chronic kidney disease (CKD) which 
contribute to increased health expenditure (Deloitte, 2014; Eckardt et al., 2013). 
Chronic diseases are also the most common cause of morbidity and early death 
(Couser et al., 2011). The World Health Organisation has identified cardiovascular, 
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
74 Chapter 4: Research Methods 
 
cancer, diabetes and chronic respiratory disease as representing a major proportion of 
the global non communicable diseases (Couser et al., 2011). Chronic kidney disease 
is regarded as a key determinant in the poor outcomes for those who have 
cardiovascular, cancer, diabetes or chronic respiratory disease (Couser et al., 2011). 
The presence of chronic kidney disease is known to be related to an eight to tenfold 
increase in cardiovascular mortality and also increased risk for those with diabetes 
(Couser et al., 2011). 
Chronic Kidney Disease is defined as the presence of kidney damage and/or 
reduced kidney function, for a period greater than three months (Chadban et al., 
2003). The classification of kidney disease has five stages; Stage 1 indicates mild 
kidney disease while Stage 5 indicates end stage kidney disease (ESKD). Globally 
the number of deaths from CKD has increased by 82% in the last two decades 
(Radhakrishnan et al., 2014). End Stage Kidney Disease (ESKD) is the most severe 
form of kidney disease, with kidney function working at less than 15mL/min/1.73m². 
The number of patients with ESKD receiving renal replacement therapy worldwide is 
greater than 1.4 million, with an annual growth rate of 8% (Radhakrishnan et al., 
2014). In the presence of ESKD, renal replacement therapy  (transplant or dialysis) is 
usually required for survival (Australian Institute of Health and Welfare, 2009). 
Dialysis is an expensive treatment and places a considerable burden on health care. 
In Australia, for example, the predicted cost of treating all prevalent and incident 
cases of ESKD between the years of 2009–20 is estimated between $11.3 billion and 
$12.3 billion (Kidney Health Australia, 2010).  In the context of an ageing 
population worldwide, increasing numbers of people with chronic diseases such as 
CKD, and the predicted expenditure on technologies such as dialysis, it is necessary 
to consider the morbidity and mortality related to this treatment and the rationale for 
undertaking dialysis within this population. 
4.5.3 Background 
The high incidence of comorbid diseases in the older population, combined 
with the rise in the number and age of cases of ESKD receiving renal replacement 
therapy, has generated discussion around the appropriateness and benefit of dialysis. 
Worldwide the most common cause of death for a dialysis patient is withdrawal from 
dialysis (Davison et al., 2015). The high incidence of withdrawal as the cause of 
death for dialysis patients  indicates that there is a proportion of people who 
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commence dialysis for whom dialysis becomes untenable, with the most common 
reason for withdrawal from treatment being psychosocial (McDonald et al., 2010). 
Research has identified that 61% of patients regretted their decision to commence 
dialysis (Davison, 2010). Furthermore, this study found that high proportion of the 
patients reported that there was no discussion regarding end of life care preferences 
within the last 12 months. The study identified that almost 50% of the patients 
wanted to have end of life care discussion with the nephrologist, however in reality 
this occurred for less than 10% of the cases  (Davison, 2010). This is one of the few 
studies examining end-of-life care preferences. None the less the findings from 
Davison’s research indicate that it may be important for patients to have access to 
information needed to assist in objective and informed decision making.  
Facilitating informed decision making regarding health treatment options is 
important when there is no explicit health outcome benefit of one treatment. Decision 
support interventions have been used when there is no clear advantage in relation to 
health outcomes and when there are benefits and risks for each option, with the 
patient values becoming the determining factor in treatment choice. Evidence has 
demonstrated decision support interventions have facilitated decision making 
through improving knowledge regarding the treatment options and their benefits and 
risks (Stacey et al., 2014). In addition, decisional conflict can be lowered in relation 
to feeling uninformed and unclear regarding their individual values (Stacey et al., 
2014).   
In the setting of chronic kidney disease there is limited literature on the 
effectiveness of decision support interventions. A Cochrane systematic review 
identified two decision support interventions specific to kidney disease, however 
neither have been formally evaluated (Stacey et al., 2014). Other research identified 
includes a quasi-experimental study which was undertaken utilising multimedia 
interactive DVD nurse guided interviews, for patients with ESKD, with the 
comparator being standard education, in assisting the patient to choose between 
dialysis modalities (Chiou & Chung, 2012). This study achieved significant 
improvements in knowledge, pre-dialysis uncertainty and decision regret in the 
intervention group (Chiou & Chung, 2012). More recently a decision support 
intervention has been developed by Kidney Health Australia called “My Kidneys – 
My Choice” (Fortnum, Smolonogov, Walker, Kairaitis, & Pugh, 2015c) which has 
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yet to be thoroughly evaluated against patient related outcomes. The dearth of good 
quality evidence regarding the use of decision support interventions in chronic 
kidney disease has prompted the implementation of this research. The study design 
of a pragmatic single blind multi-site randomized controlled trial will enable robust 
evaluation of the effectiveness of this innovative intervention. The aim of the 
research is to evaluate an evidence-based decision support intervention to assist 
patients’ 70 years and over who have advanced CKD, to choose between dialysis and 
non-dialysis management.  
Intervention development 
The decision support intervention to be tested in this research was developed 
from the Ottawa Decision Support Framework (ODSF). This framework is an 
evidence-based, mid-range theory developed to guide patients to make health or 
social decisions (O’Connor et al., 2011). The three concepts of ODSF are providing 
decision support, assessing the patients’ needs or determinants of decision, and 
evaluating decision quality and outcomes of decision as illustrated in Figure 4.1, 
page 77 (O’Connor et al., 2011). The framework was developed for health decisions 
where decisional conflict is high, in particular, for decisions that need to be made 
when there is a new diagnosis or condition. The decision regarding the choice 
between dialysis or non-dialysis management has a high level of decisional conflict 
as evidenced by previous studies identifying a high level of decisional regret and also 
withdrawal from dialysis as a common cause of death. 
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Decisional Needs
 Decisional conflict
 Knowledge and expectations
 Values
 Support and resources
 Decision:  type, timing, stage, learning
 Personal/clinical characteristics
Decision Quality
 Informed
 Values-based
Actions
 Delay, continuance
Impact
 Values-based health outcomes
 Regret & blame
 Appropriate use of costs and services
Decision Support
 Clarify decision and needs
 Provide facts, probabilities
 Clarify values
 Guide in deliberation and communication
 Monitor/facilitate progress
Counseling     Decision Tools     Coaching
 
Figure 4.1. Ottawa Decision Support Framework.  
(Copyright 1996 by O’Connor; reprinted with permission of author) 
The ODSF has been used to guide the development of over 30 distinct patient 
decision support interventions. Numerous randomized controlled trials have been 
undertaken to evaluate decision support interventions covering topics such as: 
women after menopause (O’Connor, 2006; O’Connor et al., 1998c), pregnancy in 
older women (Drake et al., 1999), breast cancer (Goel et al., 2001), and non-valvular 
atrial fibrillation (Man-Son-Hing et al., 1999). The ODSF provided guidance for 
development of the decision support intervention to be used in this study (hereafter 
referred to as OPTIONS). The development of the OPTIONS intervention 
assimilated the decision making process as defined by the ODSF incorporating the 
three concepts described above. The determinants of decisions are elements that 
influence decisions such as inadequate knowledge, personal values, unrealistic 
expectation of the health care, perceptions of others and personal resources to make a 
decision (O’Connor et al., 1998b). When these are inadequate a poor decision—
relative to the individual’s personal values—is often made. In contrast, a good 
decision from the individual’s perspective, may lead to poor clinical outcome but can 
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result in a high level of satisfaction, congruence between values and choice and a low 
level of uncertainty (O’Connor et al., 1998b). 
4.5.4 The Study 
4.5.5 Aim 
The aim of the study is to examine the effectiveness of OPTIONS for older people 
considering the choice between dialysis and non-dialysis management when they 
have reached ESKD.   
Hence the following null hypotheses will be tested: 
For patients with ESKD who are ≥ 70 years and receiving the decision 
support intervention there will be no differences in: 
Primary outcomes of: 
1. Decisional regret score  
2. Decision conflict score 
Secondary outcomes of: 
1. Knowledge score 
2. Quality of life 
4.5.6 Study Design and Methods 
The study design is a pragmatic randomized controlled trial (RCT) measuring 
the effectiveness of the OPTIONS tool in supporting the patient and their family in 
making a choice between dialysis and non-dialysis management for ESKD. The 
research is part of Author One’s doctoral studies. The methodological complexities 
of development, delivery and evaluation of the intervention, relate to the nature of 
the clinical situation, whereby participants are undertaking value-sensitive health 
decisions within everyday situations. The decisions to be made are complex and 
often have no clear ‘best choice’ for everyone, either because the outcomes are 
uncertain or due to the fact that the decision involves trade-offs between advantages 
and disadvantages of receiving treatment (Wennberg, 2002). The pragmatic RCT 
design allows for evaluation of a complex intervention (Hotopf, 2002). A complex 
intervention can be defined as having multiple interacting components and a non-
linear casual pathway (Medical Research Council, 2000). OPTIONS conforms to the 
features of a complex intervention in that there is interaction between the individual 
with ESKD, their family and the health professional delivering the intervention. The 
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individual’s response to OPTIONS is unpredictable with the possibility of several 
differing outcomes. The elements of the study that are characteristic of a pragmatic 
design include specific features of the patient and comparison group, broad inclusion 
criteria, potential for clinician variance in the delivery of OPTIONS and specific 
outcomes. To address some threats to bias, this study design includes control 
strategies for blinding at the points of randomization, data collection and outcome 
analysis. These design elements contribute to the study’s internal and external 
validity. The CONSORT flow diagram in Figure 4.2 summarises the study design.  
4.5.7 Participants 
The study population is all adult patients ≥70 years of age with an estimated 
glomerular filtration rate of ≤ 20 mL/min/1.73m² who are attending specialist 
nephrology services (renal clinics) and who have been diagnosed with chronic 
kidney disease by a nephrologist. The exclusion criteria are: non English speaking, 
those who are declared medically incompetent to make health care decisions, those 
who are eligible to receive a kidney transplant, and those who have already made a 
decision regarding treatment. This is an Australian study which will be conducted at 
four public health renal departments in Queensland. These departments vary in the 
complexity of care provided. Despite the difference in service capabilities and 
complexity of care all renal departments have formalised CKD management and 
education strategies for patients with advanced chronic kidney disease.  
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Figure 4.2. CONSORT summary diagram showing flow of participants at each stage of 
the study. 
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4.5.8 Sample Size 
Calculation of sample size was informed by a review of the literature to 
identify research utilising decision support interventions that assist CKD patients to 
make treatment choices. A study conducted in Taiwan (Chiou & Chung, 2012) 
measured the effectiveness of a multimedia education format to assist patients with 
CKD to make a treatment choice. Several measures were utilised, with the variable 
‘decision regret’ achieving a statistically significant difference between the 
experimental group and the control (Chiou & Chung, 2012). The outcome variable of 
‘decision regret’ was considered for effect size. The calculations were based on 90% 
power and a Type1 error rate (two-tailed) of 5%. The effect size was calculated to 
detect a 15% change in the outcome. Based on this, the minimum sample size 
required is 122 patients in total allowing for 20% loss to follow-up. The study will 
require a minimum of 61 patients in each study arm. 
4.5.9 Randomization and Recruitment 
Randomization will occur once the eligibility of the patient is confirmed, 
consent provided and baseline data has been collected. The allocation of the patient 
to either intervention or standard care will occur through a computer generated 
program using block randomization.  
4.5.10 Sequence generation 
The randomization process, within this pragmatic randomized controlled trial, 
has been developed to eliminate bias. Block randomization ensures there is a balance 
in the number of patients allocated to intervention or control (Efird, 2011). A block 
size of four will be used. This allocation process provides six possible ways of 
equally assigning participants to a block sequence and is more appropriate for 
smaller sample sizes which may occur at some sites. To maintain the effect of 
randomization and reduce bias, the block sizes are not revealed to the Clinical 
Research Assistant (CRA) who is managing treatment mode allocation. To 
counteract this predictability, the lead researcher is the only individual aware of the 
block size and has no involvement in recruitment, consent or allocation.  
4.5.11 Allocation concealment mechanism 
The random allocation sequence has been generated utilizing a computer 
generated block randomization list (Sealed Envelope Ltd., 2015). The lead researcher 
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then placed the code generated into sequentially numbered envelopes. The lead 
researcher is blinded to the group that is identified by the code.  
Before recruitment begins the CRA at each site will ascertain the code for 
group allocation, by contacting the associate investigator. This communication 
between the CRA and associate investigator occurs only once for each site prior to 
the commencement of recruitment. The CRA will obtain a sealed envelope (which 
are sequentially ordered and contain the computer generated allocation code) and 
then assign the participant to their allocated group. The CRA will then use the 
relevant code, to identify the treatment allocation for that participant in all of the 
documentation. This code system will ensure concealment of the group identity for 
the outcome research assistant (ORA) who will collect data at time points of one, 
three and six months, and the lead researcher who will conduct the data analysis.  
4.5.12 Implementation 
Those participants that have been randomized to receive the intervention will 
be provided with a booklet, audio recording and personal worksheet by the CRA.  
4.5.13 Blinding 
Due to the nature of the intervention it was not possible to blind the CRA, 
participants or the renal nurses. However, to minimise bias, the ORA (responsible for 
collection of outcome data) and the lead researcher (responsible for data analysis) 
were blinded to group allocation. 
4.5.14 Intervention  
This is a two-arm study with equal allocation randomization for the 
participants to receive either treatment or control. The treatment is—OPTIONS and 
control—the standard method of assisting decision making that is currently provided 
to CKD patients. In both groups the education given to the participants regarding 
treatment options will not differ, they may be given a variety of booklets and audio-
visual material and also may be invited to attend group education sessions. The 
differentiating feature between both groups is the OPTIONS intervention which has 
been designed specifically to assist with complex decision making.  
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4.5.15 Treatment 
The components of OPTIONS include a workbook, audio recording, personal 
worksheet and consultation with a trained renal nurse.  
4.5.16 Workbook and audio recording 
OPTIONS has been developed by the authors utilizing best available evidence 
regarding patient outcomes, informed by a systematic review (Brown et al., 2014). In 
addition further published evidence regarding morbidity of dialysis patients 
(McDonald, 2012), symptom prevalence, hospital admissions, quality of life and 
functional performance has also been incorporated into OPTIONS (Carson et al., 
2009; Joly et al., 2003; Kurella Tamura et al., 2009; McDonald, 2012; Murtagh et al., 
2007a; Murtagh et al., 2007b; Murtagh, Sheerin, Addington-Hall, & Higginson, 
2011; Seow et al., 2013).  
The illustrated workbook consists of pictorial icons and bullet points to help 
participants in the intervention group understand the information presented. The 
workbook includes instructions on how to use the decision support intervention, 
learning objectives, definition of ESKD, symptom identification, key points 
discussed, advantages and disadvantages of dialysis, advantages and disadvantages 
of non-dialysis management, summary of choices, steps on how to make a choice 
regarding treatment, two hypothetical scenarios outlining the decision making 
process, what to do if unable to make a decision, sources of further reading or 
support groups and references. The text of the workbook has been analysed for 
readability using FK grade-level function available on the Microsoft Word 2003 
Document program using Windows XP. The use of audio recording and workbook is 
designed for comprehension at education level of Year/Grade 8 which is consistent 
with the ODSF requirements. The workbook meets the International Patient Decision 
Aids Standards (IDPAS) (Edwards & Elwyn, 2009).  
4.5.17 Worksheet 
The worksheet will be filled out by the patient after listening to the audio 
recording and reviewing the workbook. The worksheet is designed to support the 
patient in summarising their personal values and is a discussion point for the 
consultation with the trained renal nurse.  
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4.5.18 Clinical Consultation 
The renal nurse undertaking the consultation with the patient in the 
intervention group will have undergone training to support people to make decisions 
about their health. The training involves completion of  the Ottawa Decision Support 
Tutorial (O’Connor et al., 2011). Within this tutorial they are required to describe 
concepts of decision support, identify complex decisions, explain how to assess 
patients’ decisional needs, tailor decision support and explain how to use decision 
support interventions (O’Connor et al., 2011). The renal nurse will assess the 
participants' understanding of the treatment options and if an explicit decision is 
made this will be documented in the patient’s hospital records.  
4.5.19 Control 
Standard care in the form of decision support and information presented to 
each individual patient may vary across sites and is dependent on the clinical 
expertise of the renal nurse. At all study sites there are formalised clinics for patients 
with advanced CKD. Within these clinics the patients are provided with assistance to 
make treatment choices. The clinicians providing the standard decision support will 
differ from those delivering the intervention.  
4.5.20 Outcomes 
Primary outcome variables and measures 
The primary outcomes have been chosen based on the Ottawa Decision 
Support Framework. The premise of this study is that decisional regret and decisional 
conflict will be lower using OPTIONS. The ‘decision regret scale’ (Brehaut et al., 
2003) will measure distress or remorse after a (health care) decision. The scale 
demonstrated strong correlation with decision satisfaction, decisional conflict and 
quality of life (O’Connor, 2003). This scale involves five questions and is quick and 
easy to complete. Repeated measurements will occur at one month (T1), three 
months (T2) and six months (T3) following consultation with a renal nurse. The 
scoring and interpretation of the scale will follow the framework outlined by the 
Ottawa Hospital and Health Research Institute (OHHRI).  The validity of this scale 
has an alpha coefficient between 0.81 and 0.92.  
The ‘decision conflict scale’ (O’Connor, 2010) has been developed by OHHRI 
to measure both decision conflict and uncertainty. The scale has been designed to 
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capture decisional conflict with sub scores for uncertainty, feeling informed, values 
clarity and supported in decision making. Numerous variations of this scale have 
been developed for use in either the clinical or research settings.  The scale chosen is 
a 10 item, 3 response category where 3= no, 2= unsure and 1= yes (O’Connor, 2010). 
This scale has been developed using a response format that was found most useful 
for those with limited reading or response skills. This scale is the second most tested 
version of the Decision Conflict Scale available from the OHHRI. This scale will be 
used to measure decisional conflict at one month (T1) following consultation with 
the renal nurse. The score will be calculated and used to indicate the level of 
decisional conflict and uncertainty. This will be a once only measurement (T1) 
unless the patient has been unable to make a decision, in which case a repeated 
measure will be collected at the three-month time point (T2). The scale has been 
validated for low literacy populations in Canada, USA and Chile with an alpha 
coefficient score of 0.86 when tested with English speaking women considering 
breast cancer options.  
Secondary outcome variables and measures 
The secondary outcome variables are improved knowledge and quality of life.  
Improved knowledge of options and the benefits and harms of these options is 
measured by administration of a knowledge questionnaire (O’Connor, 2004). This 
questionnaire has been shown to capture the level of understanding the patient has 
regarding treatment options, possible benefits and harms of the treatment options and 
the individuals risk perceptions. This style of questionnaire has been used for patients 
with clinical conditions such as Atrial Fibrillation, Hormone Replacement Therapy, 
Lung Cancer and Osteoporosis. The knowledge questionnaire has been adapted for 
this study to assess participants’ knowledge of risks perceptions of dialysis. The 
measurement of knowledge the patient has achieved, will only occur at after the one-
month consultation (T1). The method for scoring and interpretation of data from this 
scale has been provided by the OHHRI and will be utilised as advised. The content 
validity of the knowledge questionnaire is established by a panel to ensure the 
questionnaire taps understanding of key concepts. Content of this decision support 
intervention is based on scientific evidence.  
Quality of life will be measured using the KDQOL-SF™v1.3survey 
(Hawthorne, Osborne, Taylor, & Sansoni, 2007). This is a well validated tool in 
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kidney disease which has demonstrated high internal consistency in all domains. 
Quality of Life score will be collected at one month (T1), three months (T2) and six 
months (T3) time points. 
Additional Measurements 
Assessment of the utility of OPTIONS in preparing the patient to communicate 
with the renal nurse and make health care related decisions will provide additional 
feedback to the researchers as to the effectiveness of the decision support 
intervention. 
Preparation for ‘decision making’ scale (O’Connor & Graham, 1995) is 
designed to assess both the participant’s and renal nurses perception of how useful 
OPTIONS was in preparing them to communicate with the renal nurse and make a 
health care related decision (O’Connor & Graham, 1995). This questionnaire will be 
completed by the participant and the renal nurse at the one-month time point (T1). 
The alpha coefficient ranges from 0.92 – 0.96 and reliability was 0.944. 
4.5.21 Study Procedure 
Following ethics and local governance approval, patients who meet inclusion 
criteria will be approached by the clinical research assistant (CRA). The CRA will 
explain the study to these patients using comprehensive ethics committee-approved 
documents, and patients will be given an opportunity to ask questions and receive 
further information. This process is to ensure participants are fully informed of the 
possible burden of appointments and data collection on their time and to enhance 
retention and reduce loss to follow-up.  
Once written consent has been obtained by the CRA, they will then collect 
baseline clinical and demographic variables from the participant as outlined in Table 
4.2. Participants are then randomly allocated to either intervention or control group 
as described earlier.  They are given follow-up appointments via a letter to assist with 
regular attendance at the clinic with the renal nurses.  
At the one-month time point, the participants, randomised to receive the 
intervention, return with the booklet and worksheet completed. The renal nurse will 
then work through these with the participant to ensure they understand the content 
and that they have identified their personal values in the worksheet. Should the 
situation arise where the participant has not yet read the booklet or completed the 
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worksheet then the renal nurse will work through it with them during the 
appointment.  
Additional clinical data and primary and secondary outcome data are collected 
at time points of one month (T1), three months (T2) and six months (T3). The 
CONSORT flow chart of the study protocol is shown in Figure 4.2 
Table 4.2 Clinical and demographic variables 
 Baseline 1 
month(T1) 
3 months 
(T2) 
6 months 
(T3) 
Sex X    
Age X    
Number of people living with 
participant 
X    
Employment status 
(pensioner/self-funded 
retiree/working) 
X    
Stage of Kidney Disease (eGFR 
and Creatinine) 
X X X X 
Comorbidities – Ischaemic heart 
disease, diabetes, peripheral 
vascular disease 
X X X X 
Australian Karnofsky Performance 
Scale (Jha et al., 2013) 
X X X X 
Body Mass Index X X X X 
Hospital Days  X X X 
Alive/Deceased  X X X 
4.5.22 Data analysis 
Data analysis for this study will be conducted on an intention-to-treat basis. 
Descriptive statistics will be used to summarise patient characteristics. For 
continuous measures the differences between intervention and control group will use 
t-tests and Mann-Whitney U test depending on distributions and appropriateness of 
test. Analysis of the sub scores of Decision Conflict Scale will also be undertaken if 
differences in decision conflict score are noted. As both groups will have large 
numbers (greater than 50) the 95% confidence interval will be calculated for the 
differences in mean outcome, between the intervention group and the standard group. 
The confidence intervals for median values would also be undertaken where 
required. For categorical measures the chi-square statistics will be applied.  
A stepwise logistic regression procedure will be performed if there is a need to 
adjust for confounding. Baseline factors which may contribute to confounding are 
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socio-economic status (pensioner/self-funded/employed) and participant location. An 
α level of 0.5 will be used to indicate statistical significance. Cox regression and log 
rank test methods will be utilised to estimate and compare survival. An intra-Cluster 
Correlation post hoc analysis will be undertaken to demonstrate that clustering is 
insignificant. 
4.5.23 Ethical Considerations 
This research will be undertaken according to the National Statement of Ethical 
Conduct in Human Research (2014) produced by the National Health and Medical 
Research Council of Australia (National Health and Medical Research Council, 
2007). Approval has been obtained from the Health Board Research Ethics 
Committee (HREC/14/QRBW/425) and University Ethics Committee (QUT 
1400000937) in November, 2015 with site specific agreement obtained from the 
research governance office at each health service.  
Confidentiality of all participants’ details will be protected. Patient data will 
also be de-identified with coding sheets stored at each site. Participants will receive 
detailed information regarding the study and be invited to participate through a 
written consenting process. Clinical care will not be impacted should the participant 
not wish to be involved in the study or should they wish to withdraw from the study.  
All data analysed will be de-identified and stored securely for 15 years and then 
destroyed as per University data management policy. All the data will be collated 
and there is no intention of analysing individual data or reporting these results to 
specific participants.  
The primary investigator and associate investigators are the only individuals 
who will have access to the final trial dataset and this agreement is outlined in the 
ethics submission.  
4.5.24 Rigour 
The study design of a pragmatic RCT will enable evaluation of the decision 
support intervention through reduction of intrinsic methodological issues that occur 
when undertaking clinical research in an ‘uncontrolled environment’. Creating a 
combination of explanatory and pragmatic elements helps to ensure both internal and 
external validity by utilising a mixture of both methodologies, therefore achieving 
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validity in the research outcomes. This is a major strength of this research design and 
is relevant to testing complex interventions.  
4.5.25 Discussion 
There is a paucity of research evaluating the use of decision support 
interventions to assist older patients with advanced CKD in making treatment 
choices. The use of a robust study design and evidence-based decision support 
intervention guided by a strong theoretical framework will help to provide further 
knowledge regarding decisional conflict and decisional regret in the setting of 
advanced CKD. Research staff will be recruited at each of these sites to ensure 
appropriate blinding, with renal nurses either delivering the intervention or control to 
prevent contamination. Agreement and support by all clinical staff within the renal 
departments at these sites will ensure the maximal number of participants recruited. 
This pragmatic RCT will be the first study to develop and validate a decision support 
intervention specifically designed for the aged with advanced CKD to assist them in 
making a choice between dialysis and non-dialysis management.  
4.5.26 Limitations 
Despite the efforts to reduce bias, contamination between groups is a potential 
limitation. This may be as a result of the close environment in which the renal nurses 
work. When initiation of the study occurs, and during site visits the renal nurse 
delivering OPTIONS is made cognizant of the importance of not discussing this 
content with the renal nurse providing standard care. In addition, observer bias may 
occur if the ORA become aware of which group the patients have been allocated to. 
All efforts have been made to ensure this does not occur, including a section in the 
patient consent form encouraging them not to reveal to the ORA which group they 
have been allocated. The requirement for such a large sample size within a 
potentially frail and vulnerable population may prove difficult within the timeframe. 
The restricted time frame may also fail to capture the phenomenon of the 
intervention as there is an expectation for the participants to make a decision 
regarding treatment choice one month after receiving the information and within one 
specific counseling session. 
END OF PUBLISHED MANUSCRIPT 
References for the published manuscript are included in the thesis reference list 
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The word limitation for published manuscripts necessitates limited content. 
Accordingly, the remainder of this chapter will provide a detailed description of 
study sites, description of standard care and intervention care, recruitment strategies, 
data collection and data analysis. The processes used in data management and ethical 
considerations are also described.  
4.6  SETTINGS 
The study was conducted in South-East Queensland at four Queensland Health 
outpatient services. The initial sites for the study were Royal Brisbane and Women’s 
Hospital (RBWH), Nambour Hospital and Hervey Bay Hospital (HBH). Toowoomba 
Base Hospital (TBH) was added due to low recruitment numbers at the initial sites. 
Meetings with medical, nursing and research staff occurred on several 
occasions both prior to and post ethics approval. The meetings prior to ethics 
application were undertaken as part of feasibility study to determine model of care, 
estimate patient recruitment numbers and a realistic time frame. Meetings were held 
post-ethical approval to ensure continuing recruitment and increase staff awareness 
of study requirements and screening criteria. Approval to undertake this research was 
obtained from key medical and nursing personnel at all research sites. Despite 
considerable discussion prior to ethics approval and commencement of the study, one 
RBWH ambulatory clinic identified that they would no longer be able to support the 
study due to inadequate nursing resources. This late decision regarding withdrawal of 
this research site had an effect on recruitment numbers.  
4.6.1 Royal Brisbane and Women’s Hospital  
The Royal Brisbane and Women’s Hospital (RBWH) is a 929-bed tertiary 
referral teaching hospital located near the central business district of Brisbane. The 
RBWH is located within the Queensland Health Metro North Hospital and Health 
Services and it is the largest healthcare provider in Queensland providing a large 
number of specialist services.  
The renal service delivers kidney health services to Brisbane North and some 
areas of the Sunshine Coast. The renal service also receives referrals for specialised 
kidney care from across Queensland. The service has a particular focus on 
management of chronic kidney disease (CKD) with three ambulatory clinics 
operating out of suburbs including Nundah, Stafford and North Lakes. A review of 
Leanne Brown 
Chapter 4: Research Methods 91 
 
the CKD database identified approximately 369 patients with eGFR less than 
30mL/min. The database grouped the patients by stage of kidney disease hence the 
30ml/min cut off for Stage 4 kidney disease. There was no ability to obtain detailed 
information about their education status, whether the patients had made a decision or 
a more accurate estimate of kidney function. Utilising this information in 
consultation with key clinical staff an estimate of recruitment numbers was 
undertaken. The predicted recruitment numbers overall at the two ambulatory clinics 
where this study was conducted was 20 patients per month over three months.  
4.6.2 Hervey Bay Hospital 
Hervey Bay Hospital is a 104 bed acute care facility for the Fraser Coast region 
and works in partnership with Maryborough Base Hospital to provide care for 
communities within the Wide Bay Hospital and Health service. Maryborough Base 
Hospital provides an 88 bed sub-acute service including outpatient services for a 
range of specialities such as medicine, surgery, urology and renal medicine. The 
renal service covers both Hervey Bay and Maryborough Hospital. A review of the 
CKD database identified approximately 50 patients with eGFR less than 20mL/min. 
There was no ability to obtain detailed information about alive status and whether the 
patients had made a decision. Utilising this information in consultation with key 
clinical staff an estimate of recruitment was undertaken. The predicted recruitment 
numbers overall at the two clinics where this study was conducted was five patients 
per month over three months.  
4.6.3 Nambour General Hospital 
Nambour General Hospital is a 388-bed tertiary referral teaching hospital 
located within the Sunshine Coast Hospital and Health Service. Nambour General 
Hospital provides extensive specialist services. The renal service provides care to the 
population from Nambour, Gympie, Caloundra and Maleny Hospitals. Ambulatory 
clinics were provided at Gympie and Caloundra Hospitals. A review of the CKD 
database identified approximately 350 patients with an eGFR less than 20mL/min. 
There was no ability to obtain detailed information about whether the patients had 
made a decision. Utilising this information in consultation with key clinical staff an 
estimate of recruitment numbers was undertaken. The predicted recruitment numbers 
overall at the three ambulatory clinics where this study was conducted was 10 
patients per month over three months.  
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4.6.4 Toowoomba Hospital 
Toowoomba Hospital is a 324-bed referral hospital and provides care for the 
communities within the Darling Downs Hospital and Health Service. The renal 
service provides services to the population from Dalby, Roma, Charleville, 
Kingaroy, Stanthorpe and Warwick Hospitals. Due to the large distances some of 
these services are provided through telehealth. A review of the CKD database 
identified approximately 100 patients with eGFR less than 30mL/min. The database 
grouped the patients into stage of kidney disease hence the 30ml/min cut off for 
Stage 4 kidney disease. There was no ability to obtain detailed information about 
their location, accurate estimate of kidney function and whether the patients had 
made a decision. Utilising this information in consultation with key clinical staff an 
estimate of recruitment numbers was undertaken. The predicted recruitment numbers 
overall was seven patients per month over three months.  
There is variation in the clinical capability classification of these hospitals. The 
clinical service capability framework has been established by Queensland Health to 
help define patient complexity and clinical care. Table 4.3 summarises briefly the 
patient complexity in relation to the services. RBWH and Nambour are tertiary 
hospitals (Level 5 classification), whereas Hervey Bay Hospital and Toowoomba are 
classified as regional hospitals (Level 4) and MBH a regional hospital (level 3) 
(Queensland Health, 2012). These renal services vary in complexity of care 
provided. The referral pathway for education of patients with advanced kidney 
disease also varied between services and was primarily dependent on the 
nephrologist to refer through to the education program. The timing of the referral 
generally occurred when the eGFR was less than 20 mL/min/1.73m
2
. The format, 
quality and accessibility of information resources also varied between services.  
Table 4.3  Patient complexity and level of service 
Level Complexity 
Level 1, 2 and 3 services Low complexity 
Level 4 service Moderate complexity 
Level 5 and 6 services High complexity 
 
This is a two arm study with equal allocation randomisation for the participants 
to receive either the intervention or standard care. A detailed description of the 
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features of standard care and intervention care, including training processes is 
provided below. 
4.7 STANDARD CARE 
In this study, standard care for patients considering treatment options for 
advanced kidney disease is the delivery of decision support and education to the 
patient by a registered nurse who specialises in renal care. This is the usual method 
of assisting patients to make a treatment choice. There is no formalised training for 
the renal nurse to provide this care. This research project did not involve collection 
of information regarding qualifications of renal nurses as there was no ability to 
ensure stability of staffing. The nurses providing standard care were not involved in 
delivery of the intervention. At all study sites there are formalised clinics for patients 
with advanced kidney disease. In these clinics, the patients are provided with some 
level of education and/or assistance to make treatment choices. Australian guidelines 
(Caring for Australians with Renal Impairment) suggest that patients with CKD and 
their families should receive sufficient information regarding treatment options so 
they are able to make an informed choice (Kelly, Stanley, & Harris, 2005). Research 
by Morton et al. (2010) showed that lack of choice and medical decisions impacted 
on the patients’ perceived decision making ability, and they highlighted the variation 
between clinical practice and current guidelines.  
There is no standardised approach to patient education in this context. Delivery 
of standard care across the sites in terms of the level of education and decision 
support the patient receives is dependent on the individual nurse. Basic information 
regarding the skill set of the nurses was collected following the completion of the 
study to provide understanding of the variance within standard care. The level of 
expertise ranged from specialist nurse practitioner to generalist registered nurse with 
some knowledge of chronic kidney disease education. The educational and 
counselling skills ranged from a selection of nurses with skills and training in 
motivational interviewing to those with some degree of practical experience in 
education. Most nurses used a variety of education leaflets depending on their 
preferred resources. The use of the decision support intervention developed by 
Kidney Health Australia was not routine practice at any site. This DSI ‘My Kidney, 
My Choice’ (Fortnum et al., 2015b) was critiqued in the literature review on page 18 
of that paper and has been available for use for approximately two years. The use of 
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‘My Kidney, My Choice’ was not excluded for use in either the intervention or 
standard care group and should have no impact on study outcomes as it was used 
infrequently. The real world nature of standard care for the control group is an 
identified feature of the pragmatic RCT design. Other characteristics, namely the 
number of clinical reviews by the renal team, referral by renal physician, time with 
the nurses and interactions with multidisciplinary teams are common to both groups.  
4.8 INTERVENTION 
4.8.1 Workbook and audio recording 
OPTIONS has been developed by the authors utilizing best available evidence 
regarding patient outcomes, informed by a systematic review (Brown et al., 2014). In 
addition further published evidence regarding morbidity of dialysis patients 
(McDonald, 2012), symptom prevalence, hospital admissions, quality of life and 
functional performance has also been incorporated into OPTIONS (Carson et al., 
2009; Joly et al., 2003; Kurella Tamura et al., 2009; McDonald, 2012; Murtagh et al., 
2007a; Murtagh et al., 2007b; Murtagh et al., 2011; Seow et al., 2013).  
The illustrated workbook consists of pictorial icons and bullet points to help 
participants in the intervention group to understand the information presented. The 
workbook includes instructions on how to use the decision support intervention, 
learning objectives, definition of ESKD, symptom identification, key points 
discussed, advantages and disadvantages of dialysis, advantages and disadvantages 
of non-dialysis management, summary of choices, steps on how to make a choice 
regarding treatment, Two hypothetical scenarios outlining the decision making 
process, what to do if unable to make a decision, sources of further reading or 
support groups and references were included. The text of the workbook has been 
analysed for readability using FK grade-level function available on the Microsoft 
Word 2003 Document program using Windows XP. The use of audio recording and 
workbook is designed for comprehension at education level of Year/Grade 8 which is 
consistent with the ODSF requirements. The workbook meets the International 
Patient Decision Aids Standards (IDPAS) (Edwards & Elwyn, 2009).  
4.8.2 Worksheet 
The worksheet will be filled out by the patient after listening to the audio 
recording and reviewing the workbook. The worksheet is designed to support the 
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patient in summarising their personal values and is a discussion point for the 
consultation with the trained renal nurse.  
4.8.3 Clinical Consultation 
The renal nurse undertaking the consultation with the patient in the 
intervention group received training to support people in making decisions about 
their health. The training involves completion of the Ottawa Decision Support 
Tutorial (O’Connor et al., 2011). Within this tutorial they are required to describe 
concepts of decision support, identify complex decisions, explain how to assess 
patients’ decisional needs, tailor decision support and explain how to use decision 
support interventions (O’Connor et al., 2011). The tutorial also provides guidance for 
the intervention nurse on how to provide decisional support should the patient return 
without having read the booklet or completed the worksheet. The nurse is required to 
work through the booklet and worksheet with the patient providing impartial support 
to help them reach a decision. The approach to support the patient to complete the 
worksheet within the clinical consultation is standardised and follows the format 
outlined within the tutorial. 
During the clinical consultation—whether the patient had previously completed 
the worksheet or did so at the time of the appointment—the renal nurse will assess 
the patient’s understanding of the treatment options and elaborate on any information 
required to assist with decision making. If an explicit decision has been made, this 
decision will be documented in the patient’s hospital records.  
4.9 STUDY METHODS 
To demonstrate the complexity of recruitment and data collection for this study 
a detailed description of recruitment methods, and strategies for data collection has 
been provided to supplement information in the published study protocol. 
4.9.1 Recruitment 
The identification of eligible participants was undertaken through regular 
reviews of the pathology and clinical notes of the potential participants, prior to their 
designated clinic appointment. In some cases, the researcher attended the hospital 
and reviewed the site databases with the nurses to facilitate regular screening and 
identification of eligible participants. The storage and management of clinical 
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information needed to identify potential participants varied between sites. Screening 
was three monthly at some sites and at other sites screening occurred ad-hoc such as 
when new patients were referred. Recruitment commenced on 19 March 2015 and 
ended on 31 March 2016.   
4.9.2 Outcomes 
Study outcomes and data tools are fully described in the above protocol manuscript. 
During the process of research, low recruitment numbers and the extension of 
recruitment time affected the collection of outcome measures over an extended time 
period. Consequently, the decision was made to limit analysis of outcome measures 
to those collected at T1 and T2. Table 4.4 illustrates the outcome measures and 
adjusted time points for data collection. The primary outcome variable decision 
regret has only been evaluated at two time points – one month (T1) and three months 
(T2). Health Related Quality of Life measurement was also adjusted and only 
occurred at one month (T1) and three months (T3) as outlined in Table 4.4. 
Prior to commencement of recruitment, the measurement instrument for health 
related quality of life was changed from the use of KDQOL-SF™v1.3survey 
(Hawthorne et al., 2007) to SF-36v2® Health Survey. This was undertaken to reduce 
research burden for the participants and to lower risk of missing data. The SF-36v2® 
Health Survey questionnaire includes 36 items assessing eight dimensions of 
functioning and well-being (Appendix J). In each dimension the participant receives 
a score from 0–100 with the higher the score, the better the health. The reliability, 
validity and sensitivity of this assessment have been established for CKD patients 
(alpha coefficient >0.78 and reliability (0.77– 0.93) (Gibbons & Fitzpatrick, 2010; 
Lowrie, Curtin, LePain, & Schatell, 2003). The two component summary scores of 
SF-36v2® Health Survey—physical component summary (PCS) and mental 
component summary (MCS) can predict morbidity and mortality in end stage kidney 
disease (Erez, Selman, & Murtagh, 2016; Lowrie et al., 2003; Mansur, Colugnati, 
Grincenkov, & Bastos, 2014; Seidel et al., 2014). Quality of life will be measured at 
T1 and T2. 
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Table 4.4  Time points for collection of outcome variables 
 Baseline 1 month 
(T1) 
3 months 
(T2) 
Decision Regret Scale  X X 
Decision Conflict Scale  X X(if no prior 
decision 
made) 
Knowledge  X  
Health Related Quality of Life (SF-36v2® Health 
Survey) 
 X X 
Sex X   
Age X   
Number of people living with participant X   
Employment status (pensioner/self-funded 
retiree/working) 
X   
Stage of Kidney Disease (eGFR and Creatinine) X X X 
Comorbidities – Ischaemic heart disease, 
diabetes, peripheral vascular disease 
X X X 
Australian Karnofsky Performance Scale (Jha et 
al., 2013) 
X X X 
Body Mass Index X X X 
Hospital Days  X X 
Alive/Deceased  X X 
4.9.3 Data Analysis 
Data analysis for this study was conducted on an intention-to-treat basis. The 
evaluation of repeated outcome measures with missing data was not identified in the 
study protocol. After discussion with a statistician and prior to revealing the 
allocation code, a decision was made to use a linear mixed model (LMM). Linear 
mixed model is an appropriate analytical technique to undertake a robust analysis of 
a data set containing missing data. If a participant does not have data present for all 
time points the entire data set is omitted in a multivariant ANOVA whereas in the 
LMM analysis all observations that are available for any participant will be included 
in the analysis. (Galecki, Welch, & West, 2014).  
The linear mixed model (LMM) analysis provides a flexible approach to 
analysis of repeated measurements on each subject over time as it is able to 
accommodate uneven spacing between repeated measurements (Galecki et al., 2014). 
The outcome scores for decision regret scale and two components of SF36—Physical 
Health (PHS) and Mental Health (MHS) component summary score, are measured as 
the dependent variables. Predictor variables in the model included fixed effects of 
randomisation group, age, time and gender. The interaction is included in the model 
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independent of the results. Random effects of variables such as age, gender and time 
were evaluated.  
Cox regression and log rank test methods were utilised to estimate and 
compare survival. An intra-Cluster Correlation post hoc analysis has not been 
undertaken due to the large variation of participant numbers between sites. Further 
analyses have been added to provide information in relation to the effect of the 
intervention on time to decision made and to identify if presentation of treatment 
options has occurred in a balanced manner. The analysis used to evaluate time to 
decision made is Kaplan-Meier. Kaplan Meier has been used to test whether the 
survival curves (time to event curves) between groups are equal. The defined event 
was when a treatment decision was made. A chi square test of independence has been 
used to compare distribution of treatment choice between groups. 
4.9.4 Data Collection and Management 
Research assistant training 
Recruitment of research staff occurred within, and external to, the study sites. 
An expression of interest was sent to each site and adjacent university to seek 
interested and skilled staff. The lead researcher spent several days at each site to 
prepare the clinical research assistant (CRA) and outcome research assistant (ORA) 
for their roles within the study. The CRA undertook consent, collection of baseline 
data, and randomisation. The ORA collected outcome data and was blinded to the 
participant group allocation. The delineation of roles assisted to minimise bias during 
the data collection phases. The published protocol was used to help the research 
assistants understand the flow of patients from recruitment through to final data 
collection point.  
 Data Collection Instruments 
The data collection instruments were designed to be brief and simple to follow, 
in an attempt to reduce the questionnaire burden on the participants (Appendix K, 
page 249). Each participant was allocated a unique patient identifier to ensure de-
identification. Hard copies of questionnaires were used, with the research assistants 
providing guidance to enable the participants to complete the questionnaires. Data 
collection occurred at the clinics in a dedicated room for the participant and the 
research assistant. The questionnaires were stored securely at the local site. An A3 
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envelope containing the entire questionnaires specific to each participant, was 
identified with the unique patient identifier and group code. The questionnaires when 
completed were express posted to the chief investigator and stored securely. No 
information identifying the participant was recorded.  
Data were double checked to eliminate data entry errors, missing values, 
outliers and mistyping. The mechanisms for data cleaning included identification of 
missing values through frequencies. Reverse coding was not required. SPSS version 
23, Microsoft Excel and Health Outcomes Scoring Software were used to undertake 
data entry and analysis.  
4.10  ETHICAL CONSIDERATIONS 
This research was undertaken according to the National Statement of Ethical 
Conduct in Human Research (2014) produced by the National Health and Medical 
Research Council of Australia (National Health and Medical Research Council, 
2007). This statement contains a series of values and principles that applies to all 
human research and has been adhered to throughout this research project. Informed 
consent was obtained from all participants using a Patient Information Consent Form 
(PICF) this can be viewed in Appendix L (page 260). The PICF included information 
regarding; who was conducting the study, aims of the research, how patients would 
be involved, what data would be collected, the benefits and risks to participating in 
the study and how data would be managed to ensure patient confidentiality. The 
patients were reassured that participation in the study is voluntary and will not affect 
the clinical care they receive. A copy of the signed consent form was provided to the 
patient.  
Confidentiality of all patients’ details has been protected. Patient data has been 
de-identified. Patients have received detailed information regarding the study and 
have been invited to participate through a consenting process. Clinical care has not 
been impacted for those participants who have chosen to withdraw.   
All documentation and data has been stored within a secure environment with 
access only available to research staff. Electronic data will be stored on a password 
protected database on the Queensland Health network. Research data will be kept 
stored and secure for a minimum of five years after publication of the results.   
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A National Ethics Application Form (NEAF) was completed and submitted to 
RBWH Human Research Ethics Committee (HREC) and Queensland University 
Research Ethics Committee (UREC). Approval was obtained from both ethics 
committees to conduct research at all four sites. A Site Specific Agreement (SSA) 
was then submitted to the Research Governance Office (RGO) at each of these sites. 
Following ethics approval, the time frame for approval to conduct the research at 
individual sites ranged from three months to seven months. Additional approvals 
were sought and received from HREC and UREC for changes regarding recruitment 
time frame and addition of new sites. RGOs were updated whenever changes had 
been made to the study protocol.  
4.11 SUMMARY 
Three hypotheses were generated from the research question and theoretical 
framework of this study. The methodological framework supports the use of a 
pragmatic randomised controlled trial design to provide evaluation of a complex 
intervention. The use of the CONSORT Statement to guide the reporting of the RCT 
and publication of the study protocol ensures complete and transparent reporting of 
the study design. Within this the study population, setting, enrolment and recruitment 
strategies has been described. This RCT is the first study to evaluate a decision 
support intervention for the older person with advanced kidney disease. The 
thorough reporting of all of the study elements will inform future research studies of 
suitable methodology to evaluate the use of decision support intervention for the 
older person with advanced kidney disease.  
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 Results Chapter 5:
5.1 INTRODUCTION 
The aim of this research was to evaluate the effectiveness of OPTIONS for 
older patients with advanced kidney disease. The research process combined a 
thorough review of evidence regarding Decision Support Interventions (DSIs), a 
guiding methodological and theoretical framework and appropriate methods and data 
collection instruments. The development of the intervention utilised evidence 
generated from a systematic review and was guided by the theoretical framework. A 
robust research process has been utilised following the Ottawa Decision Support 
Framework (ODSF) to guide delivery of the intervention and evaluation of the 
outcomes. Furthermore the protocol for the study has been peer reviewed and 
published in a high ranking international journal (Brown et al., 2016).  
Despite the quality of the research design and the rigorous preparation of the 
research sites the study has not achieved the requisite sample size. The recruitment 
barriers for this study are complex are related to patient population, health 
professionals and health service context. Notwithstanding the limited sample size and 
recruitment barriers experienced, the outcomes have been reported in accord with the 
original study protocol and conform to the CONSORT guidelines.  
5.2 PARTICIPANT FLOW 
Patients (n=215) were screened using Chronic Kidney Disease (CKD) 
databases unique to each site. The reasons for exclusion were: decision already made 
(n=113), non-English speaking (n=3), not medically competent to make a decision 
(n=4), eligible for a transplant (n= 1) and other (n=27). The final number of patients 
who were invited to participate in the trial was sixty-seven (n= 67). Forty-one (41) 
patients were consented and randomised for this research study. Table 5.1 provides 
details of other reasons for exclusion and reasons for patients declining participation 
in the study. 
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Table 5.1 Reasons for exclusion and refusal 
Other Reasons for Exclusion  Number Reasons for refusal Number 
Clinically  managed by 
telehealth 
6 Transport issues 4 
Frequency of Clinic reviews did 
not match study protocol  
9 Too far to travel to appointments 1 
Distance from research site 7 Burden of participation  1 
Clinical Research Assistant 
unable to attend appointments 
2 Too unwell to be involved 3 
  Enrolled in another study 1 
  Patient unwilling to be involved 
with decision making 
16 
The CONSORT flowchart in Figure 5.1 outlines the progression of study 
participants through the study. After consent and randomisation, one participant was 
excluded from baseline assessment due to ineligibility (participant had already made 
a treatment decision, of which the CRA was unaware). All participants who were 
randomised and allocated a randomisation group have been analysed for primary and 
secondary outcomes. Adherence to study protocol data collection time points 
occurred with the average number of days between baseline data collection and T1—
28.16 ± 65.67 days, between T1 and T2 -78 ± 34.41 days and from baseline to T2—
105.5 ± 72.82 days. There was no statistically significant difference between the 
intervention and standard care groups in regards to the adherence to data collection 
time points.  
5.3 RECRUITMENT 
Eligible participants were recruited from March 2015 to 31 March 2016 with 
sites commencing recruitment at differing times as determined by local governance 
approval. Participants attended clinic visits at the time of randomisation and at the 
protocol designated time points of one month (T1) and three months (T2). The final 
participant attended the three month (T2) clinic visit in July, 2016.  
The recruitment time frame remained true to the study protocol despite not 
achieving sample size. 
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Figure 5.1. Participant flow diagram (CONSORT 2010) 
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5.4 BASELINE DATA 
5.4.1 Demographic and clinical characteristics of participants  
Forty-one participants were randomly assigned to receive either OPTIONS (n=19) or 
standard care (n=22) (Figure 5.1). Baseline demographic and clinical characteristics 
are listed in Table 5.2and Table 5.3. There were no statistically significant differences 
in these characteristics between participants receiving the intervention and those 
receiving standard care at baseline, indicating that randomisation was effective. 
Normal distribution of data was assumed for analysis.  
The average age of participants was 78 years and 73.20% of participants 
reported their status as pensioner.  Sixty-six percent (66%) of the participants lived 
with one other person. Of the 41 participants in the study 61% were identified to 
have comorbid conditions with the highest incidence (19.50%) reported for both 
Ischaemic Heart Disease (IHD) and Diabetes Mellitus (DM). Only 4.90% of 
participants had the combination of Peripheral Vascular Disease (PVD), IHD and 
DM. The mean Australian Karnofsky Performance Score (AKPS) was 81.2 
suggesting a high level of functional performance in the study group. The average 
body mass index (BMI) of participants was 30.69 kg/m². The kidney function 
indicators revealed that the average eGFR was 15.76 mL/min/1.73m², creatinine 
288.07µmol/L and almost an even distribution between stage four (56.10%) and 
stage five (43.90%) chronic kidney disease (CKD). 
5.4.2 Characteristics of participants who withdrew from the study 
A total of five participants withdrew from the study. Four of these had been 
randomised to the intervention group. Of those in the intervention group, three 
participants withdrew prior to attending the first clinic visit (T1) and one prior to 
second visit (T2). Reasons given for withdrawal were – “not ready to make a 
decision” (n=2) and suffering from a secondary life limiting illness which had a 
higher priority (either participant or partner) (n=3).  
There was no systematic bias between participants who completed the outcome 
measures and those who withdrew from the study. Although there were a greater 
number of participants who withdrew from the study in the intervention group their 
reasons for withdrawal were valid and did not appear to be related to the group to 
which they were randomised. 
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Table 5.2  Demographic Characteristics 
Baseline characteristics Total (n=41) Intervention 
(n=19) 
Standard 
Care (n=22) 
p-value* 
Gender Female (%) 43.90 36.80 50.00 0.40† 
Age 77.93±5.53 77.21 78.55 0.45 
Family number (%)    0.06† 
Alone 24.30 12.20 12.20  
One other person 65.90 24.40 41.50  
Two other people 9.80 0 9.80  
Employment Status (%)    0.56† 
Work 7.30 2.40 4.90  
Pension 73.20 31.70 41.50  
Self-Funded retiree 19.50 12.20 7.30  
*Independent samples t-test, †chi-square test for independence.  
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Table 5.3  Clinical Characteristics 
 
Baseline characteristics Total (n=41) Intervention 
(n=19) 
Standard 
Care (n=22) 
p-value* 
Co morbid conditions %)    0.45† 
DM 19.50 9.80 9.80  
IHD 19.50 4.90 14.60  
PVD 2.40 0 2.40  
DM+IHD 9.80 4.90 4.90  
DM+IHD+PVD 4.90 0 4.90  
Other 4.90 2.40 2.40  
None 39.00 24.40 14.60  
AKPS 81.22±13.08 83.68 79.09 0.27 
BMI (kg/m²) 30.69±10.91 29.67 28.77 0.60 
eGFR (mL/min) 15.76±2.92 15.52 15.95 0.65 
Creatinine (µmol/L) 288.07 ±64.17 292.68 284.09 0.67 
CKD stage (%)    0.30† 
Stage 4 56.10 22.00 34.10  
Stage 5 43.90 24.40 19.50  
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5.5 OUTCOMES AND ESTIMATION 
5.5.1 Primary Outcomes 
Decision Conflict 
Decision conflict scale (DCS) was collected from 37 participants at T1 (intervention 
n = 16, standard care n = 21). The ‘decision conflict scale’ has been measured with 
sub scores of uncertainty, ‘feeling informed’, ‘values clarity’ and ‘supported in 
decision-making’ which were also calculated and analysed and can be viewed in 
Table 5.4. The scoring and interpretation of the scale has followed the framework 
outlined by the Ottawa Hospital and Health Institute (OHHRI) (O’Connor, 2010). 
For those who recorded their treatment decision as unknown the DCS was collected 
again at T2. Sixty-eight percent (68%) of participants had made a decision at T1 with 
only one participant recorded as ‘unsure’ at T2. There was no difference between the 
treatment groups for decision conflict and all sub scores at T1 with the exception of 
uncertainty. The intervention group had a mean decision conflict score of 20.31/100 
and the standard care group 15.95/100 (p= 0.53). Within the sub scores 
measurements, the intervention group had an uncertainty sub score of 43.75/100 
whilst standard care was 21.43/100. The difference between groups just reached 
statistical significance (p=0.047) indicating the intervention group had a higher level 
of uncertainty. Examination of this data identified that for levels of uncertainty 
≥50/100 there were 5/7 participants in the intervention group and 2/4 participants in 
the standard care group who had not made a treatment decision. 
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Table 5.4  Decision Conflict Score (T1) 
Variable Intervention 
(n=16) 
Standard Care 
(n=21) 
Mean 
Differences 
between groups 
p-value 
Decision Conflict  20.31±17.36 15.95±23.00 4.36 0.53 
Uncertainty Sub 
score 
43.75 ±34.76 21.43±30.91 22.32 0.047 
Informed Sub 
score 
15.63±21.49 19.05±33.03 -3.42 0.72 
Values Clarity 
Sub score 
18.75±23.27 23.81±29.02 -5.06 0.57 
Feeling 
Supported Sub 
score 
12.50±15.51 7.14±12.44 5.36 0.25 
There were ten participants who completed the DCS at T2 (Table 5.5). The 
effect of the intervention on decision conflict at T2 almost reached statistical 
significance for total decision conflict (p=0.05). The small numbers analysed were 
not normally distributed.  
Table 5.5  Decision Conflict Score (T2) 
Variable Intervention (n=5) Standard Care 
(n=5) 
Mean Differences 
 between groups 
p-value 
Decision Conflict Scale 3.00±4.47 26.00 ±19.17 -23.00 0.05* 
Uncertainty Sub score 5.00±11.18 25.00±25.00 -20.00 0.12* 
Informed Sub score 0±0 23.33±19.00 -23.33 0.05* 
Values Clarity Sub score 5.00±11.18 40.00±37.91 -35.00 0.08 
Feeling Supported 3.33±7.45 26.66±25.27 -23.33 0.08 
*p value for Equal Variances not assumed 
Decision Regret 
The Decision Regret Scale (DRS) was measured over repeated time points—
one month (T1) (n=36) and three months (T2) (n=35) for participants. The scoring 
and interpretation of the scale has followed the framework outlined by the Ottawa 
Hospital and Health Research Institute (OHHRI) (O’Connor, 2003).  
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The analysis plan was to undertake a linear mixed model to determine fixed 
and random effects on the dependent variable of decision regret. Models using the 
subject as a random effect could not be constructed because the between-subjects’ 
variance was too small; this may be a consequence of the small sample size. Instead, 
the linear mixed model function was used to construct a marginal model (a model 
with only fixed effects) using Restricted Maximum Likelihood (REML) estimation. 
This method was chosen because maximum likelihood based models use all available 
data rather than list-wise deletion of missing data. Estimated marginal means (that is 
means calculated from the model) were calculated for group, gender and time points.  
There was no treatment effect for the lowering of decision regret over time. 
Table 5.6 displays the estimate of fixed effects on the dependent variable—Decision 
Regret. The intervention increased the predicted mean value of Decision Regret by 
0.73 (p= 0.64; CI -2.39 – 3.85). Gender 0 (male) has a mean score 0.48 units higher 
than Gender 1 (female). The time point coefficient of 1.49 represents the average 
reduction in decision regret at T2 for the overall group (p=0.50; CI -0.18 – 0.37). 
Decision regret at T2 was lower than T1 by only 1.49 (p=0.50; CI -0.18 – 0.37).  
Table 5.6  Estimates of Fixed effect on Decision Regret 
Parameter Estimate Std. Error Sig. 95% Confidence 
Interval 
Intercept 36.87 10.94 0.002 14.64 59.11 
0=Intervention 0.73 1.54 0.64 -2.39 3.85 
1=Standard 0b 0    
Gender      
0=Male 0.48 1.53 0.76 -2.63 3.59 
1=Female 0b 0    
Age 0.09 0.14 0.50 -0.18 0.37 
Time Point      
T1 1.49 1.40 0.490 -0.18 0.37 
T2 0b 0    
a. Dependent Variable: Decision Regret Score. 
b. This parameter is set to zero because it is redundant. 
Table 5.7 displays the estimated marginal mean for decision regret 52.98  ± 
15(SE) (95% CI 48.62 - 57.33) which showed no significant difference between 
intervention group and standard group 50.68  ± 1.86 (95% CI 46.92 - 54.44). There 
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was minimal difference between genders (Male 52.47  ± 1.97; 95% CI 48.46 - 56.47, 
Female 51.19  ± 2.10; 95% CI 46.92 - 55.46). The influence of time on the decision 
regret also was minimal – T1 51.32  ± 1.63 (95% CI 48.04 - 54.59) and T2 52.34  ± 
1.64 (95% CI 49.04 - 55.63) Figure 5.2 illustrates the similarity of decision regret 
between groups over the two time points.  
Table 5.7  Estimated marginal means for Decision Regret 
 Mean Std. Error 95% Confidence Interval 
 
Group    
0=Intervention 46.01 1.12 43.65 48.37 
1=Standard 45.28 1.00 43.25 47.31 
Gender     
0=Male 45.88 1.05 43.75 48.02 
1=Female 45.40 1.12 43.14 47.67 
Time Point     
T1 46.39 1.03 44.33 48.45 
T2 44.90 1.50 42.81 46.99 
 
 
Figure 5.2. Line Graph of Decision Regret Scale over T1 and T2 
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5.5.2 Secondary Outcomes 
Knowledge  
Knowledge of dialysis and the benefits and risks of dialysis was measured at 
T1, with 37 participants completing the instrument. The method for scoring and 
interpretation of this instrument has been provided by the OHHRI (O’Connor, 2004). 
The effect of the intervention on knowledge resulted in an overall difference which 
was statistically significance (Table 5.8). Bootstrapping allows inferences to be made 
without the assumption of normal distribution (Mooney & Duval, 2011). The 
Bootstrap analysis confirms that the sample mean is representative of the population 
mean and the higher level of knowledge for the intervention group is statistically 
significant. The knowledge score for the intervention group was 60.39/100 (± 25.67) 
and 27.51/100 (± 23.73) for standard care with a mean difference of 32.88 (p= 0.001; 
16.31 – 49.44).  
Table 5.8  Knowledge Score 
Variable Intervention 
N=16 
Standard 
Care 
N=21 
 
Mean 
Differences 
between groups 
p-
value 
p-
valueᵇ 
BCa 95% 
Confidence 
Interval 
Knowledge 
Score  
60.39 
±25.67 
27.51 
±23.73 
32.88  
(16.31–49.44) 
<0.001 0.001 16.20 48.22 
ᵇbootstrap results based on 1000 bootstrap samples; BCa Bias—Corrected 
Accelerated 
 Quality of Life  
Quality of life was measured by a generic measurement instrument—SF-36v2® 
Health Survey. Due to the small sample size, the analysis of the eight sub-scales of 
the SF-36v2® Health Survey measurement model has not been undertaken.  
The analysis plan was to undertake a linear mixed model to determine fixed 
and random effects on the dependent variables—mental health (MCS) and physical 
health (PCS), however there were no measureable random effects as the model failed 
to converge. A model using participant as the random effect was also tested but the 
variability between participants was too small and the model could not be made to 
run. This may have been a consequence of the small sample size. The linear mixed 
model was therefore used to calculate the maximum likelihood in the presence of 
missing data. Estimated marginal means have been calculated for group, gender and 
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
112 Chapter 5: Results 
 
time points. This mean is derived from the linear mixed model rather than from the 
raw data. The intervention had no effect on either of the component summary 
measures as displayed in Table 5.10 and 5.12. 
The intervention increased the predicted mean value of MCS to 59.84 (p= 0.42; 
95% CI -3.37–7.96). The age coefficient of -0.09 represents the minute negative 
influence age has on MCS (p=0.73; 95% CI -0.61–0.43). Gender 0 (male) has a mean 
score 0.48 units higher than Gender 1 (female). The MCS at T2 was higher than T1 
by 1.02 (p=0.52; 95% CI -4.19–2.15). Figure 5.3 illustrates how similar the MCS is 
between groups over the two time points.  
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Table 5.9  Estimates of Fixed effect on MCS 
Parameter Estimate Std. Error Sig. 95% Confidence 
Interval 
Intercept 57.54 20.44 0.008 15.99 99.09 
 Group      
0=Intervention 2.30 2.80 0.42 -3.37 7.96 
1=Standard 0b 0    
Gender      
0=Male 1.28 2.88 0.66 -4.58 7.13 
1=Female 0b 0    
Age -0.09 0.25 0.49 0.73 -0.61 
Time Point      
T1 -1.02 1.56 0.49 0.52 -4.19 
T2 0b 0    
a. Dependent Variable: Mental Health Component Score 
b. This parameter is set to zero because it is redundant. 
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The estimated marginal means for MCS in Table 5.10 showed no significant 
difference between the intervention group 52.98  ± 15(SE) (95% CI 48.62–57.33) 
and standard group 50.68  ± 1.86 (95% CI 46.92–54.44). There was minimal 
difference between genders (Male 52.47  ± 1.97; 95% CI 48.46–56.47, Female 51.19  
± 2.10; 95% CI 46.92–55.46). The influence of time on the MCS was also minimal 
—T1 51.32  ± 1.63 (95% CI 48.04–54.59) and T2 52.34  ± 1.64 (95% CI 49.04–
55.63).  
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Table 5.10  Estimated marginal means for MCS 
 Mean Std. Error 95% Confidence Interval 
 
Group     
0=Intervention 52.98 2.15 48.62 57.33 
1=Standard 50.68 1.86 46.92 54.44 
Gender     
0=Male 52.47 1.97 48.46 56.47 
1=Female 51.19 2.10 46.92 55.46 
Time Point     
T1 51.32 1.63 48.04 54.59 
T2 52.34 1.64 49.04 55.63 
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Figure 5.3. Graph of Mental Health Component Score between groups over time 
The fixed effects on the dependent variable PCS are displayed in Table 5.11. 
The intervention increased the predicted mean value of PCS to 37.75 (p= 0.82; 95% 
CI -4.98 – 6.30). The age coefficient of -0.03 represents the minute negative 
influence age has on PCS (p=0.49; 95% CI 0.91--0.56). Gender 0 (male) has a mean 
score 1.10 units higher than Gender 1 (female). The PCS at T2 was lower than T1 by 
4.16 (p<0.001; 95% CI 2.05 – 6.26). Figure 5.4 illustrates how similar the PCS is 
between groups at T1 but the groups are starting to separate at T2 with statistical 
significance noted.  
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Table 5.11  Estimates of Fixed effect on PCS 
Parameter Estimate Std. Error Sig. 95% Confidence 
Interval 
Intercept 37.09 21.84 0.10 -7.32 81.50 
Group      
0=Intervention 0.66 2.81 0.82 -4.98 6.30 
1=Standard 0b 0    
Gender      
0=Male 1.10 3.09 0.72 -5.18 7.39 
1=Female 0b 0    
Age -0.03 0.27 0.49 0.91 -0.56 
Time Point      
T1 4.16 1.04 0.000* 2.05 6.26 
T2 0b 0    
a. Dependent Variable: Physical Health Component Score 
b. This parameter is set to zero because it is redundant. 
*p < 0.001 
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Figure 5.4.  Graph of Physical Health Component Score between groups over time 
 
The estimated marginal mean for PCS in Table 5.12 showed no significant 
difference between intervention group was 33.03 ± 2.23(SE) (95% CI 33.54–42.53) 
and standard group 37.37  ± 1.93 (95% CI 33.46–41.28). There was minimal 
difference between genders (Male 38.25 ± 2.11; 95% CI 33.97–42.53, Female 37.15 
±2.25; 95% CI 32.56–41.74). The influence of time on the MCS also was minimal—
T1 39.78  ± 1.62 (95% CI 36.51–43.05) and T2 35.62 ±1.63 (95% CI 32.33–38.92).  
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Table 5.12  Estimates of marginal means for PCS 
 Mean Std. Error 95% Confidence Interval 
Group     
0=Intervention 33.03 2.23 33.54 42.53 
1=Standard 37.37 1.93 33.46 41.28 
Gender     
0=Male 38.25 2.11 33.97 42.53 
1=Female 37.15 2.25 32.56 41.74 
Time Point     
T1 39.78 1.62 36.51 43.05 
T2 35.62 1.63 32.33 38.92 
 
  
A randomised controlled trial of a decision support intervention to support  
decision making for older individuals with advanced kidney disease 
 
120 Chapter 5: Results 
 
5.6  EVALUATION OF THE UTILITY OF OPTIONS 
To evaluate the utility of OPTIONS, two outcomes were measured. The first 
was the ‘Preparation for Decision Making’ scale which assesses the participants’ 
perception of how useful OPTIONS was in preparing them to discuss the treatment 
options and make a decision (O’Connor & Graham, 1995). The intervention scored 
higher than the standard care for participant satisfaction (Table 5.13). The results 
indicate that participants were more satisfied with intervention compared to standard 
care but not significantly. 
Table 5.13  Comparison between groups of Preparation for Decision Making Scale 
Variable 
Intervention 
(n=16) 
Standard Care 
(n=21) 
Mean 
Differences 
between groups 
p-value 
Preparation for 
Decision Making 
83.44±13.26 77.74±22.30 5.70 0.37 
The second outcome evaluated was the renal nurses’ perceptions of the extent 
to which OPTIONS helped to prepare the participant in understanding the risks and 
benefits and the overall decision making process. A score was calculated out of 100 
for 16 responses. Overall there was a large variation in scores with the minimum 
score 36.36 and maximum score of 81.82. The mean score was 57.55 ±15.89. 
5.7  ANCILLARY ANALYSIS 
5.7.1 Time to Event Analysis 
A time to event analysis was undertaken to evaluate the effect of the 
intervention on time to decision. Of the 32 participants who had a decision recorded, 
23 selected dialysis. All participants in the intervention group had made a decision at 
T2 (n=15), with only one remaining unsure at T2 in the standard care group. The 
Kaplan-Meier analysis (Figure 5.5) demonstrated that the intervention did not have 
any influence on the time taken to make a decision (Log Rank p = 0.08). Five 
participants were censored as they withdrew prior to event (decision). Four 
participants were from the intervention group and one from standard care group.  
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Figure 5.5. Kaplan-Meier Survival Curve showing Time to Decision 
Note: Log-rank, p=0.08 
5.7.2 Distribution of Treatment Choice according to allocated group 
As stated previously the role of the DSI was to support decision making and 
not exert undue influence. A comparative analysis was undertaken to demonstrate the 
there was no bias within the DSI. Table 5.14 demonstrates equal distribution of 
participants in their treatment choice with 5/16 (31.3%) in the intervention group 
choosing dialysis and 4/16 (25.0%) choosing non-dialysis management. There is no 
significant difference between intervention and standard care in relation to the 
treatment choice selected. The participant count and the treatment choices made by 
the intervention and standard care group at T1 are displayed in Figure 5.6.  
Table 5.14  Distribution of Type of Decision and Intervention at T1 
Final Decision (%) Total (n=37) Intervention (n=16) Standard(n=21) 
Dialysis 43.20 31.30 52.40 
Non-Dialysis 
Management 
24.30 25.00 23.80 
Unsure 32.40 58.30 23.80 
    p= 0.36† 
†chi square test for independence 
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Figure 5.6. Bar Chart of Type of decision and allocated group 
5.7.3 Other features of participants 
A comparison of BMI, AKPS, and eGFR over time utilising a paired sample T 
test revealed there were no significant differences for all variables between T1 and 
T2. There was also no statistically significant difference between allocated groups 
over time for these variables. Analysis in relation to days in hospital and survival was 
not undertaken due to the small sample size. Five participants were recorded as 
spending time in hospital (total hospital days n=37) at T1. There were no deaths 
recorded for those participants who were enrolled in this study. The intra-cluster 
correlation analysis has not been undertaken due to the large variation between 
participant numbers at sites.  
The results reported in this chapter need to be viewed in context of the small 
sample size. Critical issues relating to recruitment resulted in small participant 
numbers. An examination of recruitment barriers has been undertaken, with three key 
themes identified. These themes are related to patient barriers, health professional 
barriers and health service research culture which are described in the Annex to 
Chapter 5. This description has been provided to enable an analysis of these barriers 
in Chapter 6. 
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5.8 SUMMARY 
This chapter describes results of the pragmatic randomised controlled trial 
evaluating the effectiveness of OPTIONS in supporting decision making. This 
research is the first pragmatic RCT to evaluate a DSI for the older patient with 
advanced chronic kidney disease. A robust study design has been applied with results 
reported in accordance with the outlined analysis plan published in the study protocol 
(Brown et al., 2016). Both primary and secondary outcomes have been examined and 
the significant effect OPTIONS had on improving knowledge regarding dialysis and 
the risks and benefits of this treatment have been reported. Notwithstanding these 
ground breaking results and the contribution to knowledge they represent, the results 
need to be viewed in context of the small sample size. The study was significantly 
underpowered with the reasons clearly identified. The results presented represent 
new knowledge regarding the effectiveness of a decision support intervention in 
supporting decision making and also identified barriers to recruitment.  
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5.9 ANNEX TO CHAPTER 5: BARRIERS TO RECRUITMENT 
Introduction 
Recruitment of the requisite participant numbers is critical to the validity of 
research findings. Due to difficulties with recruitment this study was underpowered, 
which has led to inconclusive results for the primary outcomes—decision regret and 
decision conflict. The identified barriers which have affected recruitment have been 
classified into three major themes: patient related barriers, health professional 
barriers and health service research culture. 
Patient related barriers 
The patient related barriers that influenced recruitment are multifactorial. 
These factors were responsible for refusal of participation and withdrawal from the 
study. The most commonly recorded reason in this study for refusal of consent and 
withdrawal is the patient not willing to be involved either in education or shared 
decision making approach.  
Shared Decision Making 
The literature review (Chapter 2) identified that patients want to be involved in 
a shared decision making approach when making treatment choices. To facilitate this 
shared decision making approach in advanced kidney disease this research was 
developed to evaluate a DSI. Within this study, a common theme of refusal to 
participate was highlighted, with patients being indifferent to the shared decision 
making approach. The patients’ decision to consent for participation in this research 
study was inextricably linked to the knowledge that they need to make critical life 
changing decisions in relation to treatment choices. The patient related barriers will 
be explored in the next chapter.  
Health Professionals 
The nurses’ role in screening was vital for this research both for identification 
of suitable patients and also the relationships which they developed through the 
study. The key barriers encountered by the researcher occurred during the screening 
phase.  
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Screening 
This study was conducted at multiple sites that were separate to the hospital 
where the primary investigator was based. This placed a high level of reliance on the 
nurses at each of these sites to undertake regular screening. However, nurses at all 
sites experienced difficulty in sustaining a regular screening process to identify 
eligible participants. Examination of possible contributing factors is discussed in the 
next chapter.  
Gatekeeping 
Gatekeeping is defined as the process whereby nurses responsible for screening 
prevent access to eligible patients for research recruitment (Sharkey, Savulescu, 
Aranda, & Schofield, 2010). In this study, the nurses responsible for screening may 
have selected only those patients they thought were suitable to be involved in the 
study despite a larger number of potentially eligible patients.  
Health Service Research Culture  
Examination of barriers to recruitment at the health service level is an 
important consideration. The issues evident within the research included research 
governance and infrastructure.  
Research Governance 
Ethical approval to undertake a multi-site randomised controlled trial is a 
streamlined approach with only one application submitted to the Human Research 
Ethics Committee required. Barriers were experienced when obtaining site specific 
approval (research governance). As all health services were located within 
Queensland, this barrier had not been anticipated. 
Infrastructure Barriers 
The identification of eligible patients requires access to the patients’ clinical 
records. The storage of this information and ability to easily access the clinical 
details impacted the ability to efficiently screen for eligible patients. 
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 Discussion Chapter 6:
6.1 INTRODUCTION 
The use of decision support interventions to facilitate shared decision making 
in the setting of advanced kidney disease is in its infancy. The research reported in 
this thesis represents new knowledge in a burgeoning area of interest and identifies 
the potential benefits of using a decision support intervention (DSI) to facilitate 
decision making for the older patient with advanced kidney disease. The few studies 
that have been undertaken have concentrated on differing dialysis options with 
minimal focus on non-dialysis management. This is the first pragmatic randomised 
control trial (RCT) of a DSI to support older patients with advanced kidney disease 
in deciding between dialysis or non-dialysis management. Furthermore, very few 
RCTs have been undertaken examining the effectiveness of DSIs for life limiting 
conditions. Despite the ground breaking nature of this research the discussion needs 
to be read cognisant of the fact that the study is underpowered and the implications 
this has on the clinical significance of the outcomes. 
This chapter presents a detailed discussion of results according to the three key 
concepts of the Ottawa Decision Support Framework (ODSF): namely decision 
needs (decision conflict, knowledge and stage of decision making), decision quality 
(decision regret and quality of life) and decision support (preparation for decision 
making). The aim of this RCT was to evaluate the effectiveness of OPTIONS in 
lowering both decision conflict and decision regret, improving patient knowledge 
about treatment options for advanced kidney disease, and preparing patients to make 
a decision. The Chapter concludes with an analysis of the barriers to recruitment 
identifying unique features related to patient population, health professionals and 
health service context.  
6.2 PRIMARY OUTCOMES 
The ODSF was developed for health-related decisions where decision conflict 
is high and particularly for new circumstances as is the case for the older patient with 
advanced kidney disease when they are considering whether to undertake dialysis or 
not (O’Connor et al., 2011). The evaluation of decision conflict and decision regret 
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was used to determine if the use of ODSF to guide the development of OPTIONS 
was effective in addressing decision needs and decision quality.  
6.2.1 Decision Conflict 
The intent of using a DSI is to lower decision conflict by informing patients of 
the options, benefits and risks of various treatment options in a balanced manner 
using evidence-based information. In this study the intervention group had a low 
decision conflict score, although a difference with the standard care group could not 
be demonstrated. Low scores indicate that there is less conflict with making a 
decision (O’Connor, 2010) and that decisions are more likely to be implemented (De 
Achaval, Fraenkel, Volk, Cox, & Suarez-Almazor, 2012; O’Connor, 2010).  
It is difficult to determine why both groups have such low levels of decision 
conflict, with similar results reflected in three other studies evaluating the impact of 
DSI on decision conflict in the setting of a life limiting illness (Leighl et al., 2011; 
Matlock et al., 2014; Winterbottom et al., 2015). The results are in contrast to a 
number of studies demonstrating the effectiveness of DSI in lowering decisional 
conflict in a range of other health conditions (Bailey et al., 2016; Barry & Cherkin, 
1997; Davison et al., 2014; Scariati et al., 2015; Stacey et al., 2014; Triklalinos et al., 
2014), including two studies evaluating DSI in life limiting conditions (Mitchell, 
Tetroe, & O'Connor, 2001; Wilson et al., 2005). The conflicting results are difficult 
to rationalise as the decision conflict scale has been validated in both health 
screening (O’Connor, 1995) and end-of-life decision making (Song & Sereika, 
2006). Some possible reasons may be related to lack of efficacy of the intervention, 
sample size, study design, study population or ability of decision conflict scale to 
capture the level of decision conflict within this context.  
The study reported here has also undertaken an analysis of the decision conflict 
sub scores (uncertainty, informed, values clarity and feeling supported). These results 
have contributed to a deeper understanding of the patients’ perception of the 
effectiveness of the decision making process, considering the overall decision 
conflict score was not able to identify any difference between groups. 
Uncertainty Sub score 
The intervention group had a significantly higher level of uncertainty at T1 
than the standard care group indicating that this group were unclear about their 
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treatment choice and felt uncertain as to whether they should choose dialysis. The 
high level of uncertainty at T1 may be due to this group being offered an alternative 
to dialysis and the expectation of a high degree of personal autonomy. For the older 
population, being presented with a number of treatment choices (including that of 
non-dialysis management—which could be viewed as doing nothing) and also being 
asked to be actively involved in making the decision may be confronting and result 
in an initial increase in uncertainty. The increase in uncertainty may be due to the 
‘burden of choice’ the patients’ are facing within the shared decision making process 
(Olthuis, Leget, & Grypdonck, 2014).  
Patients are encouraged to adopt an active, autonomous role by the intervention 
nurses and this may create additional stress or uncertainty until the patient has had 
time to process the information provided within OPTIONS. Previous research has 
identified that in some circumstances the degree of personal autonomy is low, with 
patients deferring the decision making to the health professionals (Clark et al., 2009; 
Greenfield, Kaplan, Ware, Yano, & Frank, 1988; Murray, Bissonnette, 
Kryworuchko, Gifford, & Calverley, 2013; Orsino, Cameron, Seidl, Mendelssohn, & 
Stewart, 2003). The results reported here illustrate that additional exposure to 
OPTIONS and further decision support resulted in markedly reduced uncertainty 
scores at T2, suggesting that over time OPTIONS can lower uncertainty and facilitate 
a high degree of patient autonomy within a shared decision making model.  
Informed Sub score 
The intervention group at both time points had lower scores on the informed 
sub score than the standard care group. These results indicated that the intervention 
made patients more aware of treatment options available to them and that they also 
had a good understanding of the benefits, risks and symptoms of dialysis and non-
dialysis management. These scores are consistent with the significantly higher level 
of knowledge in the intervention group (see Section 6.21, page 128).  
Values Clarity Sub score 
The intervention group at both time points has lower values clarity score when 
compared with the standard care group. This result indicates that OPTIONS had 
improved the clarity with which information about risks and benefits of all treatment 
options was provided and that it supported patients to make a decision that was the 
most important to them. The results of this sub score are also consistent with higher 
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knowledge score found in the intervention group (see page 132) which suggests that 
improved knowledge can assist older patients to identify what is important to them.  
Feeling Supported Sub score 
The Feeling Supported sub score was initially higher in the intervention group 
when compared with the standard care group at T1. The higher sub score for Feeling 
Supported indicates that the intervention group did not feel they had enough support 
and advice from others to make a treatment decision. The provision of OPTIONS 
and the expectation that patients make a complex decision may initially have been 
confronting and thus resulted in a subset of the intervention group feeling 
unsupported. The burden of having to make a complex decision could lead to 
feelings of being unsupported and result in additional distress with the risk of 
disempowering these patients (Epstein, 2013). The role of the DSI is to support and 
engage the patient in a decision making process with evidence demonstrating that the 
use of a DSI may help patients change their decision making preference and engage 
in a more active role of decision making (Barry et al., 2015; Davison et al., 2014). 
Over time the intervention group were supported to actively engage in decision 
making and at T2 the score for feeling supported was much lower. The shift in 
feeling supported sub score over time, for the subset of participants who had made a 
decision at T2, suggests that OPTONS was perceived as supporting decision making 
more than the usual care received by standard care group.  
The use of a DSI challenges the way in which decision making occurs in the 
older population with advanced kidney disease. The results presented here suggests 
that the use of ODSF to guide the development of OPTIONS, has supported older 
patients to engage in a shared decision making approach.  
Importance has been placed on the active, autonomous role the patient can 
have within the model of shared decision making. The shared decision making 
process may initially prove confronting for the patient and cause them to feel 
unsupported. This may have increased the level of uncertainty in decision making. 
Continual support and provision of balanced information over time may enhance 
patient autonomy and ensure the patient feels supported in the shared decision 
making process. The results reported here represent new knowledge in how 
OPTIONS could lower decision conflict (including sub scores) and facilitate shared 
decision making, for the older population with advanced kidney disease. Further 
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research with a larger sample needs to be undertaken to demonstrate that OPTIONS 
will have a significant effect on these outcomes.  
6.2.2 Decision Regret 
Decision regret is a negative emotion linked with remorse and distress and 
occurs after a decision regarding health care treatment has been made (Brehaut et al., 
2003). The measurement of decision regret for the study reported here occurred at 
two time points—one month and three months. The original intent was to collect 
decision regret over three time points (one month, three months and six months) as 
published in the study protocol (Brown et al., 2016); however, due to recruitment 
issues only two time points (T1 and T2) were captured.  
There was no observable difference in decision regret between groups at either 
of these time points. This lack of effect cannot be attributed solely to OPTIONS as 
several positive effects of the DSI were observed (low levels of decision conflict and 
significantly higher level of knowledge). The measurement of decision regret at these 
time points may have been too early to capture the influence of OPTIONS on 
lowering decision regret in this population. No prior research has measured the 
influence of DSI on decision regret in the advanced kidney disease population, so the 
appropriate timing of measurement of decision regret is uncertain. Chiou and Chung 
(2012) demonstrated the effectiveness of the multi-media educational intervention in 
lowering decision regret, captured at four and six weeks post intervention however 
these results were not replicated in the research reported here.  
For this research population it may be necessary to measure the influence of 
DSI on decision regret after the patient has commenced treatment (dialysis or non-
dialysis management), rather than after the treatment decision has been made. 
Measuring decision regret after the decision has been recommended by Brehaut et al. 
(2003) who developed and validated the decision regret scale. A recent systematic 
review (Becerra, Maria, Menear, Brehaut, & Légaré, 2016) identified the highest 
level of decision regret occurred at six months or more after a decision had been 
made. These authors also suggested that capturing decision regret over multiple time 
points produces a dynamic portrait of decision regret and may help to distinguish 
between immediate and delayed regret (Becerra et al., 2016).  
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The absence of an observed effect of OPTIONS on decision regret, despite 
improved knowledge, suggests that decision regret may need to be measured at 
several time points following the decision, including time at which treatment has 
commenced as well as when high symptom burden is evident. Features such as the 
slow trajectory of symptoms until the last few months of life (Murtagh et al., 2011; 
Yong et al., 2009) and the inability to fully comprehend the implications of non-
dialysis management until the symptoms occur may influence the level of decisional 
regret experienced if measured when symptom burden is high. Additionally, 
measurement of decision regret in those patients who have commenced on dialysis 
may capture the influence of OPTIONS on the patients’ level of understanding in 
relation to the burdens and limitations of dialysis. Decision regret should be low in 
those patients who have considered the burdens and limitations of dialysis when 
making their decision. 
This current research provides new knowledge regarding lack of sensitivity of 
decision regret scale when measured too early after a decision is made. Further 
research is required to determine the most appropriate time points to measure the 
influence of OPTIONS on decision regret in the older population with advanced 
kidney disease.  
6.3 SECONDARY OUTCOMES 
6.3.1 Knowledge 
The use of ODSF in guiding the development of OPTIONS has resulted in a DSI 
which provides evidence-based information regarding risks and benefits of the 
treatment options in a balanced manner. Adequate knowledge regarding treatment 
options reduces the likelihood of decision conflict, vacillating between choices, delay 
in decision making and the questioning of personal values (O’Connor, 1995). The 
study reported here was the first to evaluate the effect of DSI on the knowledge of 
risks, benefits and symptoms of dialysis for older patients with advanced kidney 
disease. A key finding is the significant impact OPTIONS had on the participants’ 
level of knowledge. The results demonstrated that the intervention group had a 
greater knowledge of the risks, benefits and symptoms of dialysis than those in the 
standard care group. The significantly higher level of knowledge regarding risks, 
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benefits and side effects of dialysis in the intervention group suggests that this 
information is not currently being provided to this cohort of patients.  
Other studies evaluating DSIs in CKD (Fortnum et al., 2015b; Stacey et al., 
2014) have also demonstrated that those patients who received the DSI had greater 
knowledge about different dialysis treatments. The use of DSIs is therefore effective 
in improving knowledge in relation to the treatment options.  
The reported high level of knowledge within the intervention group represents 
critical evidence in how to provide decision making support to older patients with 
advanced kidney disease, when they need to consider whether to receive dialysis 
treatment or not. The improved knowledge gained by these patients highlights that 
they have an understanding of the treatment options (dialysis and non-dialysis), and 
the impact of their decision. Improved knowledge demonstrates that OPTIONS has 
been able to deliver information in an understandable manner and that the 
information is presented in such a way to account for varying health literacy skills. It 
is important to note that health literacy levels are known to be low in CKD (Fraser et 
al., 2013) with approximately 70% of people having limited understanding of what 
kidneys do (National Health Service, 2015). Winterbottom et al. (2007) found that 
the majority of written CKD education information is difficult to understand and 
rarely includes risk information or treatment limitations.  
OPTIONS has been able to deliver information in a comprehensible manner 
that has resulted in significantly improving knowledge. Improved knowledge about 
dialysis and non-dialysis management in the intervention group represents an 
important achievement addressing health literacy of the patients. The most recent 
consumer survey undertaken by Kidney Health Australia (KHA) identified that 
simple explanations or photos are important education strategies (Fortnum et al., 
2015b). Additionally, the KHA consumer perspective survey also identified that only 
7% of the respondents had any awareness of non-dialysis management and that 
respondents wanted more information on the long-term health care outcomes of 
dialysis (Fortnum et al., 2015b). OPTIONS presented information about dialysis and 
non-dialysis management in a simple balanced manner, providing life expectancy 
data, significantly improving the knowledge of these key issues for the older patient 
with advanced kidney disease.  
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The effect of OPTIONS in improving the level of knowledge in patients with 
advanced kidney disease represents the ability to deliver information to a group that 
have low health literacy. Improved knowledge has then enabled the patients to 
understand their treatment choices and risks, benefits and symptoms and ensures that 
patients will make an informed treatment decision. The selection of a treatment that 
best matches their personal values may have a long standing impact on their quality 
of life as well as satisfaction with their decision and lower the incidence of 
withdrawal from dialysis. Further research with a larger sample size needs to be 
undertaken to evaluate the effect OPTIONS has on knowledge and engagement in 
decision making.  
6.3.2 Quality of Life  
The theory underpinning the ODSF is patients’ decision needs will affect 
decision quality with a flow-on effect on health outcomes (quality of life) 
(O’Connor, 2006). Health Related Quality of life was measured to evaluate whether 
OPTIONS influenced the patients’ mental and/or physical health outcomes. The 
patients’ physical and mental health summary scores did not differ between the 
intervention and standard care groups demonstrating neither a positive nor adverse 
impact of OPTIONS. Very few studies have been able to demonstrate that addressing 
patients’ decision needs has an effect on health related quality of life outcomes. Only 
one study identified a significant effect of the DSI on physical health (Barry & 
Cherkin, 1997) with the health related quality of life outcomes measured 12 months 
following treatment decision (prostatectomy, pharmacologic treatment or ‘watchful 
waiting’) for benign prostatic hyperplasia. The positive outcome may be linked to the 
patients preferred treatment including symptoms that they believe would not affect 
them. 
The sensitivity of quality of life measurements in detecting influences of 
OPTIONS, may be inadequate when taking into account the considerable impact 
advanced kidney disease has on patients’ overall quality of life (Almutary et al., 
2013; Chow et al., 2003; Kusek et al., 2002; Mujais et al., 2009; Pagels, Soderkvist, 
Medin, Hylander, & Heiwe, 2012). The sample reported here had a higher overall 
score for mental health summary score (MCS) and lower physical health summary 
score (PCS) when compared with two other studies (Erez et al., 2016; Perl et al., 
2016) which measured quality of life in patients with advanced kidney disease (Erez 
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et al., 2016) and on haemodialysis (Perl et al., 2016). Health related quality of life in 
patients with advanced kidney disease deteriorates slowly (Murtagh et al., 2011; 
Seow et al., 2013). To detect a significant effect of OPTIONS on health related 
outcomes a lengthy follow-up may be required. Further research needs to be 
undertaken to determine if other measures such as: anxiety, depression or emotional 
distress in the patients would prove a more sensitive measure to evaluate the effect of 
OPTIONS on health outcomes.  
This study suggests that OPTIONS does not result in any adverse impact to the 
health related quality of life of the participants. To adequately evaluate the effect of 
OPTIONS on health related outcomes would require a lengthy follow-up with a 
larger sample size and possibly alternative measurement instruments.  
6.4 EVALUATION OF THE UTILITY OF OPTIONS 
A key element to DSI evaluation is the assessment of patients’ perceptions of 
the usefulness of the DSI in enabling them to communicate with health professionals 
during clinic visits and subsequently make a health decision (Bennett et al., 2010). In 
addition, it is important to assess how clinicians viewed the DSI usefulness in 
preparing the patient to communicate with them at clinic visits. The evaluation of 
patients perception of the usefulness of the DSI is a component of International 
Patient Decision Aid Standards (IPDAS) (Durand et al., 2015).  
The overall satisfaction with being prepared for decision making in this study 
was higher for the intervention group when compared with standard care. The higher 
score in the intervention group suggests that the participants who received OPTIONS 
understood the risks and benefits and important issues as relevant to themselves and 
were better prepared for decision making. These findings concur with the high 
knowledge scores previously discussed.  
The higher satisfaction with preparation for decision making scores also 
indicates that the intervention group found OPTIONS assisted with identification of 
relevant questions to ask their health professional, to determine level of involvement 
in decision making and prepare them for further visits. This finding is consistent with 
other studies (Fortnum et al., 2015b; Winterbottom et al., 2015) who found that 
patients who received DSI reported greater satisfaction with preparation for decision 
making. The results reported here in conjunction with studies by (Fortnum et al., 
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2015b); Winterbottom et al. (2015) suggest the using a DSI better prepares the 
patient for decision making when compared to standard education services.  
The finding that OPTIONS results in higher levels of patient satisfaction in 
preparation for decision making contributes to a small body of evidence (Fraenkel, 
Rabidou, Wittink, & Fried, 2007; Vandemheen et al., 2009) suggesting that DSI are 
effective in empowering patients to make a decision in consideration of the risks and 
benefits of treatments. Further research is required on the role OPTIONS plays in 
supporting patient autonomy within the model of shared decision making. This 
should be done through evaluation of patients’ perceptions with a larger study 
sample size.  
This research is the first study to report renal nurses’ satisfaction with 
‘preparation for decision making’. As demonstrated in the literature review, there 
have been no reported outcomes measuring the health professionals’ satisfaction with 
the preparation for decision making. Renal nurses completed the questionnaire only 
if the participant had received the OPTIONS intervention. Overall renal nurses 
perceived OPTIONS had a modest impact on facilitating participants’ preparation for 
decision making although there was a large variation in response scores.  
These results are in contrast to the participants’ results which identified that 
OPTIONS was effective in preparing them for decision making. The difference in 
perception of what is important in preparation for decision making may be related to 
what the renal nurses perceived as useful compared to the participants’ opinion. The 
modest response reported may be related to fundamental barriers of adoption of 
shared decision making: perceived time constraints in engaging in shared decision 
making and lack of agreement of applicability of shared decision making for the 
patient population (Légaré, Ratté, Gravel, & Graham, 2008). The reported results of 
the renal nurses’ perceptions have generated questions regarding how best to engage 
renal nurses and other health professionals in a shared decision making approach for 
this research population. Further exploration of renal nurses’ opinions regarding 
shared decision making, and the identification of possible barriers and facilitators in 
relation to the use of OPTIONS, would provide a greater understanding into possible 
ways to generate engagement with shared decision making utilising a DSI. Further 
knowledge is required to ensure successful implementation of OPTIONS as part of 
an education program for the older patient with advanced kidney disease.  
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6.5 ANCILLARY ANALYSIS 
OPTIONS provides evidence-based information regarding risk, benefits and 
side effects of both dialysis and non-dialysis management in a balanced manner. The 
evaluation of these features of the DSI has been undertaken to identify the influence 
OPTIONS has on time to decision and also to demonstrate that OPTIONS presents a 
balanced view of the different treatment options.  
6.5.1 Time to Event Analysis 
This study found no significant difference between the intervention and 
standard care groups with regard to proportion of participants undecided. All 
participants, with the exception of one had made a treatment decision by T2. The 
time to make a decision was longer for the intervention group, however this was not 
significant. The longer time to make a decision in the intervention group reflects the 
higher levels of uncertainty at T1 as reported previously. Participants who received 
OPTIONS took longer to consider (weigh up) the risks and benefits to determine 
which treatment best matched their personal values. They were able to consider the 
treatment options with a far higher level of knowledge regarding the risks, benefits 
and side effects of dialysis.  
The ability to demonstrate the effectiveness of OPTIONS and lowering the 
proportion of participants who remain undecided to participate may have been 
impacted by recruitment barriers. A key reason for refusal to consent for this 
research was that patients did not want to be involved in further education and 
decision making processes. This refusal could be linked to the high level of 
decisional conflict that patients facing complex health decisions experience (Stacey 
et al., 2014), and which OPTIONS is designed to address. It could also be due to 
older patients autonomously making a choice not to be involved in shared decision 
making and providing permission for the health professional to adopt a paternalistic 
role (Truglio-Londrigan, Slyer, Singleton, & Worral, 2014). A study with larger 
participant numbers may be able to negate this potential bias.  
6.5.2 Distribution of Treatment Choice according to allocated group 
The theoretically guided development of OPTIONS with content based on the 
best available evidence was designed to provide impartial information to patients. A 
comparative analysis of treatment choice and allocated group, demonstrates equal 
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distribution of participants who selected dialysis or non-dialysis management in both 
the intervention and standard care group. These results provide some evidence that 
the information in OPTIONS is presented in a balanced manner and supports the 
patient to make an informed choice between dialysis or non-dialysis management. 
The ODSF has been used to tailor the development of OPTIONS in order to 
address the decision support needs of the older patient with advanced kidney disease.  
The ODSF has addressed the patients’ decision needs as evidenced by the fact that 
the participants in the intervention group have made an informed decision (high 
levels of knowledge) consistent with their values (high values clarity sub score) and 
patient empowerment and control in decision making has been facilitated 
(satisfaction with preparation for decision making).  
The study described here provides a valuable finding in relation to the effect of 
OPTIONS in significantly improving the patients’ knowledge of risk, benefits and 
symptoms of dialysis. Knowledge regarding the probable risks of treatment is 
integral to supporting the older patient in making an informed value sensitive 
decision. This reported finding also suggests that standard care is not sufficient to 
ensure the older patient with advanced kidney disease can comprehend the possible 
outcomes if dialysis is selected as the treatment. OPTIONS represents an effective 
method of improving knowledge and is able to address health literacy levels.  
6.6 STRENGTH AND LIMITATIONS OF THE RESEARCH 
The strength of this research was the rigorous methodological approach to 
evaluate the effectiveness of OPTIONS as a decision making tool for the older 
patient with advanced kidney disease. The systematic review was the first review 
comparing outcomes of patients over 65 receiving either dialysis or non-dialysis 
management (Brown et al., 2014). The outcomes from this review were used to 
provide content for the DSI. This study was framed by the positivism methodology 
with the selection of pragmatic randomised control study design chosen to reduce 
bias (selection bias), limit confounders and increase the validity of research 
outcomes. The blinding of both the outcome research assistance and chief 
investigator reduced the risk of detection and reporting bias. The theoretical 
framework guided the development of OPTIONS with outcomes such as improved 
knowledge, low decision conflict and high satisfaction with preparation for decision 
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making validating the use of this framework to develop the DSI. The publication of 
the study protocol (Brown et al., 2016) and reporting according to the CONSORT 
framework provides transparency to allow researchers to replicate this study. 
Despite the robust study design, there were limitations to this research. The 
major limitation was the small sample size. The external validity of research 
outcomes was threatened due to an underpowered study with a high risk of Type II 
error. The generalisability of the results to other CKD settings may be limited due to 
small sample size and recruitment barriers.  
The research findings reported need to be contextualised in consideration of the 
large variability of expertise in relation to the renal nurses involved with this research 
project. Nursing expertise ranged from registered nurse through to advanced practice 
nurse and nurse practitioner. Research has identified that advanced practice nurses 
and nurse practitioners function at a high level in direct care (Gardner, Duffield, 
Doubrovsky, & Adams, 2016) which includes ‘facilitation of the process of ethical 
decision making in patient care’ (Mick & Ackerman, 2000, p. 217). The influence 
nursing expertise had in decision making was controlled to some degree in the 
intervention group, through a standardised training program to develop skills in 
utilising OPTIONS to support patients to make treatment decisions. Furthermore, the 
instability of the nursing workforce involved in this research study also resulted in 
multiple renal nurses allocated to intervention or standard care at the different 
research sites over the study period. These naturalistic factors were unable to be 
controlled and may have had an impact on the outcomes. The pragmatic nature of the 
study makes it difficult to identify which key features played a critical role in 
influencing the research outcomes.  
6.7 BARRIERS TO RECRUITMENT 
The number of randomised controlled trials (RCT) undertaken in patients with 
chronic kidney disease (CKD) or end stage kidney disease (ESKD) lag behind 
research undertaken for other chronic diseases and are more likely to have a smaller 
number of participants (Inrig et al., 2014). As identified previously, this study is the 
first to evaluate a DSI utilising a robust methodology and theoretically derived DSI. 
Recruitment refers to the process of selection from notification of the study to 
the enrolment of participants. Recruitment commences with screening eligible 
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patients. This is then followed by communication between the researcher and 
potential participants, with patient consent being the desired outcome. The aim is to 
have a sufficient number of participants to fulfil the demands of sample size and 
power of the study (Gul & Ali, 2010). Barriers to recruitment within this study were 
complex and related to three specific study factors namely: the patient population, 
health professionals and health service context.  
Possible reasons for research in kidney disease performing poorly have been 
reviewed, (Palmer, Sciancalepore, & Strippoli, 2011; Strippoli, Craig, & Schena, 
2004), however critical appraisal of recruitment barriers was not included. Poor 
quality research and lack of transparency in reporting were the focus of these 
reviews. This section provides an analysis of the researcher’s experiences during the 
process of recruitment. This discussion is designed to bring new knowledge and 
insights and make a contribution to the discourse regarding challenges in conducting 
research with this population group and the research context. 
6.8  PATIENT RELATED BARRIERS 
6.8.1 Decision Making 
Older patients with advanced kidney disease are required to make a decision 
regarding whether or not to undertake dialysis. This decision requires careful 
consideration of risks and benefits as it can have an impact on quality of life and 
survival (Orsino et al., 2003). The aim of OPTIONS is to help patients understand 
that a decision must be made and to assist them in making a decision that best suits 
their personal values. Health care decisions for these patients can be difficult with 
high levels of decisional uncertainty (Becerra et al., 2016). As part of the consent 
process, patients agreed to attend three appointments with a renal nurse over a six-
month period where they would be randomised to receive standard care or OPTIONS 
to consider their treatment choice. The request for consent was inextricably linked to 
the receipt of information about treatment options and counselling to facilitate the 
decision making process. The key reason for refusal to participate was unwillingness 
to be involved in further education and decision making process.  
Several patient-related barriers had the potential to result in refusal of 
involvement in shared decision making. These patient related barriers may be due to 
the degree of autonomy the patient wishes to have, low health literacy level, denial of 
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illness and age of the population. Within a shared decision making process it is ideal 
for the patient to have a high degree of autonomy (self-determination), as occurs 
when the patient has decided and acted on their treatment decision without any 
external manipulation (Sandman et al., 2012). The degree of autonomy can be 
determined through examination of three factors—decision competence, authenticity 
and efficiency (Sandman et al., 2012).  
Decision competence is the ability of the patient to make a treatment decision 
based on their own preferences and values (Sandman et al., 2012). To have 
competence to make a decision the patient must understand what the treatment 
options are in relation to their own values.  
Authenticity is whether the treatment preference is the patient’s own decision 
without any external influences (Sandman et al., 2012).  
Efficiency is the ability to implement the decision thereby realising their own 
treatment preference (Sandman et al., 2012). If the patient does not have the ability to 
process the information and feel confident enough to have ownership of the decision 
they may exhibit a low degree of autonomy and defer the decision making to the 
health professional who they believe has the expertise to make this decision 
(Okamoto, 2015; Truglio-Londrigan et al., 2014).  
Research has found that some older patients prefer to defer the decision making 
to the health professionals (Murray et al., 2013; Orsino et al., 2003). The patients’ 
view the health professionals as having the knowledge and skills that they 
themselves do not possess  (Blumenthal-Barby, 2016; Frosch, May, Rendle, 
Tietbohl, & Elwyn, 2012; Greenfield et al., 1988; Joseph-Williams, Edwards, & 
Elwyn, 2014a; Truglio-Londrigan et al., 2014; Wetzels, Harmsen, Van Weel, Grol, 
& Wensing, 2007).  
The preference for deferring decision making to the health professional was 
identified by the renal nurses in this study as contributing to patients refusing to 
participate. This phenomenon has also been reported by Kidney Health Australia 
where 60% of the older patients reported the doctor as having the major influence in 
decision making (Fortnum et al., 2015a). The complexity of information patients are 
required to assimilate in a relatively short period of time also impacts on their 
readiness to make a decision (Jayanti et al., 2015). Difficulties experienced by 
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patients in processing the information and engagement in shared decision making can 
be partially attributed to the low levels of health literacy evident among this patient 
population (Blumenthal-Barby, 2016; Fraser et al., 2013). This lack of understanding 
and ability to process information can result in the lack of engagement between the 
health professional and patient when discussing treatment options. 
A further barrier to patients’ engagement in shared decision making is the 
recognition by the patients that a decision needs to be made. Patients may resist the 
idea that they need to make treatment choices in the presence of minimal symptoms 
(Fishbane, Hazzan, Halinski, & Mathew, 2015). Whilst the patients are in a state of 
denial regarding the need for a decision to be made they were more likely to refuse to 
consent to a study involved in supporting them to make treatment decisions. 
The final barrier is related to this ageing population who are known to have 
complex health care needs, with 49% of those aged 65–74 years having five or more 
long term conditions (Australian Institute of Health and Welfare, 2012b). The 
complex health profile impacted on the patients’ ability to attend clinic 
appointments, due to competing health care appointments or illness affecting their 
ability to travel.  
In summary, the major reason for refusal to participate appears to be closely 
linked with high levels of decisional uncertainty and the patients’ preference for a 
low degree of autonomy. These barriers have not previously been reported in other 
studies evaluating DSI in advanced kidney disease (Fortnum et al., 2015b; 
Winterbottom et al., 2015) and require further consideration when designing future 
studies for this population. Other barriers include health literacy, readiness to engage 
in decision making and older population with complex care needs. Furthermore, both 
innovative recruitment strategies and delivery of OPTIONS need to be considered to 
overcome the considerable health burden of this population. One possible solution 
may be the use of technology such as hand held devices to establish communication 
and reducing the need for patients to attend multiple clinic appointments.  
6.9 HEALTH PROFESSIONALS 
The role of renal nurses to screen was vital for this research, both for 
identification of suitable patients and also the interaction and trust they have 
established with the patients. The key barriers to recruitment occurred during the 
Leanne Brown 
Chapter 6: Discussion 143 
 
screening phase. Despite a fulsome scoping strategy with each recruitment site and 
verbal communication to establish agreed potential recruitment numbers, the sample 
size was not achieved  
6.9.1 Screening 
The coordination of a multi-centre randomised controlled trial covering 
geographical distances of up to 450 kilometres was complex. Recruitment at each 
site was dependent on key nurses. Nurses at all sites had difficulty undertaking 
regular screening for eligible participants within their clinical workload. Several 
studies involved in examining barriers to recruitment identified “clinician workload” 
as a key impediment to the recruitment process (Fletcher, Gheorghe, Moore, Wilson, 
& Damery, 2012; Mahon, Roberts, Furlong, Uhlenbrauck, & Bull, 2016; Spaar, Frey, 
Turk, Karrer, & Puhan, 2009). No quarantined time was available to enable the renal 
nurses to undertake regular screening due to implementation of restrictive budgetary 
arrangements.  
Despite full support from nursing staff at all sites, difficulties were experienced 
with sustaining appropriate dedicated time for this study due to clinical demands 
having a higher priority. The nurses involved with this research were often required 
to relieve in other roles. In some situations, they were also required to support 
medical research in addition to this research study. The absence of a fully embedded 
nursing research culture at all sites became evident when competing medical projects 
were initiated during the time of this study and received a higher priority of nurses’ 
time. Several studies have identified barriers to nursing involvement in research due 
to deficiency in necessary research skills, resources, peer support or time to conduct 
nursing research (Bonner & Sando, 2008; Chien, Bai, Wong, Wang, & Lu, 2013; 
Dunning, 2013; Hagan & Walden, 2015; Scala, Price, & Day, 2016). The chief 
investigator visited all sites regularly to support recruitment activity and address any 
concerns regarding adherence to study protocol.  
Traditionally clinical trials are funded on participant numbers, however 
important consideration needs to be given to the provision of funding for screening 
potential participants to ensure dedicated nursing time is quarantined by 
management. As the research reported here was part of a PhD study there was no 
funding available to allocate for screening. Inadequate attention to screening for 
potential participants had a significant impact on recruitment and due consideration 
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needs to be directed to this issue to ensure adequately powered studies within nursing 
research.  
6.9.2  Gatekeeper 
Gatekeeping is a common phenomenon in research as a deliberate act to ensure 
vulnerable patients are protected (Fletcher et al., 2012). The gatekeeper influence can 
impact on enrolment numbers of participants (Ridda, MacIntyre, Lindley, & Tan, 
2010). Gatekeepers can either encourage or discourage patients to participate in 
clinical trials especially for the older patient population (Ridda et al., 2010). Within 
this research, the nurses responsible for screening selected only those patients who 
they thought would benefit from this research despite a larger number being 
potentially eligible. A previous study evaluating a DSI to support patients with 
advanced kidney disease in making a treatment choice, (Winterbottom et al., 2015) 
identified variation in the rate of uptake of the DSI across the research sites.  
Gatekeeping occurred in this situation as the nurses acted as information 
agents, determining who would receive the DSI. Examination of the screening logs 
for this research identified many eligible patients who had not been approached for 
consent, identifying the possibility of the renal nurses acting as information agents.  
In some circumstances, patients were excluded by renal nurses for reasons 
other than the specified exclusion criteria such as distance from research site, current 
clinic appointments not corresponding with the requirements of the study protocol 
and patient characteristics such as frailty. Gatekeeping also occurred at the medical 
clinics. If the medical practitioner deemed the patient would not benefit from 
considering dialysis as an option, then the patient was not referred to the nurse for 
education. This practice was common if the patient had a second life-limiting illness 
such as cancer or dementia. 
Gatekeeping had a significant and unexpected effect on recruitment by filtering 
patients prior to consent. The study population characteristics may not match the 
population that this research was designed to study.  
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6.10 HEALTH SERVICE RESEARCH CULTURE  
Examination of recruitment barriers at the health service level is vital as issues 
such as research governance, research culture and infrastructure adversely impacted 
the successful recruitment of adequate sample size for this research.  
6.10.1 Research Governance 
This research was conducted at multiple sites to achieve a sufficient sample 
size within a limited time frame. The Human Research Ethics Committee (HREC) 
approval process in Queensland is a streamlined process requiring only one central 
application for a multi-site study. Once this process is complete site specific approval 
(research governance) is required from each of the participating sites. There were 
considerable differences in site requirements, with some sites requiring the same 
information provided to HREC resubmitted to them. In some cases, the research 
governance office of the hospital had part-time staff reviewing applications which 
delayed approval.  
Research governance approval at one health service site took eight months, 
with an average of three months at other research sites. Research undertaken in the 
UK and Australia found excessive scrutiny at individual sites hampered approval 
(Boult, Fitzpatrick, Maddern, & Fitridge, 2011) with 21% of centres taking six 
months or longer to obtain local research governance committee approval (Haddad, 
Chan, & Vermorken, 2015). The lack of uniformity in research governance 
requirements across the Queensland public hospital sector and delay in approval 
impacted on the timeframe available for recruitment and subsequently recruitment 
numbers.  
6.10.2 Infrastructure Barriers  
Screening potential participants was problematic as clinical information was 
stored on different databases across the study sites. The ability to extract relevant 
information was hampered by the multiple medical record numbers containing 
clinical information for each patient. Appropriate technology such as the use of 
electronic health records and unique patient identifiers may have streamlined 
identification of suitable patients to enable recruitment of participants. A survey 
undertaken by Mahon et al. (2016) identified technology as a key solution in relation 
to barriers to recruitment. To undertake sustainable research, patient registries or 
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databases need to be developed to capture relevant information. A state-wide patient 
registry utilised by all health services would facilitate screening and enable further 
research in vital areas of advanced kidney disease. Consideration needs to be given 
to the important role nursing research plays at the health service level and nationally. 
6.11 SUMMARY 
The outcomes from the pragmatic RCT, evaluating the effectiveness of 
OPTIONS in supporting the older patient with advanced kidney disease, 
demonstrates an effective method to support decision making through improving 
knowledge of risks, benefits and symptoms of dialysis. OPTIONS was developed 
using the Ottawa Decision Support Framework and then evaluated using 
recommended components of this framework. The research reported here represents 
new knowledge in how a theoretically informed decision support intervention can 
support the older patient with advanced kidney disease in undertaking a shared 
decision making approach. The study was unable to demonstrate any impact of 
OPTIONS on decision conflict and requires further examination to determine if 
OPTIONS is effective in lowering decision conflict. The study also identified that 
further enquiry needs to be made regarding selection of appropriate time points for 
measurement of decision regret. The decision support intervention was able to 
improve participants’ satisfaction with preparation for decision making but this was 
not reflected in the nurses’ perception of how prepared the participants were. The 
research findings have been impacted by unique recruitment barriers. An analysis of 
these represents new knowledge of the barriers and blockages experienced when 
undertaking research with this population in the Australian regional service context.  
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 Conclusions Chapter 7:
The results of this study provide new insight in how best to support the older 
patient with advanced kidney disease in making a treatment choice between dialysis 
or non-dialysis management. Outcomes from the pragmatic randomised controlled 
trail demonstrated that OPTIONS significantly improved a patients’ knowledge of 
risks, benefits and symptoms of dialysis. These findings are of clinical importance 
because they indicate that current educational strategies may not be adequate in 
informing patients about this complex and value sensitive decision. Further research 
is needed to strengthen the evidence on this topic and deepen our understanding of 
the role OPTIONS could play in lowering decision conflict and regret and improve 
patient-health professional communication. The major limitation of small sample 
size in this research was as a consequence of unique recruitment barriers, namely 
patient population variables, health professional culture and health service context.  
Notwithstanding the study limitations and barriers, the research has achieved 
new insights, knowledge and contribution to this field of knowledge. These outcomes 
from the research provide the basis for research recommendations that will contribute 
to ongoing practice, educations and research. 
7.1 RECOMMENDATIONS ARISING FROM THE RESEARCH 
The following recommendations are made: 
Practice Implications 
This study has shown that patients’ knowledge can be improved if information 
regarding treatment options is delivered in an appropriate manner.  
 It is therefore recommended that a comprehensive education strategy for 
older patients with advanced kidney disease utilising strategies identified 
within this study be implemented nationwide.   
The use of evidence-based information within a decision support intervention 
has been identified has a key element in improving the knowledge of risks, benefits 
and symptoms of dialysis. The importance of evidence-based education practice is 
emerging as an important strategy in the decision making process.  
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 It is recommended that evidence-based information be synthesised and 
presented in a simple and balanced manner as part of the decision support 
strategy to assist patients to exercise autonomy in decision making.   
Education 
The use of a multi-site approach in this study design was a strategy to increase 
recruitment numbers within the time frame of a PhD. However, the requirements for 
separate local research governance applications impeded the timely commencement 
of recruitment.  
 It is therefore recommended that information strategies are developed and 
disseminated by research teams to inform health facilities of critical barriers 
and the need to streamline research governance processes for multi-site 
research be recognised. 
Nursing staff played a key role in this research for both recruitment of 
participants and delivery of intervention or standard care. It was identified when 
examining the barriers to recruitment that there was an absence of a fully embedded 
research culture at the sites. For nursing research to be successful and evidence-based 
practice incorporated into clinical care, an enabling and sustainable research culture 
needs to be developed.  
 It is therefore recommended that effective research training be embedded 
within the clinical environment and identified as a key priority on health 
service management agenda.  
Further Research 
The reported study identified serious barriers in recruiting requisite participant 
numbers. Whilst findings from the pragmatic randomised controlled trial illuminated 
the role a decision support intervention contributes to supporting the older patient in 
making a treatment decision the evidence is not strong enough due to the widespread 
recruitment barriers.  
 It is therefore recommended that further research be undertaken 
into the decision making process of the older patient with 
advanced kidney disease and also their engagement in the CKD 
educational programs. This research is necessary to determine 
appropriate strategies needed to support patient autonomy when 
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making complex decision within the model of shared decision 
making.  
 An examination of the impact health literacy and age has on the 
ability to recruit participants for advanced kidney disease research 
is needed, with identification of strategies to overcome these 
barriers. 
 Further exploration should be undertaken to examine the role 
health professionals play as information agents and the positive 
and negative consequences that arise when there is control over 
the information that is provided to patients. 
 Enquiry should be made into barriers relevant to research culture 
within health service districts and identification of strategies 
needed to develop research capacity for the health service. 
7.2 FUTURE RESEARCH 
This research provides an evidence base in relation to the effectiveness of 
decision support interventions within the setting of older patients with advanced 
kidney disease. Further studies are required to build upon this body of knowledge 
and determine if DSIs are appropriate to utilise in facilitation of shared decision 
making for the older patient with advanced kidney disease. The research reported 
here can inform the methodological approach for further evaluation of DSIs in 
facilitating shared decision making to assist the patient to make value based 
decisions relevant to advanced kidney disease. The review of barriers to recruitment 
provides an analysis of factors that need to be considered when undertaking research 
to ensure successful attainment of requisite sample size.  
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Appendices  
Appendix A  IPDASi v3 Dimensions and Items  
(Elwyn et al., 2009) 
Dimension Item 
Information 1. The decision support technology describes the health condition 
or problem (intervention, procedure or investigation) for which 
the index decision is required 
Providing 
information 
about options in 
sufficient detail 
for making a 
specific decision 
2. The decision support technology describes the decision that 
needs to be considered (the index decision) 
 3. The decision support technology describes the options available 
for the index decision 
 4. The decision support technology describes the natural course of 
the health condition or problem, if no action is taken 
 5. The decision support technology describes the positive features 
(benefits or advantages) of each option. 
 6. The decision support technology describes the negative features 
(harms, side effects or disadvantages) of each option 
 7. The decision support technology makes it possible to compare 
the positive and negative features of available options  
 8. The decision support technology shows the negative and 
positive features of options with equal detail (for example using 
similar fonts, order, and display of statistical information) 
Probabilities 1. The decision support technology provides information about 
outcome probabilities associated with the options (i.e. the likely 
consequences of decisions) 
 2. The decision support technology specifies the defined group 
(reference class) of patients for which the outcome probabilities 
apply 
 3. The decision support technology specifies the event rates for the 
outcome probabilities (in natural frequencies) 
 4. The decision support technology specifies the time period over 
which the outcome probabilities apply 
 5. The decision support technology allows the user to compare 
outcome probabilities across options using the same 
denominator and time period 
 6. The decision support technology provides information about the 
levels of uncertainty around event or outcome probabilities (e.g. 
by giving a range or by using phrases such as “our best estimate 
is…”) 
 7. The decision support technology provides more than one way of 
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Dimension Item 
viewing the probabilities (e.g. words, numbers, and diagrams) 
 8. The decision support technology provides balanced information 
about event or outcome probabilities to limit framing biases 
Values 1. The decision support technology describes the features of 
options to help patients imagine what it is like to experience the 
physical effects 
 2. The decision support technology describes the features of 
options to help patients imagine what it is like to experience 
psychological effects 
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Appendix B: Appraisal instruments 
MAStARI Appraisal instrument 
 page  
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Appendix C: Data extraction instruments 
MAStARI data extraction instrument 
Insert page break 
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Appendix E:  Characteristics of excluded studies 
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Appendix F: Decision Support Intervention 
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OPTIONS - AudioScript  
Audioscript dialogue has been recorded on CD 
“Making Choices. Choosing between dialysis and non-dialysis management for the older patient” 
Hello my name is Angus, I know that the decision about the treatment you would like to receive if 
your kidney function reaches less than 10 is very difficult, and emotional. This program has been 
developed to help you through this process. 
I’ll be your guide for this workbook, which prepares you for an informed discussion with your renal 
health professional team about your own values and the pros and cons of dialysis and non-dialysis 
management for end stage kidney disease. 
When you hear the following sound…. 
SOUND 
….Please turn to the next page in your workbook.  You can stop the CD at any time if you are not 
ready to go on to the next page. 
Let’s start by looking at the next page:  “This workbook is for you if….” 
SOUND 
This workbook has been developed for men and women 70 years of age and over, if or when you 
have been told by your renal health professionals that your kidney function is less than 20% from 
chronic kidney disease, otherwise known as CKD. Other terms you may have heard is “kidney 
failure” or” renal failure” or “end stage kidney disease”. The numbers in percentages used are a 
rough guess as to how much of your kidneys are working. If you have been told you kidney are 
around 20% then this means that only 20 % of your kidneys are working. This means we need to 
start talking about what treatment you would like to do.  
This workbook is for you if, you want to consider the options available to you as your kidney 
function drops further below 20%. This workbook is useful if you want to make your preference 
known to your health professionals and family and/or close friends.   
In this workbook, you’ll learn about: 
 End Stage Kidney Disease (ESKD)  
 The effects and management of End Stage Kidney Disease 
 Treatment choices you need to consider now so when your kidneys reach end stage kidney 
disease (working at less than 10%) you can receive the treatment that you have chosen, that 
is either dialysis or non-dialysis management 
 The pros and cons of these treatment choices and 
 How to weigh the pros and cons of dialysis and non-dialysis management for you 
personally. 
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Let’s look to the next page “What do your kidneys do?” 
SOUND 
Your kidneys are vitally important to keep you alive and healthy.  Your kidneys keep your blood 
clean from waste products and remove extra fluid, which is passed in your urine (pee). Your 
kidneys also manage your blood pressure and balance chemicals in your blood. They keep your 
bones healthy and play an important role in preventing you from developing anaemia.  Chronic 
kidney disease is the term used when your kidneys are damaged and are no longer working 
properly.  This diagnosis is made after you have had signs of kidney problems or damage for longer 
than 3 months.  When you have chronic kidney disease this means that your kidneys no longer work 
properly and won’t get better. If anything over time your kidneys will get worse.  
When your kidney function reaches end stage kidney disease (i.e. working less than 15%) you may 
have some obvious symptoms.  You may have puffy ankles or puffy lower legs.  You may feel sick 
a lot of the time and vomit sometimes.  You may have problems concentrating or remembering 
things.  You also may get itchy and often you will feel tired all the time. 
SOUND 
Chronic Kidney Disease can affect your life in many different ways.  The most common things that 
bother people with chronic kidney disease are listed below.  Please place a tick mark in the box next 
to all the things that bother you. 
Chronic kidney disease may cause some problems with your breathing including shortness of breath 
and needing to sleep using extra pillows. 
Some people have difficulty with their daily activity and lifestyle. These can include: 
 Feeling short of breath when walking or doing activities around the house, shed or garden; 
 Having difficulty undertaking or completing daily activities such as bathing, dressing, and 
preparing meals; 
 Having less energy than you used to; 
 Having difficulty falling asleep or sleeping poorly; 
 Experiencing headaches regularly; 
 Feeling like your legs want to keep moving and unable to relax when sitting or sleeping 
because of jumpy legs; 
 Feeling nauseous or unwell sometimes or regularly; 
 Experiencing itchy skin frequently especially when sleeping at night; 
 Swollen ankles or legs; 
 Chest pain when walking or doing simple activities or even when resting; 
 Burning feet or painful feet; and 
 General overall pain 
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The possible emotional effects of chronic kidney disease are many, and examples are: 
 Feeling anxious 
 Feeling depressed or unable to cope 
 Feeling irritable or angry; and  
 Feeling embarrassed by not being able to work very far or forgetting things easily. 
Socially, some people report: 
 Not being able to participate in social activities; 
 Feeling isolated; and 
 Change in money situation through increase in expense of medications or unable to work 
due to illness 
Chronic Kidney Disease may also cause people to have: 
 Difficulty concentrating; or 
 Forgetfulness 
There may be other effects that chronic kidney disease has had on your life.  Please write them 
down or get someone to write these down for you.  You may stop the CD while you add your 
concerns. 
PAUSE 
Now let’s go to the next page to learn about ways in which you can manage chronic kidney disease 
and the symptoms you may experience. 
SOUND 
Although there are many difficulties that you may experience with chronic kidney disease, there are 
a number of things that you can do to deal with these problems. Again please place a tick mark in 
the box next to the strategies you have used in the past year to cope with or manage chronic kidney 
disease. 
People may use medications prescribed by the doctor to help manage symptoms.  Fluid tablets are 
used to help control the swelling in your legs and also to stop the fluid building up in your lungs. 
You may feel the need to alter this dose depending on your breathing, the swelling in your legs and 
the changes in your daily weight.  Other medications to help manage the symptoms may be tablets 
you take to help settle your “jumpy” legs or to ease your cramps. Some of these you may buy over 
the counter and it is important for you to tell your renal health professionals. You may take 
medication before you eat any of your meals to try and help with managing nausea. The itch you 
experience may require the use of cream or medication to help provide relief.  If you use a spray or 
medication to manage your chest pain it is important for your renal health professionals to be aware 
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of this. You may have been prescribed medication to help you deal with anxiety or depression. To 
manage pain you may take medications regularly or when needed. Also if you are having problems 
sleeping there are medications to assist with this. 
Other things that are done to help you manage the symptoms include altering your daily activities or 
lifestyle.  You may change how often you exercise. You may need help to do some activities such 
as cleaning or mowing.  Chronic kidney disease can make you tired and you may need to sleep at 
least once during the day.  The symptoms may have also meant you no longer work or you have had 
to reduce the amount of work you do. A fluid and/or diet restriction may also be needed. To deal 
with the emotional impact some people say talking about your feelings, seeking alternative health 
strategies, and learning relaxation exercises, praying or seeking spiritual support and taking things 
one day at a time helps them to cope with the emotional effects of chronic kidney disease.  
You may have developed other ways to cope with chronic kidney disease.  Stop the CD for a few 
moments and write these down or get someone to help you record this. 
PAUSE 
Now, let’s turn to the next page to learn about the treatment options for chronic kidney disease 
when it reaches end stage. 
SOUND 
Dialysis 
You are approaching end stage kidney disease and it is necessary at this point to consider what 
treatment you would like to undertake.  You are receiving this decision aid now as it takes time to 
consider the treatment choices.  At this point you may not have many symptoms and finding it hard 
to understand why you need to make the decision now. To prepare patients for dialysis can 
sometimes take between 6- 12 months. The current guidelines indicate that people first need 
education about treatment options when the kidney function is around 20%. It is also important to 
understand that your symptoms can be managed as they start to occur. 
Dialysis is the process where waste and extra fluid are removed from your blood. It also balances 
the chemicals in your blood. This process can be carried out two different ways:  Peritoneal Dialysis 
or Haemodialysis 
Peritoneal Dialysis (PD) is a type of dialysis that can be done at home.  It involves an operation 
where fine plastic tubing is placed in the stomach area.  This operation is sometimes done under 
local anaesthetic but more often a general anaesthetic is used. This operation needs to be done one 
to two months before it is predicted you will need to start dialysis.  The tube stays in the stomach 
until you no longer wish to continue with peritoneal dialysis. The dialysis is carried out by running 
special fluid into your stomach cavity.   
Peritoneal dialysis can be done two different ways. The first choice is called continuous ambulatory 
peritoneal dialysis.  Which is done 4 times a day.  Or it can be done overnight where the fluid 
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moving in and out is controlled by a machine, this is known as automated peritoneal dialysis.  You 
remain connected to this machine overnight and then you disconnect from the machine. Both of 
these types of peritoneal dialysis must be carried out every day forever or until you decide to stop 
having treatment or you or your renal team change your treatment to haemodialysis.  Regular health 
reviews will occur to ensure your symptoms are controlled and quality of life maintained. 
 
Haemodialysis is a type of dialysis that can be done at a dialysis centre or at home.  You need to 
have surgery (on your arm normally) to have two blood vessels joined together called a vein and 
artery, this is known as an aterio-venous fistula. The operation is generally carried out using local 
anaesthetic, occasionally general anaesthetic is required. You normally need to be referred for this 
surgery at least 6 months before you are expected to start on dialysis. When the fistula is ready and 
the renal health professionals have determined it is time for you to start dialysis two needles are 
placed in your fistula and blood is drawn out and pumped through a dialysis machine.  The machine 
uses an artificial kidney to clean your blood of the waste products, to remove the excess fluid and 
balance your chemicals.  
If you don’t have a fistula and you need to start dialysis then a tube may be placed into a blood 
vessel, called a vein, in your neck so that blood can be removed for cleaning through the machine. 
This type of dialysis can take 4 to 5 hours each time you do dialysis. You need to do this three times 
a week. Every week forever unless you choose to stop dialysis or you or your renal team change 
you to peritoneal dialysis. Regular health reviews will occur to ensure your symptoms are controlled 
and you have a good quality of life. 
SOUND 
Before we move on to discussing the pros and cons of dialysis it is important to understand the 
impact kidney disease has on life expectancy. The life expectancy of people with end stage kidney 
disease is less than life expectancy of healthy people at the same age. I will first provide you with 
some life expectancy information related to the general population.  
For the age category 65 – 74,  97 out of every 100 individuals are still alive. If you look at the block 
of faces you can see the survival rate for this age group in the general population is 97 out of 100 
people.  This has also been illustrated for the older age groups as well. If you look at the second 
block of faces. This block represents 100 people in the general population between the ages 75 – 84. 
As you can see, 92 out of 100 people are still alive. The third and final block of 100 faces represents 
100 people in the general population aged 85 years and over. As you can see 85 of 100 people are 
still alive.  This information may help you view the information presented in the pros and cons of 
dialysis in relation to the life expectancy in the general population.  
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Now that you have some understanding of dialysis and we have covered the life expectancy of the 
general population, I will explain to you the pros and cons of undertaking dialysis (either type). 
Please turn the page to consider these. 
SOUND 
The pros of dialysis are that it may lengthen your life by a year or more and relieve some of your 
symptoms like breathlessness and fluid overload.   
The first pro is that dialysis may lengthen your life by a year or more, however this outcome 
changes are you get older. Look at the top block of 100 faces.  This block represents 100 people on 
dialysis between the ages of 65 to 74.  As you can see, 85 out of 100 patients are still alive after one 
year on dialysis.   
Look at the second block of 100 faces.  This block represents 100 people on dialysis between the 
ages of 75 to 84.  As you can see, 80 out of 100 patients are still alive after one year on dialysis.  
The third and final block of 100 faces represents 100 people on dialysis aged 85 and older.  As you 
can see, 69 out of 100 patients are still alive after one year on dialysis.   
The second pro is that if you have no significant medical problems you will live longer than if you 
chose non-dialysis management, this may be up to two years longer. 
The final pro is that dialysis will help manage too much fluid and should reduce swelling in the legs 
and shortness of breath related to fluid overload. 
Now we will move on to discuss the cons of undertaking dialysis.  Please turn the page 
SOUND 
The cons of undertaking dialysis are you may not live longer than one year, your symptoms may not 
be relieved by dialysis and if you have health problems like angina or poor mobility dialysis may 
not help you live longer and may make your mobility worse.  You also might spend more time in 
hospital  
The first thing to identify in the cons is if you have medical problems such as angina or a history of 
a heart attack, dialysis may not extend your life any longer than non-dialysis. 
You also may not live longer than one year as indicated by the first block of faces. If you are 65 to 
74 years old then the block of faces show that 15 patients out of 100 will not survive one year on 
dialysis. 
If you are between the ages of 75to 84 years then the block of faces indicate that 20 patients out of 
100 will not survive one year on dialysis. 
If you are over 85 years old then the block of faces indicate that 31 out of 100 patients will not 
survive one year on dialysis. 
Another con is if you live in a nursing home have poor mobility and need help with bathing and 
eating, then dialysis may affect your ability to mobilise or care for yourself. Your ability to care for 
yourself or mobility may get worse the longer you are on dialysis.  The block of faces indicates that 
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after 3 months of dialysis 61 patients out of 100 found that their mobility or ability to do activities 
of daily living got worse.  After 1 year of dialysis, 97 patients out of 100 found that their mobility or 
ability to do activities of daily living had got worse. The change in mobility or ability to do 
activities of daily living was compared with the year before when the residents hadn’t started 
dialysis, where no changes in mobility and activities of daily living were observed.  
Symptoms of chronic kidney disease may not be relieved by dialysis.  Studies have shown that 47% 
of patients undertaking dialysis report pain, 30% patients suffer from restless legs, 55% experience 
itching, 44% of patients suffer sleeping problems, 71% patients suffer from tiredness. 
Uou may spend approximately 25 days per year in hospital as an inpatient.  If you are undertaking 
haemodialysis at a dialysis centre you will be having dialysis 3 days every week. Each dialysis lasts 
4 – 6 hours. This also may involve travelling via car, public transport, taxi or ambulance to get to 
the nearest dialysis centre. 
Another concern is that dialysis may make you feel tired and washed out and there are restrictions 
related to fluid and diet that can become a burden. 
On the next page we’ll summarize the pros and cons of dialysis. Please turn the page 
SOUND 
In summary  
The outcomes for those with end stage kidney disease are summarised below: 
The pros of undertaking dialysis. If you have no significant medical conditions then you will live 
longer if you receive dialysis and also if you undertake dialysis your life may be lengthened by a 
year or more. Regular health reviews will also occur to ensure your symptoms are controlled and 
you have a good quality of life. 
An example is for the 75 to 84 age group, 80 out of 100 patients on dialysis will be alive after 1 
year. 
The cons of undertaking dialysis are - Health problems such as angina or a history of heart attack 
can affect your outcomes and dialysis may not help you live any longer.  Also if you have poor 
mobility and need help with activities of daily living then this may get worse should you go on 
dialysis.  You also may spend more time in hospital as an inpatient. 
Look to the next page where we will talk about what is involved in choosing non-dialysis 
management. 
SOUND 
Non-dialysis management involves controlling symptoms and suffering, with the aim of 
maintaining your quality of life for as long as possible.  Medications can be used to treat symptoms 
such as shortness of breath, restless legs, itchy skin, nausea, headaches and pain.  In the last month 
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of your life pain medications and sedatives can be used to ensure you have a pain free and dignified 
death.   
Non-dialysis management is provided through clinic appointments.  The frequency of the 
appointments may increase as the need to manage your symptoms increases.  If you cannot longer 
make it to clinics home visits may be provided or the renal health professionals can discuss with 
your GP and community palliative care nurses to meet your care needs. 
Let’s review the pros and cons of this treatment options 
SOUND 
The pros of non-dialysis management are that all treatment is aimed at keeping you well and 
symptom free for as long as possible.  You can receive this care in your home and you will have 
fewer hospital inpatient admissions.  16 days per year compared with 25 days if you were on 
dialysis.  You have a four times greater chance of dying at home than in hospital compared with if 
you were receiving dialysis.  You may still live for between 9 and 14 months after your kidney 
function drops below 10%, even without dialysis. Your quality of life is not worse compared with 
those people who choose dialysis. Additionally no surgery is required 
SOUND 
The two main cons of non-dialysis management are that you may die sooner than if you undertook 
dialysis and your symptoms may get worse and affect your last few months of life. 
 
Before we go on, let’s review the pros and cons of each treatment choice. 
SOUND 
First let’s review what is involved in dialysis.  Your blood is cleaned by a dialysis machine or by 
running fluid in and out of your stomach cavity. You need to have surgery either for a fistula or 
placement of a plastic tube in the stomach.  Treatment can be undertaken at home or in hospital. The 
pros of choosing dialysis is that you may live longer than 1 year and it’s it also likely to be longer 
(between 20 to 24 months)  than if you chose non-dialysis management. (PAUSE) You may have 
thought of other pros. (PAUSE) 
The cons of this option are that dialysis may not help you live longer if you have additional medical 
conditions such as angina or heart problems.  Your symptoms may not be reduced and you will 
probably spend more time as an inpatient in hospital. You will need to have some form of surgery. 
Dialysis may worsen your mobility if it is already is impaired. (PAUSE) You may have thought of 
other cons? (PAUSE) 
 
Lets review what’s involved with non-dialysis management.  The aim of non-dialysis management 
is to make sure the symptoms are controlled as best as possible and we help you maintain a good 
quality of life for as long as possible.  This management involves regular visits to see the renal 
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health professionals and your general practitioner (GP). Sometimes there is additional involvement 
from the palliative care team when this is needed.  The pros of non-dialysis management is there is 
no surgery involved, you can receive you care in your home and also choose to die in your home or 
the place of your choice.  You may still live approximately between nine and fourteen months.  
Your quality of life is no worse than those receiving dialysis.  You are also less likely to die in 
hospital.  You may have thought of other pros. (PAUSE) 
The cons of non-dialysis management is you may die sooner than if you undertook dialysis.  Also 
your symptoms may get worse in the last one to two months of your life.  You may have thought of 
other cons? (PAUSE) 
Now it is time to learn how to weigh the pros and cons in making your decision about your 
treatment when your kidneys are no longer working more than 10%. On the next few pages I will 
review the five steps to doing this and some questions you need to ask yourself.  Then I will show 
you how others have answered these questions and the reasons why. 
SOUND 
Step 1 asks what are the pros and cons of dialysis and non-dialysis management. 
In Step 2 you will ask yourself how important are each of the pros and cons of the treatment choices 
to you?  You should colour the boxes to show how important each one is to you. 
Step 3 asks you to list any questions that need to be discussed before you decide.  What do you need 
to discuss with your renal health care professionals? Write these down in the space provided. 
Step 4 asks you to tick the box showing who you think should make the decision about your 
treatment options.  Are you more comfortable leaving your renal health professionals to make the 
decision? Do you want to make a shared decision? Do you want to decide for yourself without any 
input from anyone? Or, are you unsure at this time? 
Step 5 asks you to tick your overall leaning about your treatment options.   
It may help to hear how other people feel about making this decision.  I’ll describe two different 
people’s decisions and the factors they identified as important to them. 
SOUND 
The first example is John.  In step 1, he lists his personal pros and cons of dialysis.  Under the first 
pro, lives longer, John writes he is not ready to die yet.  
When John considers the next pro, relief of symptoms such as shortness of breath and tiredness, he 
writes that he doesn’t want to feel ill and struggle with breathing.  Under the next pro, may lengthen 
my life by up to a year or more, John writes that it is his 60th wedding anniversary in 18 months and 
he wants to live to celebrate this. In the next box John has identified two further pros. The first 
being religious beliefs, John is religious and with his religion he believes everything should be done 
to stay alive. His second pro in this box is that his family wants him to stay alive for longer. 
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Moving on to John’s thinking about the “cons” of dialysis, he doesn’t have any medical conditions 
and is still able to do gentle exercise on a daily basis. The next con is discomfort, which is on some 
concern to John.  Under the con of complications John has identified that he is concerned about 
ending up in hospital with an infection as he knows that there is a risk when undertaking dialysis.  
John then moves to the last box, “other cons”.  The other concern that John has is the amount of 
time involved with undertaking haemodialysis. 
Next in Step 2, John colours in the boxes with a pencil to show his values.  In each box John fills in 
the amount that show how important each pro and con is to him.  He fills in the large portion of the 
box if the item is very important, and only a small part if the item is less important.  Those things 
that are not important at all he leaves blank. 
On the pro side, he thinks about living longer, this is very important to him so he colours it 
completely.  He partially colours in the box for relief of symptoms such as tiredness and shortness 
of breath, which is moderately important to him, because even though he doesn’t want to feel ill and 
struggle with breathing he knows that there are medications that will help.  For the pro lengthen his 
life by up to a year or more, he colours the box completely to show that it is very important to him, 
especially because he wants to be alive to celebrate wedding anniversary at the end of next year.  
The last box “other pros” he colours in completely as well because his religious beliefs are very 
important to him. 
When thinking about the cons of dialysis, he doesn’t colour in the box marked medical conditions 
or poor mobility because this isn’t a concern of his, he is fit and health.  He partially colours in the 
box marked discomfort because this is moderately important to him, however he is aware there may 
be medications to help with this discomfort. Under complications he colours a small amount as this 
is slightly important to him. John has partly coloured in the “other cons” and identified that his is 
worried about spending a lot of time undertaking dialysis, this has a slight importance to him. 
In Step 3, John writes down that he will ask his renal health professional team what he can do so 
that he doesn’t need to do dialysis. 
In Step 4 John thinks that he would feel most comfortable with the decision being made with the 
health professionals. 
In the final step, John ticks the line to indicate his overall leaning, after considering all the pros and 
cons, and how they are important to him.  He is strongly leaning to dialysis, so he places a tick at 
the end of the line near the word dialysis.   
Let’s look to the next page for Daphne’s decision. 
SOUND 
In Step 1, Daphne reviews her personal pros and cons of dialysis.  In the first “pro”, live longer, 
Daphne writes that she has lived a good life and accepts death.  In thinking about the next “pro” 
relieving symptoms such as shortness of breath and feeling tired, she writes that she isn’t worried 
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about it as has felt tired for a long time. The shortness of breath isn’t too bad and is happy to take 
medication to help with this. When Daphne thinks about living for longer than a year or more, she 
writes that she has a grandson’s 21st next year and would like to be able to celebrate this. The other 
pro she writes down is her husband would like everything to be done for her.  
For the first “con”, medical condition or mobility, Daphne writes that she does experience angina 
regularly and takes medication to manage this, she also needs her husband to help her with 
showering and uses a wheelie walker.  In the discomfort box, Daphne writes that her symptoms she 
has may not go with dialysis and she doesn’t want to sit on the machine for a long time. In the 
complication box Daphne has written that she doesn’t want to end up in hospital and would like to 
stay home as much as possible. Under “other cons”, Daphne writes that quality of life is more 
important to her than quantity or living longer.   
You can see by the shading of the boxes in Step 2 that living longer is not important to Daphne and 
the relief of symptoms has a slight degree of importance.  Lengthening her life for more than a year 
is moderately important to her.  The fact her husband wants everything done has a slight level of 
importance.  On the “con” side, the possibility of finding dialysis too burdensome is extremely 
important to Daphne.  The fact that discomfort may not be relieved by dialysis is also extremely 
important to Daphne.  The complication of ending up in hospital is also extremely important to her.  
Her concern for quality of life over quantity of life is moderately important to her. 
In Step 3, Daphne identifies two questions for her health professionals 
How long will I live? 
What happens if I feel really sick? 
In Step 4, Daphne indicates the she should decide about treatment choice after considering the 
opinion of others. 
Step 5 shows Daphne’s leaning: she is strongly leaning toward non-dialysis management. 
SOUND 
After reviewing the pros and cons of the options you may still be unsure which way you are leaning. 
This may be because: 
You still have questions about the treatment choices 
You need to discuss treatment choices with others; or 
You are still not sure what is most important to you in the decision. 
It is important to discuss your decision with your family and/or close friends and the renal health 
professionals. 
 
This completes the last part of the workbook. If you’re interested in reading more about chronic 
kidney disease and treatment choices there is a list of resources at the back of this book. You can 
 Appendices 227 
also ask your renal health professionals.  The references to the studies that were used to develop this 
kit are also found at the back of the workbook.  The members of the research tea who prepared this 
kit are also listed at the front of this book.  Good luck with your decision-making and thank you for 
listening.  
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Appendix H  Ethics Approval  
From: Research Ethics [mailto:ethicscontact@qut.edu.au] 
Sent: Tuesday, 20 January 2015 10:38 AM 
To: Glenn Gardner; Ann Bonner; Mrs Leanne Brown; Leanne.brown2@health.qld.gov.au 
Cc: Janette Lamb 
Subject: Ethics application - approved - 1400000937 
Dear Prof Glenn Gardner and Mrs Leanne Brown 
 
Project Title:  A randomised controlled trial of a clinical information tool to support patients decision 
making for management of end stage kidney disease 
 
Ethics category:                  Human - Administrative Review  
QUT approval number:     1400000937 (As per Royal Brisbane & Women's 
Hosptial, Approval number: HREC/14/QRBW/425) 
QUT clearance until:         24/11/2017 
 
We are pleased to advise that your application has been reviewed and administratively approved by 
the Chair, University Human Research Ethics Committee (UHREC) based on the approval gained from 
the responsible HREC. 
We note this HREC has awarded the project ethical clearance until 24/11/2017. 
CONDITIONS OF APPROVAL 
Please ensure you and all other team members read through and understand all UHREC conditions 
of approval prior to commencing any data collection:  
   - Standard: Please see attached or 
http://www.orei.qut.edu.au/human/stdconditions.jsp 
   - Specific:   None apply 
Administrative review decisions are subject to ratification at the next available UHREC meeting. You 
will only be contacted again in relation to this matter if UHREC raises additional questions or 
concerns. 
 
Projects approved through an external organisation may be subject to that organisation's review 
arrangements. Researchers must immediately notify the QUT Research Ethics Unit if their project is 
selected for investigation / review by an external organisation. 
 
VARIATIONS 
All variations must first be approved by the responsible HREC before submission to QUT for 
ratification.  Once approval has been obtained please submit this to QUT using our online variation 
form:  
     http://www.orei.qut.edu.au/human/var/ 
MONITORING 
Please ensure you also provide QUT with a copy of each adverse event report and progress report 
submitted to the responsible HREC. 
Please don't hesitate to contact us if you have any queries. 
We wish you all the best with your research. 
 
Kind regards 
Janette Lamb on behalf of Chair UHREC 
Office of Research Ethics & Integrity 
Level 4   |   88 Musk Avenue   |   Kelvin Grove 
p: +61 7 3138 5123 
e: ethicscontact@qut.edu.au 
w: http://www.orei.qut.edu.au 
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